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Abstract
Bone is a common site of metastasis for many solid malignancies. Bone-metastatic
cancers pose a significant clinical problem worldwide and is among the main causes for
cancer patient morbidity and mortality. Patients with advanced bone-metastatic diseases
often present with either osteolytic or osteogenic bone diseases as their cancers progress.
These bone pathologies are products of the cancer co-opting the local bone remodeling
stroma to yield important growth nutrients and factors. Unfortunately, skeletal metastases
remain incurable and are fatal. Identifying and understanding the causal multicellular and
molecular interactions underlying skeletal malignancies can yield crucial ideas for
targeting and inhibiting disease progression. In this thesis, we focused on two major
skeletal malignancies: multiple myeloma and prostate cancer.
Multiple myeloma frequently induces pathologic bone loss in patients by enhancing
osteoclastic bone resorption. Matrix metalloproteinase 13 (MMP-13) is highly abundant
in the bone and is primarily expressed by mesenchymal stromal cells (MSCs) in multiple
myeloma. Analysis of public datasets and patient biopsies reveal multiple myeloma
induce upregulation of MMP-13 in MSCs. Myeloma-induced MMP-13 processes and
activates cytokines secreted by MSCs which are important for osteoclast formation and
activity, such as CXCL7. Depletion of MMP-13 and/or CXCL7 in MSCs significantly
impede MSC induction of osteoclastogenesis. Genetic and pharmacologic ablation of
MMP-13 significantly improves overall survival myeloma mouse models, providing clear

x

rationale for the clinical translation of MMP-13 inhibitors for the treatment of multiple
myeloma and osteolysis.
Our second area of interest revolves around prostate cancer. Primary prostate
cancer is largely curable. Patients diagnosed with disseminated disease often undergo
periods of remission owing to chemotherapies and androgen deprivation therapies, but a
significant subset eventually relapse with castrate-resistant prostate cancer (CRPC).
CRPCs frequently manifests in the bone and establish mixed bone pathologies. Androgen
receptor variant 7 expression is a common mechanism of castrate resistance and induces
the expression of androgen vasopressin 1A (AVPR1A), an important regulator of the
mitogenic pathway. We demonstrated that AVPR1A is vital for growth and maintenance
of drug-resistance in CRPC cells. Pharmacologic inhibition of AVPR1A using Relcovaptan
significantly reduced CRPC tumor growth and improved overall survival in a
subcutaneous, an orthotopic, and a bone metastasis mouse model. Specifically, in the
bone metastasis model, AVPR1A is expressed by stromal osteoclasts and regulates bone
resorption. Relcovaptan-treated tumor-bearing mice also demonstrated significantly
reduced cancer-induced bone pathology, supporting the clinical translation of
Relcovaptan for the treatment of advanced stage prostate cancer.
Our understanding of molecular and cellular drivers of tumor-bone interactions
continue to expand. Dysregulated bone remodeling lies in the center of various skeletal
malignancies and involves various bone marrow cell types in addition to osteoclasts,
osteoclasts and cancer cells. An emerging question is, “how do all of these components
interact with each other over time in cancer-induced osteal pathologies?” To address this,
we utilized mathematical models and here we present our findings on using unique

xi

modeling approaches to define cellular interactions in the bone microenvironment.
Mathematical modeling allows for describing the complex relationships between various
cellular species and predicting the consequences of disrupting these relationships. To
eventually build models of skeletal malignancies as prostate cancer and multiple
myeloma, we began by building a model of normal bone healing response to injury. We
devised an ordinary differential equation (ODE)-based model that is powered by in vivo
experimental data to ensure biologically-relevant simulations. Our bone injury model was
able to discover specific osteoblast and osteoclast behaviors that are currently difficult to
test experimentally, but it was also able to accurately predict temporal dynamics of bone
cell population data in an independent biological study. These findings demonstrate that
we have a computational tool at our disposal to begin modeling skeletal malignancies and
interrogating various treatment options, with hopes to inform clinical translational efforts.
Taken together, our studies herein address important cellular and molecular
factors that govern cancer-bone interactions and cancer-induced bone disease, and
reveal a number of therapeutic opportunities for the treatment of these incurable lesions.
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Chapter 1.

Clinical significance of cancer bone metastasis and fundamental

understanding of the bone microenvironment

1.1

Bone metastasis: clinical significance
The World Health Organization, in its most recent report, estimated 9.6 million

people around the world succumbed to cancer in 2018 alone. Cancer is the second
leading cause of deaths worldwide, contributing to 1 in every 6 deaths 1. In the United
States, despite a 29% decrease in cancer death rate since 1991, a study performed by
Siegel et al. from the American Cancer Society nonetheless predicts more than 1.8 million
new cancer cases and 600,000 cancer deaths in 20202, 3. As the average human lifespan
continues to rise, the accompanying rise in annual cancer diagnosis and deaths remains
an ever more pressing problem.
The most common cancers in the United States are breast, lung, prostate,
colorectal and melanoma skin cancers3. Patients diagnosed with localized primary
disease of these cancers, with the exception of lung cancer, have high 5-year survival
rates. However, morbidity and mortality in these cancers are attributed to advance stages
when the cancer has metastasized to distal vital organs, such as brain, lung, liver and
bone. Survival prognostics are drastically diminished when patients are diagnosed with,
or progress to metastatic disease4 (Table 1-1).

1

Table 1-1. SEER 5-year survival statistics among top five most common cancers
Overall 5-year
Localized
Distal
survival
Disease
Disease
(%)
(%)
(%)
Breast
89.9
98.8
27.4
Lung and Bronchus
19.4
57.4
5.2
Prostate
98
100
30.5
Colorectal
64.4
89.9
14.2
Melanoma
92
98.7
24.8

Lung cancer is the second most common cancer in the United States and is the
only cancer on Table 1-1 that originates in a vital organ. Half of patients do not survive
past five years even when diagnosed with localized primary disease, and 30-40% of all
patients eventually develop bone metastasis. These cancers commonly metastasize to
the skeleton5-7. Similarly, other deadly malignancies can metastasize to the bone, such
as thyroid and kidney cancer, whereas, multiple myeloma and osteosarcoma for example,
originate in the bone. Patients with skeletal malignancies not only experience bone pain,
but are also susceptible to reduced mobility, bone fractures, anemia and leukopenia. In
fact, published pan-cancer surveys have revealed 70% of all cancer-related deaths
present with evident bone metastasis in post-mortem autopsy, emphasizing the
prevalence of bone metastasis in cancer-induced mortality. While this statistic alone
presents a correlation rather than a causation, it is not difficult to imagine the bone
metastasis-related morbidities playing an enormous role in the patient’s demise 8, 9.
Therefore, a strong case is made that understanding the mechanisms by which cancers
metastasize to the bone will have broad applications in combating overall cancer mortality.

2

1.2

Metastatic cascade and skeletal malignancies
Bone metastasis accounts for the majority of cases of skeletal malignancies, 76%

of which are from breast, lung and prostate cancers combined 10,

11.

Whereas

hematological cancers such as multiple myeloma, spread systemically by freely
traversing the circulatory system throughout the skeleton and into distal organs12-14, solid
cancers undergo the “metastatic cascade” process. In brief, this process requires that
cancer cells 1) disseminate from their primary site through endothelial-mesenchymal
transition (EMT) and intravasate into the bloodstream, 2) survive mechanical sheering
forces in circulation, and 3) dock and extravasate into a secondary site, where they must
4) subsequently undergo mesenchymal-endothelial transition (MET). Some cancers must
also escape dormancy to mature into an overt metastatic lesion 15-20.
Given these hurdles, cancer metastasis is therefore a very inefficient process. In
the primary tumor, cancer cells can overtime accumulate varying degrees of metastasispermissive functional mutations, such as to invade, disseminate, intravasate, or et cetera.
The common genetic and molecular enablers, or drivers, of metastasis have been and
continue to be heavily studied. In skeletal malignancies, studies have increasingly
described the specific ways in which cancers crosstalk with key stromal populations in
the bone microenvironment to establish bone lesions.

1.2.1 Genetic drivers of bone metastasis
Cancers such as breast, lung and prostate cancers preferentially home to the bone,
where their growth further incurs osteolytic and/or osteogenic pathologies that contribute
to patient morbidity21, 22. Each of these cancers possess unique genetic traits that enable
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their successful colonization of the bone microenvironment. For example, in breast cancer,
Kang et al. identified two sub-populations within the highly heterogeneous MDA-MB-231
cell line that specifically metastasize to the bone from the orthotopic site in vivo. Whereas
clones that have upregulated CXCR4, IL11, CTGF, MMP-1, and OPN will form detectable
overt bone lesions, other isolated bone-homing clones will form dormant but persisting
micrometastases23-26. Expression of cell adhesion molecules such as VCAM1 are also
implicated in bone metastasis26, 27. The mechanism of action for some of these genes
have been described at the molecular level. For example, cancer cells expressing surface
CXCR4 are drawn to the bone, where it’s ligand, CXCL12 (SDF1) is highly expressed.
Similar chemokine mechanisms include the CXCL5/CXCR2 axis28, 29.
In addition to genetic studies examining breast-to-bone osteotropism in
experimental models, broader genetic studies have also revealed bone metastasis
signature in humans30-32. In human patient biopsies, for example, Smid et al and SavciHeijink et al have independently derived a 31-gene and 15-gene signature that can predict
bone metastasis in breast cancer patients, respectively30,

33, 34.

A separate gene

expression analysis of clinical specimen has also independently yielded an additional
gene signature that characterizes breast cancer-to-bone micrometastasis30, 35. Whereas
these markers may be valuable in predicting bone metastasis, much remains to be
learned about how some of these dysregulated genes contribute at the molecular level.
Similar strategies have been employed to identify bone metastasis-related genes
and signatures in prostate and lung cancer20, 36-40. In prostate cancer, gene expression
profiling of cell lines, as well as bioinformatic analysis of human clinical microarray
datasets, have identified genes such as TMPRSS2-ERG fusion, ARv7, AVPR1A and

4

MTA1 to enhance cancer cell invasion and bone metastasis41-50. Additionally,
experimental GEMM models of prostate cancer have also identified prostate-to-bone
genetic signatures51, 52. Similarly, studies with lung cancer patients have identified genes
such as CSF1, HDAC4, TCF4 to be risk factors for development of bone metastasis 37-40,
53-56.

These gene signatures hold promise in the clinic as prognostic tools for the

development of metastatic disease. Interestingly, meta-analyses revealed little overlap,
indicating that we are still at the beginning of our understanding regarding the genetic
drivers of bone metastasis. This allows us to appreciate the vast ways cancer genomes
can be altered, all to acquire bone metastasis potential.

1.2.2 Molecular mechanisms that govern cancer-bone interactions
The mineralized bone matrix contains numerous growth factors such as plateletderived growth factor (PDGF), insulin-like growth factor (IGF), fibroblast growth factors
(FGF) and transforming growth factor beta (TGFβ)23, 57. Multiple myeloma and subsets of
breast cancer, for example, are highly osteolytic and they recruit bona fide bone-resorbing
cells, the osteoclasts, that excavate/ solubilize growth factors once sequestered in the
dense bone matrix22,

58.

Tumor-derived parathyroid hormone-related protein (PTHrP),

vascular endothelial growth factor (VEGF) and interleukin 11 (IL-11) play an important
role in the activation of osteoclasts57, 59. In fact, high plasma PTHrP levels predict bone
metastasis and are correlated with osteolytic bone disease in breast cancer60-62. Activated
osteoclasts promote bone degradation, resulting in compromised bone integrity and
causing hypercalcemia. Importantly, this process releases TGFβ and other bonesequestered factors that can stimulate cancer cell survival and growth23, 59. In agreement
with these findings, pharmacological inhibition of TGFβ, PTHrP, and genetic silencing of
5

PTHrP or SMAD4, a signal transducer downstream of TGFβ, can abrogate this
osteoclast-mediated vicious cycle of tumorigenesis23, 59, 63.
Conversely, prostate cancer bone metastasis frequently results in net pathological
bone formation: the disease is thus generally considered osteogenic. Bone-metastatic
prostate cancer produces factors normally found in the bone matrix, such as PDGF, IGF
and adrenomedullin (ADM) that can stimulate osteoblast differentiation and activation64.
Prostate cancer-derived endothelin 1 (ET-1) has also been shown to engage endothelin
A receptor (ETAR) on osteoblasts to enhance bone formation65-67. Interestingly,
differential proteolytic processing of mature PTHrP1-36 has been shown to stimulate both
osteolysis and osteogenesis58, 68, 69. As the breadth and function of each cleavage product
continues to be studied, prostate cancer-derived PTHrP1-16 has specifically been
implicated in osteoblast activation and bone formation in various studies by signaling
through PTH1R present on surface of precursor and mature osteoblasts, without altering
osteoclast behavior58, 69, 70. Maturing and activated osteoblasts can secrete factors such
as osteonectin (SPARC), syndecan 1 (SDC1) and osteopontin (OPN), and calcium ions
as they build bone, and these factors can act as growth or pro-metastasis signals for the
prostate cancer19,

22, 58.

The bioactivation and availability of these molecular factors

derived from both bone resorption and formation are controlled by the proteolytic activity
of various matrix metalloproteinases (MMPs), which additionally process matrix proteins.

1.2.2.1 MMPs control bioavailability and bioactivity of bone-remodeling cytokines
Tissue matrices constantly undergo growth, turnover and remodeling, and these
processes are driven in large part by a class of proteolytic enzymes called matrix
metalloproteinases (MMP). The human MMP family comprises of 23 members, each with
6

its unique ortholog in mice71. MMPs all generally possess collagenolytic activity and can
cleave non-collagen substrates72-75. Additionally, non-catalytic activities have recently
been described in some MMPs76-79. The function of each MMP is therefore based on
where it is expressed and what it processes. Processing by MMPs can either improve or
reduce the bioavailability or bioactivity of cytokines and factors, and thus MMPs are
considered the “master regulators of cell-cell communication”80.
In bone, aged and/or damaged tissue requiring repair begins with clearance of
unhealthy tissue. Bone tissue is specifically turned over and remodeled by osteoclasts.
Catalytic activities of MMPs influence the bioavailability of various cytokines that are
important for the recruitment and fusogenesis of osteoclasts precursors. Furthermore,
activated osteoclasts can express endogenous or uptake extracellular MMPs and secrete
acids into the resorptive pit (lacunae) on the bone surface to process bone collagen and
solubilize mineralized bone calcium, respectively81-85.

1.2.2.2 MMP inhibitors in cancer
Various cancers exhibit dysregulated MMP expression and take advantage of their
proteolytic activity. The pathological expression of MMPs can promote cancer growth and
proliferation, enhance cancer invasion and metastasis, and mediate therapeutic
resistance77, 86-89. The pro-tumor roles of MMPs have therefore inspired the development
of a series of broad-spectrum MMP inhibitors. These endeavors eventually failed in the
clinic since they failed to acknowledge that select MMPs play anti-tumor roles in specific
cancer contexts83,

90.

Studies in the recent decades have immensely improved our

understanding of MMP anti-tumor roles. Various preclinical models of selective-MMP
ablation have become available91-96. These murine models, when used in conjunction with
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genetically-manipulated syngeneic cancer cell lines, have further aided the dissection of
stromal versus tumoral MMP contributions to cancer progression. For example, MMP-3,
-8 and -9 suppresses tumor growth initiation, metastasis and intratumor-vascularization
in mouse models of skin and breast carcinoma90, 97. Moving forward, as we improve our
understanding of MMP behavior and function in different disease contexts, clinical
development efforts are expected to shift towards matching potent and selective MMP
inhibitors with cancer patients whose diseases are exacerbated by aberrant MMP
expression87, 90, 92, 98-100.

1.2.3 Bone remodeling is a tightly coupled process
Osteolysis and osteogenesis in a normal healthy remodeling bone are tightly
coupled101-107. Osteal pathologies result from significant disturbances in the bone
remodeling mechanism where osteoblast and osteoclasts activities are no longer
balanced. For example, in osteal arthritis, chronic inflammation drives osteolysis without
a corresponding compensating osteogenesis, resulting in net loss of bone over time108.
In cancer bone metastasis, these imbalances provide essential factors and cytokines
which drive cancer survival and progression. Therefore, we must identify how each
cancer uniquely disrupts the bone remodeling regulatory machinery to truly grasp why
bone lesions manifest with differing forms of osteal pathologies.
Bone remodeling involves various osteal cellular populations and factors, and
centers around the regulation of osteoclast and osteoblast effector activities. Tight
restraints on these bone remodeling populations ensure 1) maintenance of bone health,
and also 2) that the bone will eventually return to homeostasis following a prompt
response to environmental stimuli.
8

In brief, as the bone ages, apoptotic bone cells (osteocytes) secrete osteolytic
signals and stimulate osteoclast resorption to clear the compromised bone tissue. Factors
derived from bone resorption subsequently trigger osteoblasts to mature and deposit
fresh tensile woven bone107, 109-111. Osteolytic and osteogenic activities then alternate as
the new bone is remodeled to completion with Haversian and Volkmann canal
vasculatures for adequate nutrient and oxygen delivery112, 113 (Figure 1-1a). This constant
turnover process maintains the strength of the bone.
a

b

Figure 1-1. Bone remodeling under homeostasis and bone injury. (a) aging bone triggers
osteolysis (green arrow) followed by osteogenesis to return to homeostasis. Bone
resorption is indicated by red arrow. (b) bone fracture initially triggers osteogenesis
followed by osteolysis to return to homeostasis.

In pathological settings such as in fractures, osteoblasts sensing bone damage
quickly expand and generate bone matrices to seal and stabilize the fracture; osteoclasts
subsequently expand and activate to remodel the excess bone back to homeostatic
volumes and densities (Figure 1-1b). In extreme cases, such as a non-union long bone
fracture, the bone undergoes initial abundant bone and cartilage deposition spanning the
periosteal and endosteal surfaces. This scaffold is largely resorbed over time by
osteoclasts to re-establish the medullary canal. Subsequently, milder waves of osteoclast
and osteoblast will remodel the bone and return it to homeostasis. These scenarios
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underscore the necessary crosstalk between osteoclasts and osteoblasts, which are
established both through exchanges of cytokines and growth factors, as well as by other
intermediary cell types in the bone marrow.

1.2.3.1 Myeloid precursor cells and osteoclasts
Osteoclast are historically regarded as the tissue-resident macrophages of the
bone, because they are myeloid cells with tissue-specific functions. On the surface of
bone, RANKL- and M-CSF-stimulated monocytes and other immature myeloid cells fuse
to form macroscopic multinucleated cells with resorptive ability. Osteoclast formation is
therefore dependent on the abundance of precursor cells as well as availability of
osteoclast-promoting cytokines. Myeloid chemoattractants and growth factors such as
monocyte chemoattractant protein-1 (CCL2) and colony stimulating factor 1 (M-CSF)
have been shown to recruit and expand osteoclast precursors, whereas cytokines and
chemokines such as tumor necrosis factor alpha (TNF), interleukin-1 beta (IL-1β), platelet
basic protein (CXCL7), fractalkine (CX3CL1), Dendritic cell-specific transmembrane
protein (DC-STAMP) and stromal cell-derived factor 1 alpha (SDF) have been shown to
promote osteoclast formation114, 115.
When active, an osteoclast will form a vacuum seal over bone and secrete acids
and proteases (such as cathepsin K) into the lacunae, resulting in the solubilization of
calcium and degradation of the collagen-rich osteoid matrix, respectively116. Studies
characterizing osteoclast function have respectively measured and inferred homeostatic
bone resorption rates of osteoclasts of varying sizes in vitro and in vivo, and they have
noted a positive correlation between osteoclast size and bone-resorptive activity116-119.
Although results demonstrated that osteoclasts resorption rates can range in orders of
10

magnitude, studies have also found that certain cytokines can transiently regulate basal
osteoclast activities, including TNF and IL-1120-123. Additionally, osteoclasts have been
shown to express or uptake extracellular sources of matrix metalloproteases, such as
MMP-2, MMP-9 and MMP-13, which they then can use to enhance collagenolytic activity
on the bone matrix116, 124, 125. Conversely, factors such as OPG, IL-37 and estrogen have
been shown to suppress osteoclast activity by limiting RANKL bioavailability and inducing
osteoclast apoptosis110, 126, 127.

1.2.3.2 Mesenchymal stromal cells and osteoblasts
Osteoblasts, like adipocytes and chondrocytes, are derived from multipotent
mesenchymal stromal cells (MSC). Although adipocytes and chondrocytes each have
their respective functions to store fatty acid and produce cartilage, the main role for
mature osteoblasts is to build bone. Important osteoblast formation factors include
members of the TGFβ superfamily, BMPs, IGFs and FGFs128, 129. These factors trigger a
RUNX2- and Sp7-mediated transcriptional program that underlies MSC-derived
precursor osteoblast maturation130, 131. Differentiating osteoblasts are traditionally defined
by expression of RUNX2, osteopontin (OPN), osteocalcin (OCN) and alkaline
phosphatase (ALP) markers109. Recent lineage tracing studies have pinpointed where
along the osteocyte and chondrocyte differentiation path these markers are turned on and
have provided clues as to the type of cellular signals that cells at varying maturities are
tuning into130, 132.
Bone formation can be subdivided into two steps133. Osteoblasts synthesize and
secrete type I collagen to form the osteoid matrix on the bone-forming surface109, 134.
Calcium is then absorbed by mature osteoblasts through facilitated transport and combine
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with intracellular phosphate by alkaline phosphatase to form hydroxyapatite, which is
deposited into the fresh osteoid collagen matrices135-137. Similar to osteoclasts, studies
have also measured the rate at which osteoblasts build bone 109; however, osteoblastic
bone formation rates do not appear to vary as much as those of osteoclasts109.
Osteogenesis is therefore presumably controlled by expansion and regression of the
osteoblast population rather than their bone-building activity.
Once osteoblasts have formed bone, they can either undergo apoptosis, further
differentiate into osteocytes, or remain as bone-lining cells103, 138. Osteoblasts which are
incorporated into the bone matrix eventually become osteocytes. Whereas the main role
of osteocytes is to form a dendritic network within the osteoid to monitor bone matrix
integrity, bone-lining cells cover the surface of bone and can regulate the flow of calcium
in and out of the mineralized bone109. Bone-lining cells can be distinguished by their
expression of ICAM-1, although studies have implicated plasticity of bone-lining cells to
revert to osteoblasts in times of bone remodeling139, 140.

1.2.3.3 Other immune components to the bone marrow niche
The concept of bone turnover has traditionally focused only on the coupled
interaction between osteoclasts and osteoblasts. However, the bone marrow
compartment is heterogeneous, and increasing evidence suggests the important
participation of other bone marrow cell types in controlling osteoblast and osteoclast bone
remodeling. For example, a recent discovery of a new bone-specific macrophage
population able to directly sense damaged or ageing bone tissue challenges the
traditional dogma assigning osteoclasts as the resident macrophages of the bone. Osteal
macrophages (osteomacs), also myeloid in nature, are distinguishable from osteoclasts
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based on F4/80 and TRAcP expression and cellular morphology141. Osteomacs originate
from the yolk sac (whereas osteoclasts can be differentiated from inflammatory myeloid
cells) and is frequently found adjacent to osteoblasts and osteoclasts residing on surface
of bone142-145. Osteomacs can efficiently detect tissue damage-associated inflammatory
factors, as well as phagocytose apoptotic cells and cellular debris through efferocytosis 141,
142, 144, 146.

These environmental signals drive osteomacs to polarize into various

inflammatory states to promote various downstream processes, including 1) stimulating
osteoblast bone anabolism, 2) secreting factors to recruit circulatory cells, and 3),
secreting cytokines to regulate osteoclast bone catabolism. In these regards, it is
conceivable that osteomacs play a central role mediating osteoclast and osteoblast bone
remodeling activity response to environmental stimuli.
Although the importance of immune cells such as T and B cells on bone remodeling
is relatively less studied, when activated, these cells are known to express inflammatory
factors that nonetheless have implications for modulating osteoblast and osteoclast
activity. Activated T lymphocytes secrete factors such as TNF, RANKL and IFNγ, and
these factors are known to enhance osteoclast resorption147-149. T cell secretion of IL-17
and WNTs can drive osteoblast bone formation as well150, 151. Interestingly, studies have
additionally shown that physical engagement of T cell with osteoblast precursor stromal
cells through cell surface markers can regulate differentiation and life span of
osteoblasts149. This physical interaction between T cells and MSCs enhances MSC
survival, and influences their subsequent parathyroid hormone (PTH) sensitivity as they
differentiate into osteoblasts149, 152. Osteoblasts derived from immune competent and T
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cell-deficient mice secrete different ratios of OPG/RANKL in response to PTH stimulation,
thereby affecting induction of osteoclast formation and bone resorption 152, 153.
The contribution of B cells to bone remodeling is relatively less known. Although
Pettit et al. have reported no difference in bone healing in the absence of B cells, B cells
have nonetheless been shown to directly contribute to the majority of the RANKL decoy
receptor, OPG, found in the bone marrow154,

155.

RANKL is an important stimulus for

osteoclast differentiation from precursor cells. In rheumatoid arthritis, B cell expression of
RANKL and OPG is associated with the degree of osteoclast-mediated bone erosion in
patients156. In multiple myeloma, malignant B cells are well-known to drive osteal
pathologies characterized by extensive osteolysis.

1.2.4 The vicious cycle in cancer bone metastasis
Once disseminated, tumor cells (DTCs) that arrive in the bone can become
dormant or generate active lesions. The mechanism governing dormancy and awakening
is just starting to be understood. Active lesions can emerge at varying timepoints post
primary treatment. Upon survival, establishment of osteal malignancies can pathologically
elevated bone resorption (osteolysis) or formation (osteogenesis). Although these
microenvironmental responses are crucial to the growth for the cancer, they are also
detrimental to the integrity and function of the bone and bone marrow. Cancers such as
multiple myeloma are regarded as almost exclusively osteolytic, whereby the induction of
bone destruction releases pro-cancer growth factors once sequestered in the bone
matrix12, 157-160. Other cancers, such as breast and prostate cancer induce bone diseases
consisting of mixtures of both pathologic osteolysis and osteogenesis. In osteogenic bone
lesions, differentiating and activated bone-forming osteoblasts are known to secrete
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factors to aid the growth of cancer cells. This parasitic relationship in which the cancer
perturbs skeletal remodeling to fuel its own growth is known as the “vicious cycle” and is
a sign that the cancer has successfully co-opted the bone marrow stroma36, 58, 161, 162. The
molecular regulatory mechanisms underlying the vicious cycle have been extensively
studied across different metastatic cancers and highlight a range of key factors and
pathways involved in the process, although our knowledge of the molecular and cellular
underpinnings continue to expand.

1.2.5 Existing bone-targeted therapies
Currently, there are no known curative treatments against cancer bone metastasis;
however, various treatments have been extensively used to provide palliative care by
targeting the vicious cycle and reducing cancer-induced bone pathology163,

164.

Bisphosphonates such as zoledronate and tiludronate are a class of anti-resorptive drugs
that bind to bone surfaces undergoing active remodeling and inhibit osteoclastic bone
resorption165, 166. Denosumab is an anti-RANK ligand antibody-based drug that inhibits
osteoclast formation and therefore bone resorption167, 168. Since osteoblast and osteoclast
activities are coupled, these osteoclast-targeted drugs also have knock-on effects on
bone formation. Other drugs such as endothelin A inhibitor, Atrasentan, directly target
osteoblasts to reduce bone formation169.
Some therapeutic approaches are aimed at the cancer itself in bone lesions.
Radium-223 dichloride is an alpha particle-emitting calcium mimetic which is deposited
into the bone at sites of active bone remodeling by osteoblasts actively forming new bone.
Its localized radiation induces cell death in osteoblastic bone lesions in prostate cancer
and osteosarcoma170-172. Bone-seeking matrix metalloproteinase inhibitors (BMMPIs), as
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their names suggest, can home to the bone and inhibit matrix metalloproteinase activity,
which generally promotes various hallmarks of cancer and metastasis173, 174.
Bone metastasis is a clinically significant problem, and we are still unraveling the
mechanisms that control cancer-bone interactions. In this chapter, the vast range of
genetic and molecular factors underlying normal bone remodeling and turnover are
discussed. Further identification and characterization of the specific ways in which
cancers hijack these complex mechanisms to yield essential growth factors and cytokines
are warranted and can aide in the discovery of more effective therapies.
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Chapter 2.

Host-derived matrix metalloproteinase-13 activity promotes multiple

myeloma-induced osteolysis and reduces overall survival
Note to reader: Portions of this chapter have been published in Lo and Shay et al. AACR
Cancer Research doi: 10.1158/0008-5472.CAN-20-2705 175, and have been permitted for
reproduction by AACR Copyright License (Appendix C).

2.1

Multiple myeloma and osteolytic bone disease
As reported in a recent census by the World Cancer Research Fund, multiple

myeloma affected more than 18 million people around the world in 2018176. In the United
States, multiple myeloma is the 14th common cancer, and the American Cancer Society
predicts more than 32,000 and 12,000 new diagnoses and deaths, respectively, in 2020
alone177, 178.
Multiple myeloma (MM) is an incurable mature plasma cells malignancy in the
bone marrow. Plasma cells, or mature B cells, produce antibodies as part of the innate
immune system, and each B cell produces clonal antibodies associated with specific
foreign antigens the body had once encountered. Upon exposure to a recurring foreign
pathogen, B cells awaken to rapidly expand and produce antibodies to mount an
immediate immune response specific to the antigen expressed by the pathogen. The
activation of quiescent B cells is tightly regulated as to prevent non-specific proliferation
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of clonal B cells that can predominate and strain the circulatory system, as is the case in
multiple myeloma.
Active myeloma is a B cell malignancy preceded by Monoclonal Gammopathy of
Undetermined Significance (MGUS) and Smoldering Myeloma (SM) stages, wherein the
patient’s B cells counts are elevated but not actively progressing. In active disease,
malignant clones disperse throughout a patient’s skeleton in circulation, each progressing
into a macroscopic bone lesion. As such, multiple myeloma releases great levels of
antibodies into systemic circulation while displacing normal bone marrow, leading to
characteristic symptoms such as renal failure, and anemia and leukopenia, respectively.
In addition to blood antibody levels, the state of hypercalcemia and the number of
osteolytic lesions in bone scans are also considered by the International Staging System
(ISS) and the Durie-Salmon Staging System when assessing patient’s disease stage and
severity179-181. These additional symptoms are associated with late stage disease as
multiple myeloma further induces pathologic osteolytic destruction of bone. Patients with
osteolytic multiple myeloma experience bone pain, susceptibility to pathologic fractures,
and spinal cord compression158. Interaction with the bone stroma can protect multiple
myeloma cells from applied therapies, and resorption of bone matrix generates growth
factors that further drive the progression of the disease182.

2.2

Multiple myeloma standard of care
Chemotherapies such as melphalan, bortezomib and carfilzomib are standard

treatments for multiple myeloma patients to target active disease

183 178, 184-187.

Although

patients may initially respond well to these therapies, the majority eventually relapse with
refractory disease and require subsequent treatment with inhibitors such as proteasome
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inhibitors (PI) and immunomodulatory drugs (IMIDs) until they exhaust available
options188-190.
Multiple myeloma patients are additionally treated with bisphosphonates, such as
zoledronate and tiludronate, which suppress osteoclast activity. Other anti-resorptive
agents, including denosumab, a receptor activator of nuclear kappa B ligand (RANKL)
inhibitor, which effectively reduce osteoclast formation and/or activity. These inhibitors
primarily protect against skeletal-related disease191. Patients are still faced with an
approximately 53% 5-year overall survival, which further breaks down to 74% and 52%
for localized and systemic disease, respectively177,

178.

Despite the advent of new

therapies, multiple myeloma remains fatal and there is an urgent need to enhance our
understanding of the disease so that new therapies can be developed.
Defining the molecular mechanisms underlying tumor-bone interactions can yield
novel therapeutic targets, for example, the anti-RANKL inhibitor Denosumab. Matrix
metalloproteinases have been shown as potent regulators of host-tumor interactions by
regulating the bioavailability and bioactivity of many non-matrix molecules, such as
cytokines and growth factors.

2.3

What is MMP-13—its role in Multiple Myeloma
Osteoclasts are the primary cells involved in mineralized bone matrix resorption.

Over 90% of bone is comprised of mineralized type I collagen and therefore enzymes
with collagenolytic activity are crucial for appropriate bone remodeling. Cathepsin K is an
acidophilic collagenase suited to working in the low pH of the osteoclast lacunae192-194.
However, collagenolytic MMPs, namely MMP-1, -2, -8, -13 and membrane-bound MMP14, -15 are expressed in bone and ablation of these MMPs in mice has demonstrated
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skeletal phenotypes in particular for MMP-1494,

195-201.

These phenotypes can be

attributed to extracellular matrix (ECM) turnover and the processing of non-matrix
molecules such as growth factors and cytokines. Counterintuitively, MSCs and
osteoblasts express the majority of these MMPs compared to osteoclasts 195, 202-204. In
multiple myeloma, myeloma cells express a range of MMPs which aid in its progression,
such as by increasing myeloma growth, bone destruction and tissue invasion76, 205-207.
Here, our analyses of human multiple myeloma biopsies for MMP-13 expression
demonstrate the presence of the protease in bone-lining osteoblasts and MSCs. This is
consistent with studies reporting that MMP-13 is widely expressed in the skeleton by cells
of mesenchymal stromal cell (MSC) lineage, including chondrocytes, osteoblasts and
osteocytes73, 208, 209. Additionally, MMP-13 appears not to be expressed by osteoclasts
although reports have localized MMP-13 in peri-osteoclast cells and in the cement lines
of the bone matrix208, 210.
Matrix metalloproteinase 13 (MMP-13) is a collagenase that can cleave types I, II
and III collagens. Expressed as a latent peptide, MMP-13 is activated once the N-terminal
signal peptide and pro-peptide domains are proteolytically removed195. The active
enzyme consists of Zn-dependent catalytic domain tethered, via a hinge region, to a
hemopexin domain which recognizes substrates (Figure 2-1). MMP-13 is expressed
predominantly by chondrocyte, osteoblasts and perivascular tissue in the skeleton.
Remodeling of bone extracellular matrix both during development and wounding are its
main physiological roles, but MMP-13 is also overexpressed in various cancers195, 211, 212.
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Figure 2-1. MMP-13 Protein Structure. Signal peptide and pro domain are removed to
activate MMP-13.

Specifically, in the context of bone remodeling, delayed endochondral ossification,
cartilage growth plate and other osteal abnormalities during development are consistent
characteristics across various MMP-13 knockout mouse models94, 95, 213. Studies have
also demonstrated MMP-13 is highly upregulated in several cancers73, 214-217. Our group
has specifically demonstrated MMP-13 overexpression at the tumor-bone interface in
breast cancer (Table 2-1.)218. Given MMP-13’s strong bone phenotype and presence in
cancer, we have posited that host-derived MMP-13 might contribute to multiple myeloma
bone metastasis.

Table 2-1. MMP Expression at Tumor-Bone Interface. Our unpublished data listing top 5
most overexpressed MMPs in bone metastatic breast cancer. Data generated through
analysis of laser capture dissection microarray of human patient biopsies.
% Increase at Tumor-Bone
MMP
Interface/ Tumor Area Alone
MMP-13
3403%
MMP-7
1311%
MMP-3
366%
MMP-9
326%
MMP-2
320%
To date, no studies have examined the contribution of host-derived MMP-13 on
multiple myeloma progression. This is in large part due to the paucity of myeloma models
that allow for the ablation of host-derived genes of interest. The spontaneously arising
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murine myeloma cell line 5TGM1 is syngeneic to the KaLwRiJ sub-strain of C57BL/6. The
cells do grow in C57BL/6 mice, and we have previously reported that 5TGM1 engraftment
in C57BL/6 recombinase activating gene-2 (RAG-2)-null mice is feasible92,

219.

We

therefore crossed C57BL/6 MMP-13-null mice with RAG-2-null mice to address the
contribution of host-derived MMP-13 to the progression of MM. Our findings show that
ablation of MMP-13 in the host compartment significantly improved overall survival of
myeloma-bearing mice as a result of decreased bone resorption. Surprisingly, this was
not due a deficiency in type I collagen turnover but rather differences in the bioavailability
of factors, namely CXCL7, that promote osteoclast precursor recruitment and formation.
To determine the translatability of MMP-13 inhibition as a therapeutic approach, we also
tested and demonstrated the efficacy of a highly selective MMP-13 inhibitor using an
immunocompetent in vivo model. Taken together, our data identify, for the first time, a
causal role for host-derived MMP-13 activity in driving the progression of multiple
myeloma.

2.4

Materials and Methods

2.4.1 Human patient specimens, MMP-13-null mice, multiple myeloma cell lines,
and MMP-13 inhibitors.
Deidentified human patient specimens were collected through Moffitt Cancer
Center’s Institutional Review Board-approved Total Cancer Care protocol (MCC14690).
All patients involved in this study provided written informed consent in accordance with
recognized ethical guidelines as detailed in the Belmont Report. Animal experiments were
performed under the University of South Florida-approved Institutional Animal Care and
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Use Committee (IACUC) protocol, IS0000309, IS0003489 and IS0005900. RAG-2/MMP13 double-null mice were generated by crossing RAG-2-null mice with MMP-13-null mice,
on

a

C57BL/6

background.

Luciferase-labeled

myeloma

cells,

5TGM1-Luc

(RRID:CVCL_VI66) and U266-Luc (RRID:CVCL_0566) were obtained from University of
Texas, Health Science Center at San Antonio, TX (2012)
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and University of Virginia,

VA (2014), respectively. MM1.S were obtained in 2015 from ATCC (Cat#: CRL-2974;
RRID:CVCL_8792) and OPM2 was obtained in 2015 from Dr. Kenneth Shain (Moffitt
Cancer Center; RRID:CVCL_1625). Cells were cultured in RPMI containing 10% FBS,
1% penicillin and streptomycin, used within 30 passages. Cells have recently tested
negative for mycoplasma by PCR in July 2020 (Bulldog Bio, Cat #: 25233), and were
additionally authenticated against ATCC, DSMZ or ExPASy STR profiles. Compound 1
((S)-17b in reference 220), Compound 2 ((S)-17c in reference 220) and Compound 4 (52
in reference 221) were synthesized as described in the respective references 221, 222. For
the majority of the studies, unless otherwise explicitly stated, we used Compound 1 as
the MMP-13 inhibitor and denoted it as MMP-13i.

2.4.2 Bioinformatics analysis of NCBI GEO and MMRF human datasets
NCBI dataset GSE47552 consists of RNA sequencing data from CD138+ cells
isolated from healthy donors and MGUS, SMM and MM patients (n=99). MMP-1, MMP-8
and MMP-13 expressions was extracted and analyzed using the web built-in GEO2R
software per NCBI instructions. NCBI dataset GSE46053 consists of transcriptomic
sequencing data from healthy donor- and myeloma patient-derived MSCs which were or
were not conditioned using human myeloma (MM1.S) conditioned media (n=37).
Myeloma-induced MMP-1, MMP-8 and MMP-13 expressions were extracted and
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analyzed using the web built-in GEO2R software per NCBI instructions. Multiple Myeloma
Research Foundation (MMRF) IA14 is a record repository for the CoMMpass study, which
tracks genomic status throughout myeloma disease progression in newly-diagnosed
treatment-naïve patients. Analyses of 770 enrolled individuals with RNA sequencing data
paired with their longitudinal clinical data was performed using built-in analytical tools
online to compare gene expression with progression free survival and overall survival.

2.4.3 Immunohistochemical (IHC) and immunofluorescence (IF) staining
Non-sequential FFPE, rehydrated tissue sections were rinsed with 1XTBST.
Endogenous peroxidases were quenched using methanol peroxide. Antigen retrieval was
performed using proteinase K (20μg/ml) at 25°C for 10 minutes. 4% paraformaldehydefixed in vitro chamber slides proceeded directly with the following. Cells and tissues were
blocked at 25°C for one hour, and incubated overnight at 4°C in primary antibody diluted
in blocking reagent: α-human/mouse MMP-13 at 1:200 (Triple Point Biologics, Cat#: RP1MMP-13), α-human CD138 at 1:200 (BD Pharmingen, Cat#: 553712; RRID:AB_394998),
and α-mouse IgG2b (Bethyl Laboratories, Cat#: A90-109A; RRID:AB_67157 at 1:200 and
A90-109P; RRID:AB_67160 at 1:1000 for immunofluorescence and western blot,
respectively). Isotype controls were used to assess antibody specificity. Sections were
then washed in 1XTBST, and incubated either with species-specific biotinylated or
fluorescently-labeled (Invitrogen) secondary antibodies at 1:1000 in blocking buffer for 1
hour at 25°C for IHC and IF staining, respectively. For IHC, biotinylated targets were
visualized after 1XTBST washes using an avidin-biotin peroxidase complex and DAB.
Sections were counterstained with hematoxylin, dehydrated and mounted for brightfield
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microscopy. For IF studies, stained slides were counterstained with DAPI and aqueously
mounted for wide-field fluorescence microscopy.

2.4.4 Mesenchymal stromal cell and osteoclast precursor isolation and
differentiation.
Mesenchymal stromal cells (MSC) were isolated from both male and female bone
marrow flushes and fragmented bone chips harvested from neonatal RAG-2-null/ wildtype and MMP-13-null mice223,

224.

Tissues were digested in MSC medium (α-MEM

containing 15% FBS) and 1mg/mL collagenase for 1 hour at 37°C with shaking at 150rpm
and were cultured in MSC medium for 3 days. Adherent populations were enriched by
carefully removing non-adherent cells over time. MSCs were validated in osteogenic
assays and expanded for further analysis.
Murine femoral and tibial bone marrow were plated in 10cm petri dishes in 10mL
α-MEM medium containing 10% FBS to generate primary osteoclasts in vitro. Nonadherent population was re-plated in fresh dishes with media containing 25 ng/ml of MCSF (Peprotech, Cat#: 315-02-10) to enrich for myeloid osteoclast precursor population.
Myeloid progenitors were subsequently plated at 2-3x105 /well in 48- or 96-well cell culture
plates and treated every 48 hours with osteoclastogenic medium: α-MEM containing 10%
FBS, 25ng/ml M-CSF, and 100ng/ml RANKL (Peprotech, Cat#: 315-11-10) for 4 to 7
days. For treatment studies, MMP-13i (Compound 1) was added to osteoclastogenic
media (10nM-10μM) to assess its effect on differentiation. For MSC conditioned media
studies on osteoclast formation, control and CXCL7-immunoprecipitated MSC
conditioned media (24-hours in α-MEM with 15% FBS) was collected from wild-type and
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MMP-13-null MSCs and used at 1:1 ratio with regular osteoclast media supplemented
with RANKL but without MCSF. For treatment studies with recombinant CXCL7 protein,
precursor cells were periodically fed with differentiation media containing full-length or
MMP-13-processed recombinant CXCL7 (Beta Lifesciences, Cat#: BL-0262PS) for up to
5 days. Differentiated cultures were fixed in 4% paraformaldehyde and stored at 4°C in
1XPBS.

2.4.5 In vitro osteoclast tartrate-resistant acid phosphatase (TRAcP) staining,
resorption assay and osteoblast differentiation and alizarin red staining
TRAcP was performed on fixed in vitro differentiated osteoclasts co-cultures to
detect multinucleated osteoclasts using Histostain-TRAcP Kit per manufacturer’s
instructions (Invitrogen, Cat#: 85-0199). For in vitro resorption assays, bone marrow
myeloid precursor cells were seeded at 6x104 cells per 24-well in Osteo-Assay Surface
plates (Corning, Cat#: 3988XX1) and cultured as above. Cells were further cultured for
three days following osteoclasts formation to permit resorption. Osteoclasts numbers and
resorptions were detected per manufacturer’s instructions thereafter.
MMP-13 immunofluorescence in bone marrow stromal cells and osteoclast
cultures was performed. After differentiation, cells were fixed in ice-cold methanol for 7
minutes, washed in 1XPBS prior to blocking for 30 minutes at 25°C using 3% milk in
1XPBS. The cells were then washed with 1XPBS, and incubated with primary antibody
(α-mouse MMP-13, 1:250 dilution in blocking solution; Triple Point Biologics, Cat#: RP1MMP-13) for 1 hour at 25°C. 1XPBS-washed cells were incubated with secondary
antibody (Alexa-fluor 488 α-mouse conjugated antibody diluted 1:1000 in blocking
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solution; Invitrogen, Cat#: A32723; RRID:AB_2633275) for 30 minutes at 25°C. Cells
were washed again with 1XPBS and mounted in aqueous mounting media containing
phalloidin-488 to visualize actin (1:5000; Invitrogen, Cat#: A12379) and viewed via widefield fluorescence microscopy.

2.4.6 Real time PCR (RT-PCR), Immunoprecipitation, western blot, and cytokine
array
Total RNA was extracted from cells with TRIzol (Invitrogen) as per manufacturer’s
instructions. For MMP-13 and Cytokine RNA expression, cDNA was generated by a
standard reverse transcription reaction, and RT-PCR mixtures were generated using
SYBR Green reagent (Applied Biosystems, Cat#: 4309155) and reactions were
performed and quantified using ABI-7900HT instrument and SDS 2.3 software under
manufacturer’s instructions (Applied Biosystems; RRID:SCR_018060; Table 2-2).
Table 2-2. Primer Sequences for qRT-PCR Analysis. List of genes and forward/reverse
primer sequences used to interrogate their expression in both human and murine samples.
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Standard cell lysis protocols were used to isolate total proteins from cell cultures.
For immunoprecipitation experiments, wild-type and MMP-13-null MSCs were washed
with 1XPBS and serum-starved in α-MEM for 1 hour at 37°C prior to incubation with fresh
α-MEM for 24 hours to generate conditioned media. Conditioned media were pre-cleared
with rProtein G with hour-long rocking at 4°C and subject to washes and
immunoprecipitation using additional rProtein G (15µL/sample; Invitrogen) and α-mouse
CXCL7 antibody at 1µg/0.5mg total protein constituted in 1XPBS to 1mL final volumes
(abcam, Cat#: 231102; RRID:AB_949345). Immunoprecipitation was performed at 4°C
overnight on rocker and the resulting media was sterilized using sterile filter and
centrifugation for use either in in vitro cultures or protein blotting. Refer to Supplementary
Materials and Methods for isolation of bone marrow supernatant.
For immunoblotting, 25 μg of total protein was electrophoresed and transferred to
nitrocellulose. Of note, to blot for less abundant proteins, conditioned media samples
were concentrated using Vivaspin-6 3000 MWCO spin filters per manufacturer
recommendations (Sartorius, Cat#: VS0691). Transferred blots were blocked for 1 hour
at 25°C (1XTBST containing 5% non-fat dairy milk) prior to overnight incubation in primary
antibodies: α-mouse MMP-13 at 1:1000 (Triple Point Biologics, Cat#: RP1-MMP-13), and
α-mouse CCL-2 (Thermofisher Scientific; Cat#: MA5-17040; RRID:AB_2538512), αmouse CXCL7 (R&D Systems, Cat#: AF793; RRID:AB_355606), and α-mouse β-Actin at
(Cell Signaling, Cat#: 3400S) all at 1:1000. Of note, α-mouse CXCL7 antibody binds to
Lys40-Tyr113 and detects active protein. The next day, blots were washed extensively
prior to detection with HRP-labeled secondary antibody and ECL using Odyssey Fc
Imaging System (LI-COR; RRID:SCR_013430 and RRID:SCR_013715). ELISA was
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used for the quantification of ICTP (AVIVA Systems Biology, Cat#: OKEH00680) and
CXCL7 (RayBiotech, Cat#: ELM-TCK1-5) in ex vivo isolated specimens and culture
media per manufacturer instructions.
For cytokine array analysis, 18-hour conditioned media from wild-type or MMP-13null MSCs treated with vehicle or MMP-13i were collected in phenol-free α-MEM after
hour-long serum starvation. Cytokine blotting using C2000 Cytokine Array Kit was
performed with conditioned media per kit instructions (RayBiotech, Cat#: AAM-CYT2000-4; RRID:AB_1547202) and detected using Odyssey Fc Imaging System (LI-COR;
RRID:SCR_013430 and RRID:SCR_013715).

2.4.7 Isolating Bone Marrow Serum
For bone marrow flushes and supernatant isolation, bone marrow was collected
by centrifugation and resuspended in 1XPBS. Resuspended marrow was further
decellularized by additional centrifugation at 3,500rpm for 5mins. Resulting serumcontaining supernatant was incubated in recombinant MMP-13 overnight at 37°C before
BCA and western blot analyses (Millipore Sigma, Cat#: 444287).

2.4.8 In vitro CXCL7 proteolytic processing and proteomic studies
To determine direct MMP-13 processing of full length CXCL7 protein, recombinant
mouse (Sino Biological, Cat#: 50145-M07E) and human full-length CXCL7 peptides (Beta
Lifesciences Cat#: BL-0262PS) were incubated with or without recombinant active MMP13 enzyme (Millipore Sigma, Cat#: 444287) at 5 and 1ng/μL, respectively, in 25mM Tris
buffer at pH 8.0, including 2.5μM ZnCl2 and Brij at 0.005%. Mixtures were incubated
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overnight at 37oC. Products were either resolved by western blot analysis for CXCL7 on
18% PAGE gels using α-human (abcam, Cat#: ab206996) or mouse CXCL7 antibodies
(R&D Systems, Cat#: AF793), or subject to mass spectrometry analysis. Both the human
and mouse antibodies detect active CXCL7 peptide. For proteomic analyses, MMP-13
generated CXCL7 products were cleaned using detergent removal kit (ThermoFisher,
Cat#:88305), followed by digestion with Lys-C (Promega, Cat#: VA1170) and
Chymotrypsin (Promega, Cat#: V106A) to derive truncated peptides for liquid
chromatography – tandem mass spectrometry (LC-MS/MS) at the Moffitt Proteomics and
Metabolomics Core using the Q-Exactive HF-X with a Dionex RSLCnano (ThermoFisher).

2.4.9 In vivo 5TGM1 myeloma studies
For genetic ablation studies, 5TGM1-Luc cells (1x106 in 100uL 1XPBS) were tail
vein injected into age-matched 6-week old mice that were RAG-2-null or RAG-2-MMP-13
double null (n=20). Multiple myeloma affects men and women equally; therefore, all in
vivo studies included male and female mice to remove potential sex disparity as a
confounding factor in our observations and analyses. Tumor burden was monitored using
bioluminescence imaging with IVIS system. Quantitation was performed by secondary
research personnel on de-identified and randomized data in a blinded fashion using the
Living Image software (Perkin Elmer; RRID:SCR_018621). Murine whole blood was
collected weekly by submandibular phlebotomy and serum levels of IgG2b determined by
ELISA analysis according to manufacturer’s instructions, also in randomized and blinded
methods (Bethyl Laboratories, Cat#: A90-109P; RRID:AB_67160 and starter kit Cat#:
E101). Mice were euthanized upon reaching the clinical endpoint (hind limb paralysis
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and/or >10% reduction in body weight). Tumor-bearing tibias were excised and fixed in
10% buffered formalin overnight for further histological analyses.
For pharmacological ablation studies with MMP-13i (Compound 1), age-matched
6-week old immunocompetent KaLwRiJ mice (n=30) were inoculated with 5TGM1-Luc by
tail vein route (1x106 in 100uL 1XPBS). Both male and female mice were included to
account for potential sex disparity as confounding factor. Tumors were allowed 7 days to
seed prior to randomization into treatment groups and initiation of daily intraperitoneal
injections using vehicle (1XPBS containing 10% DMSO and 10% Tween-80) or MMP-13i
at 20mg/Kg body weight (diluted at 5mg/mL in vehicle). Tumor burden was monitored
using bioluminescence imaging and quantitated with IVIS Living Image software in
blinded methods as described (Perkin Elmer; RRID:SCR_018621). Mice were weighed
and monitored for toxicity and well-being daily and euthanized upon reaching the clinical
endpoint of hindlimb paralysis. Tumor-bearing tibias were excised and fixed for further
histological analyses. All in vivo studies were independently repeated.
2.4.10 High-resolution μCT, histology and histomorphometry
Long-bones were scanned at 6μm increments across 1000μm thickness in the
metaphysis 500μm from the growth plate using μ35 instrument for high-resolution μCT
analysis (Scanco; RRID:SCR_017119). Tabecular bone volume to total volume ratio
(BV:TV) was determined from reconstructed images using manufacturer’s software
(Scanco; RRID:SCR_017119). Following reconstruction, 3D models of woven bone was
built and analyzed by blinded researcher using consistent thresholding on de-identified
bone scans data to assess bone quality. For histomorphometry, bones were subsequently
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decalcified (changes of 14% EDTA pH 7.4 every two days for 3 weeks) and nonsequential FFPE tissue sections were stained with H&E. ImageJ (RRID:SCR_003070)
was used for trabecular bone measurements, with the area of analysis beginning 500μm
from the growth plate, and extending for 1000μm towards the diaphysis. Osteoclast
TRAcP staining was performed to as described previously (Invitrogen, Cat#: 85-0199) on
FFPE sections, and the osteoclasts data was manually calculated from multiple 20X fields
of view using brightfield microscopy.

2.4.11 Statistical Analysis
Quantified data are represented as mean with SEM when applicable. Statistical
analyses were performed by the Moffitt Biostatistics Core when scaling in vivo studies to
ensure robustness, power and detectable hazard ratios given 5% type I error by a twosided log-rank test. For statistical analyses of any two treatment groups, Student t test
was applied. For statistical analyses of three groups or more, One-way analysis of
variance (ANOVA) was performed. Differences were considered significant if p<0.05 and
noted with asterisks (n.s. represents insignificance).

2.5

Results

2.5.1 MMP-13 expression in human multiple myeloma
MMP-13 is highly expressed in the cancer-bone microenvironment88, 215, 226. Using
publicly available datasets, we initially examined MMP-13 expression levels in isolated
CD138+ bone marrow plasma cells derived from healthy control individuals and patients
with varying stages of multiple myeloma (n=99; GSE:47552). Analyses suggest that,
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although MMP-13 was detected, there does not appear to be a difference at the mRNA
level between control and patients diagnosed with monoclonal gammopathy of
undetermined

significance

(MGUS),

smoldering

multiple

myeloma

(SMM),

or

symptomatic multiple myeloma (MM) (Fig. 2-2a). Interestingly, analysis of a separate
dataset from the Multiple Myeloma Research Foundation (MMRF) CoMMpass cohort
showed that in CD138+ myeloma cells, 56% of patients (433 of 770) expressed no MMP13. Of the patients that did express MMP-13, albeit at very low levels, MMP-13 derived
from myeloma cells did not correlate with progression free survival but did correlate with
overall survival (MMRF data repository, IA14, Fig. 2-3).

Figure 2-2. MMP-13 is highly abundant in bone-lining mesenchymal stroll cells (MSC) in
human multiple myeloma (MM). (a) MMP-13 status in CD138+ cells do not correlate with
multiple myeloma disease staging. Publicly available GEO dataset of CD138+ cells
across progressive myeloma in human patients were analyzed for MMP-13 expression
(GSE:47552; n=99 patients). “Control” denote healthy donor B cells; monoclonal
gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma
(SMM) represent progressive stages of multiple myeloma (MM). (b) MMP-13 is overexpressed by human MSC when exposed to multiple myeloma conditioned media.
Publicly-available GEO transcriptomic dataset of human MSC treated with conditioned
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media from MM1.S human myeloma was analyzed (GSE:46053; n=37 samples;
***p<0.0005). (c) MMP-13 is highly expressed in human multiple myeloma biopsies.
Human multiple myeloma bone biopsies were immunohistochemically stained for MMP13 and showed signal in marrow stroma and bone cement lines (n=30; 2 representative
samples shown). (d) MMP-13 is highly expressed by bone-lining cuboidal osteoblasts at
tumor-bone interface. Multiple myeloma patient bone marrow biopsies were
immunofluorescently stained for MMP-13 (red) against CD138 (B-cell/ myeloma marker
in green) and nuclear DAPI (blue) to derive source compartment of MMP-13 expression
(n=30; 3 representative samples shown). Magnified images show strongest signals in
CD138- bone lining cells.

Figure 2-3. Human myeloma-derived MMP-13 expression correlates with poor overall
survival. Transcriptomic data containing MMP-13 expression in CD138+ cells was used
to stratify patient data into MMP-13-expressing (MMP-13High; n=433) and MMP-13-null
(MMP-13Low; n=337) groups in the Multiple Myeloma Research Foundation (MMRF)
dataset (IA14). Longitudinal data for a minimum of 5 years since the time of diagnoses
for patients was plotted as Kaplan Meier curves for progression-free survival (a) and
overall survival (b). Plots indicate MMP-13 is not correlated with disease progression but
is with survival.
We performed similar analyses on other collagenases (MMP-1 and MMP-8). MMP1 expression is significantly increased in active disease while no differences were
apparent for MMP-8 (Fig. 2-4a and b). As MMP-1 is normally found during development
and in sex organs, we do not dispute its possible contribution to myeloma neogenesis 227.
Cancer-derived stimuli including interleukins and PTHrP are known to induce MMP-13
expression in bone stroma69,

209, 226, 228.

In keeping with this observation, incubating

human multiple myeloma cells (MM.1S) with primary bone marrow-derived mesenchymal
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stromal cells (MSC) identified that MMP-13 expression and that of MMP-1 and MMP-8
was significantly enhanced in the MSCs upon exposure to myeloma conditioned media
(Fig. 2-2b and Fig.2-4c and d; GSE:46053, n=37)73,

229.

Of these MMPs, MMP-13

expression is largely confined to the skeletal tissues making it an attractive therapeutic
target as opposed to systemically expressed MMPs. We therefore next examined the
cellular sources of MMP-13 protein in human multiple myeloma biopsies (Fig. 2-2c) and
consistently observed positivity in the stromal compartment, specifically cuboidal bonelining cells compared to CD138 stained myeloma cells (3 representatives shown, Fig. 22d). Interestingly, and in keeping with previous reports125, 208, 230, we detected MMP-13
positivity in the bone matrix itself within bone cement lines (Fig. 2-2c and d).

Figure 2-4. Expression of other type I collagenases in human multiple myeloma and
myeloma-stimulated MSC. (a and c) analyses of publicly available GEO datasets
showing expression of other type I collagenases, MMP-1 and MMP-8, in progressive
myeloma staging in patients (GSE:47552; n=99 patients). “Control” denote healthy donor
B cells; monoclonal gammopathy of undetermined significance (MGUS) and smoldering
multiple myeloma (SMM) represent progressive stages of multiple myeloma (MM). Oneway ANOVA statistical test was performed to compare each myeloma stage group to
control group; asterisks denote statistical significance: *p<0.05, **p<0.005 ***p<0.0005.
(b and d) MMP-1 and MMP-8 are also over-expressed in MSC when exposed to MM.
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Student t-test was performed on GEO dataset of human MSC treated with conditioned
media from MM.1S human myeloma (GSE:46053).
2.5.2 Murine MMP-13 expression in the multiple myeloma-bone
microenvironment.
Given the high level of expression of MMP-13 by bone-lining cells in human
specimens of multiple myeloma and its potential role in the processing of type I collagen,
we hypothesized that MMP-13 could contribute to the progression of the disease.
Addressing the contribution of stromal genes in multiple myeloma has been challenging
but we circumvented this issue by generating RAG-2/MMP-13 double null animals that
are receptive to engraftment with the murine multiple myeloma cell line 5TGM1219.
Immunohistochemical analysis of wild type (WT) and MMP-13-null (MMP-13-/-) tissues
revealed that MMP-13 staining was largely confined to bone-lining cells and the cement
lines of the bone matrix, whereas, as expected, MMP-13 expression was not detected in
MMP-13-null animals (Fig. 2-5a)94. RT-PCR and immunofluorescence for MMP-13
demonstrate its presence in MSCs but not in osteoclasts of wild type bone marrowderived primary cultures (Fig. 2-5b and c). RT-PCR further reveal high MMP-13
expression variability across myeloma cell lines (Fig. 2-6). We also observed that 5TGM1
myeloma conditioned media (RPMI) significantly increased MMP-13 mRNA expression
in wild type MSCs compared to RPMI media control (Fig. 2-5d).
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Figure 2-5. MMP-13 is expressed in murine bone-lining stroma and wild-type MSCs but
absent in osteoclasts. (a) MMP-13 is expressed by bone-lining cells in wild type mice but
absent in MMP-13-null animals. RAG-2-null (WT) and RAG2/MMP-13-null (MMP-13-/-)
mice bones were harvested and processed for MMP-13 immunohistochemical (brown)
against hematoxylin staining. (b) MMP-13 expression in myeloma and WT MSC and bone
marrow co-cultures is evaluated by PCR. Murine and human MMP-13 expression was
detected in RNA isolated from multiple myeloma cell lines (5TGM1 and U266,
respectively) and various cell types found in the bone marrow of mice by PCR (BM= whole
bone marrow; OCL= osteoclast co-culture). BM and OCL cultures from MMP-13-/- mice
and de-ionized water were used as negative controls. (c) MMP-13 is not detectable in
OCL but is present in WT MSC. OCL were cultured from BM flushes using recombinant
M-CSF and rank ligand for 7 days, and MSC were isolated from collagenase-treated
murine bone chips. OCL and MSC cultures were stained by immunofluorescence for
MMP-13 (red) and actin (green) at 20X and 40X, respectively, using fluorescent
microscopy. (d) multiple myeloma stimulates murine MMP-13 expression in WT MSC.
5TGM1 murine multiple myeloma cells were cultured in serum-containing α-MEM for 24
hours to derive multiple myeloma conditioned media. RNA was isolated from WT and
MMP-13-/- MSC treated for 6 hours with multiple myeloma conditioned media. cDNA was
generated from RNA samples for quantitative PCR of MMP-13 mRNA expression (n=3
experiments done in triplicates). One-way ANOVA Tukey test was performed for each
group against wild type control group (**p<0.005 and ***p<0.00005).
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Figure 2-6. Myeloma vary in MMP-13 expression. RT-PCR performed for human and
murine MMP-13 expression in panel of human and murine myeloma cell lines. U266-PSR
and RPMI-8226-PSR are bortezomib-resistant clones of U266 and RPMI-8226,
respectively (n=3/group). Expression data was normalized to 5TGM1 levels.
2.5.3 Host-derived MMP-13 impacts multiple myeloma overall survival
Given the robust expression of MMP-13 in the bone stroma, we next determined
whether host-derived MMP-13 contributes to myeloma progression in vivo. In three
independent studies, wild type or MMP-13-null animals (n=10/group) were inoculated with
luciferase-expressing 5TGM1 cells. Tumor burden was monitored on a weekly basis by
bioluminescence imaging. Log-scale analysis showed no difference between the groups
regarding tumor growth rate (Fig. 2-7a and b). Measurement of weekly serum IgG2b
concentrations confirmed bioluminescence data (Fig. 2-7c). Since we are interrogating
myeloma-induced bone disease, the clinically-relevant survival endpoint for the 5TGM1
model is hind limb paralysis. Surprisingly, despite no apparent difference in tumor growth
rates, overall survival in the MMP-13-null multiple myeloma-bearing mice was significantly
higher than that of the wild type group with median survival times of 43 and 39 days,
respectively (p=0.0011; Fig. 2-7d). Of note, for the 5TGM1 model, this increase in overall
survival is in keeping with reports for approved myeloma therapies such as melphalan,
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bortezomib and bisphosphonates183, 231. Immunohistochemical analysis for IgG2b in ex
vivo myeloma-bearing bone tissue confirmed that the amount of multiple myeloma burden
in the wild type and MMP-13-null groups was similar (Fig. 2-7e).

Figure 2-7. Host genetic MMP-13 ablation impedes myeloma-induced osteolysis and
improves overall survival in vivo but does not impact tumor growth over time. (a) 5TGM1
multiple myeloma colonizes skeleton of RAG2-null (WT) and RAG2/MMP-13-null (MMP13-/-) mice. Mice (n=20) were inoculated with luciferase-tagged 5TGM1 (106 cells/mouse)
by tail-vein route to establish skeletal lesions. Mice were imaged once a week for
bioluminescence. Representative images of tumor burden measurements 28 days after
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inoculation. Images show multiple myeloma detected in lower limbs, spine and lower jaw.
(b) bioluminescence quantitation over time shows no difference between WT and MMP13-/- group. (c) 5TGM1 cells secrete IgG2b antibodies, which was used as a surrogate
tumor burden indicator. Serum IgG2b was measured by ELISA over time and
corroborated bioluminescence data. (d) MMP-13-null mice show improved overall
survival. Mice were euthanized upon presentation of hindlimb paralysis. Results were
summarized in a Kaplan-Meier plot and statistically analyzed using log-rank test, showing
MMP-13-/- mice experience significantly-delayed progression to clinical endpoint (median
survival at 39 versus 43 days for WT and MMP-13-/-, respectively). (e) mice carried similar
bone marrow tumor burden at study endpoint. Tibias were harvested from mice
euthanized at endpoint for ex vivo analyses. Sections were stained for IgG2b by
immunohistochemistry and showed extensive myeloma tumor burden across groups.
Stained sections were quantified by area of IgG2b per total area of section (n=20). (f)
tibias were harvested from 12-week old tumor-naive WT and MMP-13-/- mice for microcomputed tomography (μCT) scanning and quantitation to assess baseline bone status
(BV:TV) Bones were scanned for 1000μm in the mid shaft at 6μm increments and
contoured to highlight the bone marrow space (n=20). (g) tibia from MM-bearing WT and
MMP-13-/- mice were also collected at endpoint for same scanning and quantitation. Bone
status from tumor-bearing tibias was normalized to tumor-naive data as BV:TV Ratio. (hk) other metrics of bone integrity was also revealed through μCT and suggest MMP-13-/is involved in MM-induced bone pathology.
2.5.4 MMP-13 contributes to multiple myeloma induced bone loss
MMP-13-null mice have previously been shown to have hypertrophic growth plates
and delays in endochondral ossification during skeletal development 94, 195. Adult mice
have increased trabecular bone volume that persists into adulthood94, 95, 232. Using high
resolution μCT, we confirmed this increased trabecular bone volume: total volume (Naïve
BV:TV) in age-matched (12-week old) tumor-naïve MMP-13-null mice compared to wild
type controls (Fig. 2-7f). The age of the mice was chosen to correspond with the
approximate age at which the multiple myeloma-bearing mice reached their clinical
endpoint. To determine multiple myeloma BV:TV differences between the groups, we
used the ratios obtained from tumor-naïve mice as a means of normalization (Tumor
BV:TV). Despite having an initially higher BV:TV ratio, we observed that bone loss was
significantly reduced in the MMP-13-null mice compared to their wild type counterparts

40

(Fig. 2-7g). We also noted that trabecular bone (Tr.) parameters such as spacing,
patterning factor, thickness and number were significantly different in MMP-13-null
myeloma-bearing animals compared to wild type, results that are consistent with reduced
bone loss in the MMP-13-null multiple myeloma-bearing animals (Fig. 2-7h-k). Analysis
of BV:TV in non-sequential sections from tumor-bearing tibia confirmed μCT results (Fig.
2-8a and b). To identify the potential causes for reduced bone volume in the MMP-13-null
mice, we initially examined type I collagen fragment levels given the ability of MMP-13 to
process this substrate. MMP processing of type I collagen into cross-linked
carboxyterminal telopeptide of type I collagen (ICTP) is distinguishable from cathepsin K
activity which generates N- and C-terminal peptides (NTX, CTX)82, 202, 233, 234. Using an
ICTP specific ELISA, we observed no differences between wild type versus MMP-13-null
bone marrow supernatants derived from multiple myeloma-bearing animals (Fig. 2-9).
Because of their role in mediating bone resorption, we also examined osteoclast numbers
and found no differences in numbers of osteoclasts/mm of tumor-bone interface or size
between the wild type and MMP-13-null groups (Fig. 2-8c-e). Since these analyses were
done at study endpoint, temporal differences between the groups might not have been
observable. We therefore repeated the study, and at day 21 post multiple myeloma
inoculation (5TGM1), we harvested tumor bearing tibias. Again, we observed no
differences in osteoclast number between the groups (Fig. 2-10).
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Figure 2-8. Osteoclast size and number are not affected by host MMP-13 status in tumorbearing tibias at disease endpoint. (a) tumor-bearing tibias were embedded in paraffin
and sectioned at 5µm thickness for H&E staining (n=20). Staining allowed for visualization
of trabecular bone and bone marrow compartments. (b) H&E-stained sections were
quantified for ratio of trabecular bone to total volume (BV:TV) and verified µCT findings
(student t-test; *p<0.05). (c) sequential bone sections from each bone were stained for
tartrate-resistant acid phosphatase (TRAcP) to visualize osteoclasts (red) against
hematoxylin background. Representative images shown. (d-e) TRAcP-stained
osteoclasts residing on surface of trabecular bone were counted and their sizes measured
and statistically analyzed by student t-test (n=20).
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Figure 2-9. Bone turnover is not significantly impacted by direct type I collagenase activity
of MMP-13 in vivo. Bone marrow serum was harvested from 7-week old WT and MMP13-/- mice tibias and femurs (n=6). ELISA was performed and showed no difference in
abundance of ICTP fragments, an indicator for collagen processing by type I collagenases.

Figure 2-10. Myeloma initially induces similar osteolysis in WT and MMP-13-null mice.
(a) multiple myeloma establishes and grows at comparable rates in WT and MMP-13-/mice. Mice (n=10) were inoculated with luciferase-tagged 5TGM1 (106 cells/mouse) by
tail-vein route to establish skeletal lesions. Mice were imaged once a week for
bioluminescence and subsequently collectively euthanized at 21 days. Representative
images and quantitation of tumor burden measurements (BLI) throughout 21 days after
inoculation were shown. (b) tibias harvested from tumor-bearing WT and MMP-13-/- mice
were fixed and scanned by μCT for bone status as previously described. Bone status was
subsequently normalized to tumor-naive bone status as BV:TV ratio and analyzed by
student t-test (n.s.p>0.05). (c) tumor-bearing WT and MMP-13-/- mice contained same
number of osteoclasts at mid-progression. Scanned bones were decalcified and TRAcP
stained for quantitation and analysis of osteoclasts per tumor-bone interface by student
t-test.
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2.5.5 MMP-13 regulates osteoclastogenesis and function
Given no difference in osteoclast size in vivo at either study mid- or end-point, we
speculated that temporal differences in osteoclast formation and/or activity might be
responsible for the slower bone resorption in the MMP-13-null myeloma-bearing animals.
We therefore conducted in vitro studies. Since osteoclasts do not express MMP-13 (Fig.
2-5c), we performed osteoclastogenic assays over 7 days using whole bone marrow
derived co-cultures from the wild type and MMP-13-null mice. Contrary to our in vivo
observations, our in vitro data demonstrate significantly more but smaller multinucleated
osteoclasts in the MMP-13-null cultures (Fig. 2-11a-c; *p<0.05). This is in contrast with
previous reports indicating fewer numbers of osteoclasts in 5-day in vitro cultures 208, 215.
Further, when normalizing to osteoclast numbers, we also observed MMP-13-null
osteoclasts were less resorptive than wild type controls (Fig. 2-11d and e). We next
examined the rate of osteoclast formation in vitro and found that wild type osteoclast
formation peaks one day earlier compared to MMP-13-null osteoclasts and that relative
osteoclast numbers between groups vary depending on assay duration (Fig. 2-11f and g;
**p<0.005). These results combined demonstrate that MMP-13 is critical for efficient
formation of osteoclasts and their activity.
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Figure 2-11. MMP-13-ablation delayed bone marrow osteoclastogenesis and reduced
osteoclast bone resorption in vitro. (a) osteoclasts were differentiated using whole bone
marrow co-cultures from 5-7-week old WT and MMP-13-/- mice. Co-cultures (20,000
cells/well in 96-well plate; n=3/group) were fed with fresh osteoclast media containing MCSF and rank ligand every other day for 7 days in vitro and fixed for TRAcP staining. (bc) MMP-13-/- bone marrow co-culture generated more but smaller osteoclasts than WT
counterparts. TRAcP stained cultures were quantitated for number and sizes of
multinucleate osteoclast manually in ImageJ. (d) resorption assay evaluated WT and
MMP-13-/- osteoclast activity. Equal numbers of WT and MMP-13-/- precursor osteoclasts
were plated onto bone-mimetic hydroxyapatite for differentiation and resorption.
Osteoclasts were removed after 7 days and assay was imaged using bright-field
microscopy to show area in which osteoclasts solubilized mineralized calcium (white). (e)
MMP-13-/- osteoclasts exhibit reduced activity than WT osteoclasts. The total cleared area
of resorption versus residual hydroxyapatite-coated surface (dark grey) was quantitated
(n=3/group). (f) osteoclast differentiation assay was up-scaled and repeated to assess
temporal rate of differentiation (n=3/group/time point). plates were fixed at days 4, 5, 6
and 7 of differentiation for TRAcP staining and quantitation, representative images shown.
(g) temporal quantitation analysis of multinucleate osteoclasts by WT and MMP-13-/- bone
marrow reveal MMP-13-/- osteoclasts were slower to form than WT osteoclasts.

45

2.5.6 MSC-derived MMP-13 mediates secretion of key factors driving
osteoclastogenesis
Since we observed no differences in type I collagen turnover between myelomabearing wild type and MMP-13-null mice but did note defects in osteoclast formation rates
and function, we next examined if the absence of MMP-13 led to differences in
production/bioavailability of factors that could influence osteoclast behavior. To this end,
we focused on MSCs, since they are a major source of MMP-13. We generated
conditioned media from wild type and MMP-13-null MSCs and performed cytokine array
analysis that identified differences in several factors that potentially could impact
osteoclast behavior (Fig. 2-12a). We included a treatment group using a novel selective
inhibitor of MMP-13 catalytic activity (MMP-13i) recently described in literature as control.
Incubation of wild type MSCs with MMP-13i mirrored decreases noted with MMP-13-null
MSCs. Importantly, these results indicated MMP-13 enzymatic activity regulated MSC
cytokine/growth factor bioavailability (Fig. 2-13). RT-PCR analysis was used to validate
cytokine array data at the transcript level (Fig. 2-12b). Using a candidate approach, we
focused on CXCL7 since, in MMP-13-null MSCs, it had elevated mRNA levels but
reduced protein levels in the conditioned media (Fig. 2-12a and b). CXCL7 is known to
be induced and proteolytically cleaved from the latent pro-platelet basic protein (PPBP)
by MMP-3 and cathepsin G 235-239. Interestingly, we observed that MMP-3 expression was
increased at the transcriptional and protein level in MMP-13-null MSCs, but this increase
was insufficient to compensate for MMP-13 loss and rescue CXCL7 bioavailability (Fig.
2-12a and b). Western blot analysis corroborates CXCL7 cytokine array results in both
MSC lysate and conditioned media (Fig. 2-12c). Notably, treatment of wild type MSCs
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with MMP-13i reduced conditioned media CXCL7 levels, comparable with genetic model
and further support MSC CXCL7 is regulated by MMP-13 (Fig. 2-12d). Proteolyticallyactivated CXCL7 has previously been shown to promote osteoclastogenesis but has not
been described as an MMP-13 substrate 240, 241. Immunoblotting demonstrated truncation
of recombinant human CXCL7 full length peptide upon incubation with recombinant
human active MMP-13 (Fig. 2-12e). Mass-spectrometry identified novel MMP-13 direct
cleavage sites on both human and murine full-length CXCL7 pro-peptide (Fig. 2-14a).
Interestingly, recombinant CXCL7 which has been pre-incubated in active MMP-13
significantly increased osteoclast formation in MMP-13-null cultures (Fig. 2-14b). To test
the importance of specific MSC-derived CXCL7 in osteoclast formation, we
immunodepleted the chemokine from wild type MSC conditioned media and subsequently
observed significantly reduced wild type osteoclast numbers to those induced by MMP13-null MSC conditioned media (Fig. 2-12f and g). These results indicate that MMP-13
regulation of CXCL7 bioavailability from MSC is critical for osteoclast formation. Of note,
exogenous MMP-13, in the form of recombinant active enzyme, is able to partially rescue
CXCL7 levels in MMP-13-null whole bone marrow co-cultures (Fig. 2-15).
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Figure 2-12. MMP-13 ablation enhances MSC expression of various myeloid-recruiting
cytokines but reduces key pro-osteoclastogenic cytokine CXCL7. (a) MMP-13 status
impacts MSC secretion of cytokines. WT and MMP-13-/- MSC were starved and cultured
in serum-free α-MEM for 24 hours to derived conditioned media (CM). CM was used in
cytokine array analysis for cytokines expression. Relative fold changes >1 indicated more
in MMP-13-/- than in WT and vice versa. Cytokines with greatest changes and known roles
in osteoclast biology were plotted and tabulated. (b) MMP-13-/- MSC upregulate
transcription of CXCL7. RNA was isolated from WT and MMP-13-/- MSC for cDNA
synthesis and quantitative PCR analysis. qPCR was performed for hits from cytokine
array. c CXCL7 protein is downregulated in MMP-13-/- MSC. CXCL7 western blot analysis
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was performed on MSC cell lysate (n=6) and pooled CM (n=2). (d) MMP-13-mediated
CXCL7 was validated in WT MSC treated with MMP-13 inhibitor (MMP-13i; Compound
1, see methods section) by ELISA. (e) recombinant CXCL7 was incubated with
recombinant active MMP-13 overnight at 37C for proteolytic cleavage and assessed by
Western Blot. (f) CXCL7 was immunoprecipitated (IP) out of WT and MMP-13-/- MSC CM.
WT and MMP-13-/- MSC CM were incubated with anti-CXCL7 antibody and protein G
sepharose beads overnight to precipitate CXCL7. Resultant CM was collected and
corresponding beads washed for validation by western blot (top and bottom panel,
respectively). (g) CXCL7-depleted WT CM failed to generate osteoclast. Osteoclast
differentiation assay was performed using WT bone marrow co-culture with WT, MMP13-/-, and CXCL7-depleted CM which was supplemented with rank ligand. Wells were
fixed at day 4 and quantitated for number and size of osteoclasts. Resulting quantitation
was statistically analyzed by One-way ANOVA Tukey test (n.s.p>0.05, *p<0.05,
**p<0.005).

Figure 2-13. Genetic and pharmacologic inhibition of MMP-13 yields changes in MSC
cytokine expression. Cytokine array results from MMP-13-/- MSCs treated with or without
MMP-13i (Compound 1) were normalized to WT MSC data. (a) MMP-13i group was
compared with MMP-13-/- group to evaluate any additional effects from MMP-13i. (b)
MMP-13i treatment of WT MSC decreased expression of cytokines downregulated in
MMP-13-/- MSCs.
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Figure 2-14. MMP-13 directly processes CXCL7 and promotes osteoclast formation. (a)
human and mouse recombinant CXCL7 peptide were incubated with active MMP-13 and
subject to western blot and mass spectrometry. Western blot analysis demonstrated
differences in CXCL7 bioavailability, and mass spectrometry identified novel cleavage
sites on CXCl7 by MMP-13. (b) quantitation of osteoclast differentiation co-culture assay
treated with MMP-13-processed recombinant CXCL7.
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Figure 2-15. Exogenous MMP-13 rescues CXCL7 levels in bone marrow. (a) western
blot analysis demonstrating CXCL7 levels in conditioned media of bone marrow cells
derived from WT and MMP-13-null bone marrow co-cultures treated with recombinant
active MMP-13 enzyme. (b) additional western blot showing CXCL7 status in WT and
MMP-13-null bone marrow serum treated with/without recombinant MMP-13 enzyme.
2.5.7 Pharmacological MMP-13 ablation with novel inhibitor improves overall
survival
Recent reports demonstrated that MMP-13 derived from multiple myeloma cells
can contribute to osteoclast fusogenesis in a non-catalytic manner. Our data thus far
indicates that bone stroma-derived MMP-13 activity is important for regulating the
bioavailability of important osteoclastogenic factors such as CXCL7. To further explore
whether MMP-13 activity is necessary for osteoclast formation, we used a series of highlyselective MMP-13 inhibitors that had IC50’s in the nM range. These synthetic compounds
were demonstrated to selectively target the catalytic domain of MMP-13 in previous
studies (Fig. 2-16a and b)221, 222, 242. Of these reagents, we observed that Compound 1
(MMP-13i) potently suppressed the formation of wild type osteoclasts in vitro at
concentrations <100 nM. Compound 2 behaved similarly to Compound 1, whereas
Compound 4 initially promoted osteoclast formation at lower concentrations before
inhibiting osteoclastogenesis at higher concentrations (Fig. 2-17a). It appears that
Compound 4 exhibits off-target activities beyond MMP-13 inhibition. In consideration of
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these findings, all subsequent studies were conducted using Compound 1, which is
denoted as MMP-13i throughout the report. MMP-13 inhibition by MMP-13i compromised
the viability of multiple myeloma cell lines (MM1.S, 5TGM1, OPM2, U266) albeit at
concentrations >1 μM (Fig. 2-17b). Interestingly, MMP-13i did not affect the viability of
MSCs or CD11b isolated monocytes at concentrations <5 μM (Fig. 2-16c).

Figure 2-16. Novel compounds selectively inhibit MMP-13. (a) Molecular structure of
novel selective MMP-13 compounds (Compound 1 = (S)-17b and Compound 2 = (S)-17c
in reference 47, and Compound 4 = 52 in reference 48). (b) IC50 values for inhibition of
off-target MMPs tested for each MMP-13 inhibitor compound. (c) Compound 1 (MMP-13i)
significantly reduces viability of osteoclast but not osteoblast precursor. Bone marrow-
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derived CD11b-isolated osteoclast precursor (monocyte) and bone-derived osteoblast
precursor (MSC) cells were cultured in concentration gradients of MMP-13i for 48 hours
in 96-well plates (n=3/group). Cells were assessed by MTS assay for metabolic activity
and viability and analyzed by One-way ANOVA statistical test against control group
(*p<0.05).

Figure 2-17. A selective MMP-13 inhibitor suppressed myeloma and osteoclast formation
in vitro, and improved overall survival in vivo. (a) osteoclast differentiation assays were
performed in the presence of titrations of three MMP-13 inhibitors (n=3
wells/concentration for each compound). Inhibitor compounds were administered every
other day alongside changes of osteoclast differentiation media. Plates were fixed at day
7, TRAcP stained and quantitated for osteoclast numbers. One-way ANOVA statistical
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test was performed to assess osteoclast inhibition at each concentration of compounds
against control group (*p<0.05). All inhibitor studies outside of this experiment was
performed using Compound 1 (MMP-13i). (b) Compound 1 (MMP-13i) strongly inhibited
myeloma viability. myeloma cell lines (MM1.S, 5TGM1, OPM2 and U266) were cultured
in concentration gradients of MMP-13i for 48 hours in 96-well plates (n=3/group). Cells
were assessed by MTS assay for metabolic activity and viability and analyzed by Oneway ANOVA statistical test against control group (*p<0.05). (c) MMP-13i treatment
delayed multiple myeloma growth in immunocompetent syngeneic mouse model of MM.
luciferase-tagged 5TGM1 cells (n=106 cells/mouse) were inoculated into 5-6-week old
syngeneic KaLwRiJ mice (n=30) by tail vein to establish skeletal lesions. Mice were
randomly divided into Vehicle (10% DMSO 10% Tween80 in 1XPBS) and MMP-13i (20
mg/kg) group 7 days following tumor inoculation (n=15/group). Tumor growth was
monitored by bioluminescence imaging and depicted as spider plot (BLI) twice a week
until each mouse eventually reached endpoint hindlimb paralysis. (d) mice treated with
MMP-13i experienced extended overall survival. Mice were euthanized upon presentation
of hindlimb paralysis and their tibias fixed for histology. Survival data was depicted in
Kaplan Meier plot (median survival: 35 vs 42 days for Vehicle and MMP-13i, respectively).
(e) tibias harvested from MM-bearing mice (n=30) as well as 7-week old tumor naive
KaLwRiJ mice (n=6) were subject to μCT scanning and quantitation. MMP-13i treatment
significantly increased bone status in tumor-naive mice (student t-test: *p<0.05). Tumorbearing mice treated with MMP-13i taken down significantly later than vehicle-treated
mice showed same bone status, as analyzed by student t-test (n.s.p>0.05). (f) schematic
summarizing MSC-derived MMP-13 regulation of CXCL7 bioavailability and osteoclast
activity in myeloma vicious cycle and bone disease.

To determine the in vivo efficacy of the MMP-13i, 6-week old immunocompetent
syngeneic KaLwRiJ mice (n=30) were inoculated with luciferase-labeled 5TGM1
myeloma cells to establish skeletal lesions for 7 days and subsequently treated with
MMP-13i daily (20 mg/kg). Bioluminescence was used as a correlate for tumor burden
and readouts demonstrate a delay in myeloma growth (Fig. 2-17c) and a corresponding
significant increase in overall survival in the MMP-13i treated group compared to vehicle
control (median survival times 35 versus 42 days, respectively, Fig. 2-17d). We noted that
MMP-13i treatment resulted in a trend of decreased osteoclast numbers (Fig. 2-18) with
no difference in BV:TV ratios between the vehicle control and MMP-13i treatment group
in tumor-bearing mice. MMP-13i treatment of tumor-naïve mice did however demonstrate
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an increase in BV:TV compared to controls (Fig. 2-17e). Taken together, in vivo and ex
vivo results demonstrated that genetic ablation of MMP-13 in the host compartment or
inhibition of MMP-13 activity using highly selective reagents protects against myelomainduced bone disease and significantly enhances overall survival (Fig. 2-17f).

Figure 2-18. MMP-13i (Compound 1) -treated tumor-bearing mice presented with
diminished osteoclast numbers at end point. (a) μCT-scanned tibias were decalcified and
subsequently paraffin embedded for sectioning and TRAcP staining analysis for
osteoclast numbers (n=10). (b) osteoclast number trended down for MMP-13i-treated
tumor-bearing mice, as analyzed by student t-test (n.s.p>0.05)
2.6

Future for selective MMP-13 inhibitors in multiple myeloma
Multiple myeloma induces systemic skeletal lesions that greatly impact patient

quality of life. The vicious cycle of myeloma-bone interaction leads to the increased
bioavailability of cytokines and growth factors that enhance tumor growth and contribute
to therapy resistance182, 243. Mechanisms that govern the reciprocal interactions between
the myeloma and surrounding bone microenvironment are therefore of potential
therapeutic importance. Here, we have shown that ablation of the collagenase MMP-13
from the host stroma can significantly extend the overall survival of myeloma-bearing
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animals. Interestingly, the observed effect did not appear to be due to collagen turnover
but rather the ability of stromal MSC-derived MMP-13 to regulate the availability of
multiple cytokines including CXCL7 that regulate osteoclast formation and activity. This
effect also is dependent on the catalytic activity of MMP-13 since an MMP-13 selective
inhibitor could significantly extend overall survival in multiple myeloma-bearing mice.
Although we have used mice systemically null for MMP-13, the studies herein have
focused primarily on MMP-13 derived from MSCs and osteoblasts given our
immunolocalization data in human and mouse samples of multiple myeloma. Previous
reports have also demonstrated this lineage to be a major source of MMP-13 with noted
expression in chondrocytes and osteocytes95. Interestingly, MMP-13 expression may not
contribute significantly to osteoblast bone formation activity in multiple myeloma given
that tumor-bearing mice progress into osteolytic disease. Rather, our results suggest
MMP-13 primarily regulates cytokine bioavailability to stimulate osteoclast formation and
bone resorption. Underscoring the importance of MMP-13 in osteoblast biology, tissuespecific knockout of MMP-13 using type Iα collagen promoter-driven CRE recombinase
recapitulates the developmental bone phenotypes noted in systemic MMP-13-null mice95.
Importantly, MMP-2 and -14 null mice also exhibit bone phenotypes, but they fail to
compensate for the loss of MMP-13 indicating a distinct role for this protease in bone
remodeling. MMP-1 exhibits high homology with MMP-13 in mouse. It will be interesting
comparing and contrasting the results presented herein with the effects of silencing MMP1 in myeloma progression and possibly identify redundancies in activities between the
two homologs.
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Cancer cells also induce MMP-13 in MSCs and osteoblasts, supporting the notion
for stromal MMP-13 contribution (Fig. 2-2b and Fig. 2-5d)73,

215.

Our analysis of

immunofluorescence staining reveals MMP-13 expression both at the bone-lining and
bone marrow stroma. Given our data showing MMP-13 inhibition directly reduces survival
of myeloma cells (Fig. 2-6) and impacting osteoclast formation and activity (Fig. 2-11), it
is interesting to speculate the relative contributions of MMP-13 to the cancer and its
corresponding osteal pathology across spatially-distinct microenvironments/interfaces
within the bone marrow compartment. To date, however, few studies have examined
whether stromal genes of interest such as MMP-13 impact multiple myeloma progression,
particularly in vivo. This is largely due to the limited availability of genetically-engineered
models that are receptive to myeloma engraftment244. Here, using RAG-2 MMP-13 double
null mice, our data suggests that although MMP-13 is considered a collagenase, host
MMP-13 contributes to myeloma-induced bone destruction by regulating the
bioavailability of non-matrix molecules that impact osteoclast recruitment, formation and
function. It is also important to note that several MMP-deficient mice carry a passenger
mutation in caspase-11, including the MMP-13-null mice used in this study245. However,
the in vitro and in vivo data obtained with our MMP-13 selective inhibitor support in large
part those obtained with the RAG-2-MMP-13-null mice indicating negligible if any
contribution of caspase-11. The similarities between the MMP-13-null studies in
immunocompromised mice and MMP-13 inhibitor studies in immunocompetent KaLwRiJ
mice also suggests immune cells such as T-cells might not be involved in the effects
mediated by host MMP-13246-248.
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Ex vivo, our analysis of MSC conditioned media revealed the regulation of several
non-matrix molecules that have reported roles in controlling osteoclast biology including
CXCL7240, 241. Here, we report for the first time that CXCL7 bio-activation and availability
is regulated by MMP-13 and is critical for MSC-induced osteoclast formation. Previous
studies have shown that CXCL7 is expressed as an inert pro-peptide, PPBP, and
undergoes rounds of proteolytic cleavage to eventually yield the active 7.6 kDa peptide249.
CXCL7 has been identified as a potent mediator of neutrophil chemoattraction and
activation in various pathologies but plays noted roles in osteoclastogenesis237, 240, 250.
Consistent with this role, we noted significantly less neutrophils present in the bone
marrow of MMP-13-null mice (data not shown). Although MMP-3 and cathepsin G have
been shown to participate in proteolytic activation of PPBP, we posit MMP-13 regulates
the process given the low levels of active CXCL7 detected in the conditioned media
derived from MMP-13-null MSCs and wild type MSCs treated with MMP-13i249. Of note,
MMP-3 expression is increased in MMP-13-null MSCs (Fig. 2-12a) and MMP-3 has been
reported to activate latent MMP-13202. However, the increased levels of MMP-3
expression are insufficient to generate protein levels of active CXCL7 compared to wild
type controls supporting a role for MMP-13 in the process. Although we noted the
dysregulation of other factors in the MMP-13-null MSC conditioned media that can impact
osteoclast biology, immune depletion of CXCL7 from conditioned media significantly
inhibited the process. Further experiments are warranted to examine if MMP-13processed CXCL7 can influence the migration of myeloid cells, and also, specifically, the
fusion of osteoclast precursors. To our knowledge, we are the first to demonstrate MMP13 as a catalytic activator of CXCL7. This point is furthered by our observation that
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platelets derived from MMP-13-null animals contained less active CXCL7, suggesting the
possibility for other cellular sources of the MMP-13/CXCL7 bioavailability axis which can
also contribute to myeloma disease (data not shown). Additionally, the detected
differences in non-matrix factors in MMP-13-null MSC conditioned media reinforce a role
for MMP-13 catalytic activity. This position is further supported by data showing that when
wild type MSCs are treated with a selective MMP-13 inhibitor, the profile and levels of
downregulated growth factors mirror those observed with the MMP-13-null MSCs (Fig. 213a). In agreement, studies have also demonstrated how MMP-13 activity regulates the
degradome of MC3T3 osteoblasts73, 251.
As stated, in the context of skeletal malignancies, MMP-13 can also be derived
from cancer cells with bone-metastatic breast cancer cells noted to express large
amounts of MMP-1376, 252-254. Indeed, our own studies show expression of MMP-13 in
CD138+ cells, and our analysis of the MMRF dataset also correlated MMP-13 status with
overall survival (Fig. 2-2d, 2-12b-c and Fig. 2-3b). Interestingly, in contrast with data in
other studies, CD138+ cell MMP-13 expression did not correlate with disease staging in
our analysis of patient dataset. Furthermore, studies, such as by Fu et al. evaluated serum
MMP-13 levels, making it difficult to dissect the stromal versus tumor contributions76.
These findings together reveal variability in the contribution of myeloma-derived MMP-13
to disease progression (Fig. 2-2a and Fig. 2-3)76, 255. Previous reports have shown that
MMP-13 derived from multiple myeloma cells (5TGM1) can contribute to osteoclast
fusogenesis and that this effect is independent of the catalytic activity of MMP-1376. This
non-catalytic role for MMPs in osteoclast fusion has also been reported for MMP-1478. In
our experiments, 5TGM1-derived MMP-13 did not compensate for the loss of MMP-13 in
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the bone stroma compartment suggesting spatial localization might be important. Our
work with MMP-13 selective inhibitors further support a catalytic role for host-derived
MMP-13 in contributing to the progression of the disease. The selectivity of the inhibitor
was supported in experiments showing that the addition of the MMP-13i to MMP-13-null
MSCs elicited no further effect on either downregulated or upregulated cytokines or
growth factors (Fig. 2-13b). The clinical administration of MMP inhibitors to treat cancer
have not been successful because of their broad-spectrum nature and dose-limiting side
effects77. However, the relatively deep catalytic pocket of MMP-13 and restricted tissue
expression of the protease to the tumor-bone microenvironment make it an ideal
candidate for selective inhibition232, 253, 256-258. Here using a selective MMP-13 inhibitor
(IC50 of 2.7nM), we demonstrate that inhibition of MMP-13 activity in vivo recapitulated
the effects observed in our MMP-13-null studies in regard to significantly improving overall
survival in myeloma-bearing mice Importantly, both genetic and pharmacologic ablation
of MMP-13 yielded comparable improved overall survival in mice as does standard of
care treatments.
However, it is important to note differences between the genetic and
pharmacological approaches taken in this study. For example, we did not observe a
protective effect on myeloma-induced bone destruction with the MMP-13i. We suspect
that this is due to the short duration (between 31-54 days) of treatment compared to
genetically null mice where MMP-13 is absent from birth. Therefore, over a longer
treatment period, we would expect a more apparent protective effect of inhibiting MMP13 on cancer-induced bone disease. Supporting this position is the fact that treatment of
wild type tumor-naïve mice for the same period of time significantly increases bone
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volume (Fig. 2-17e). Although we observed a decrease in osteoclast numbers in MMP13 inhibitor treated animals, this reduction did not reach statistical significance.
Pharmacokinetic/ pharmacodynamics studies have not been performed with the MMP13i and so it is possible that higher doses or improvement of inhibitor half-life in vivo could
more potently protect against osteoclastogenesis and myeloma-associated bone
disease. Furthermore, we note that the activity of these osteoclasts has not been
examined in vivo. Using existing methodologies, such as quantitating the hematological
abundance of the TRAcP enzyme, we could examine the physiological impact of MMP13 inhibition on bone resorption, though this may require specific conditions, such as
fasting the mice. Importantly, we do not rule out that the non-catalytic function of MMP13 in osteoclast fusion might also explain why a more dramatic effect on osteoclast
numbers between the MMP-13 inhibitor and vehicle control groups was not noted.
Nevertheless, given the increase in overall survival noted in the MMP-13i cohort, we posit
that MMP-13 catalytic activity plays an important role in the progression of the disease.
Whereas pharmacological inhibition of other MMPs expressed abundantly in different
tissues, the advantage of targeting MMP-13 in myeloma is that MMP-13 is highly
expressed in the bone. In both our genetic and pharmacological ablation models, other
than the hindlimb paralysis, mice present as wildtype mice do in terms of body weight and
other indications of wellbeing (data not shown), evidencing the lack of adverse side
effects and the safety of this approach. In support of targeting MMP-13 activity
therapeutically for skeletal malignancies, previous studies using a different MMP-13
inhibitor (5-(4-phenoxy)-5-(2-methoxyethyl)-pyrimidine-2,4,6 (1H,3H,5H)-trione; IC50 =
0.57nM) reported efficacy in a bone-metastatic breast cancer model by mitigating
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metastatic tumor burden and tumor-induced bone disease259, 260. Ongoing studies by our
group will leverage MMP-13 specific fluorescent triple-helical peptides (fTHP) for analysis
of MMP-13 catalytic activity in vivo or ex vivo and should help delineate between the
potentially catalytic and non-catalytic functions259, 261, 262.
In conclusion, we have shown for the first time stromal MMP-13 contributes to the
overall survival of multiple myeloma-bearing animals. Our data demonstrate that this is
due to slower rates of bone turnover that is not dependent on the ability of MMP-13 to
process type I collagen but rather the regulation of bioavailable CXCL7 that in turn is
critical for osteoclast formation and function. We further demonstrate the efficacy of a
novel highly selective MMP-13 inhibitor. Collectively, these data point to MMP-13 as being
a valid target for the treatment of multiple myeloma.
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Chapter 3.

Novel therapeutic approaches to late-stage bone-metastatic prostate

cancer
Note to reader: Portions of this chapter have been published in Zhao et al. Science
Translational Medicine doi: 10.1126/scitranslmed.aaw4636
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and have been permitted

for reproduction by Science Journals Default License (Appendix D).

In 2020 alone, approximately 33,330 deaths from prostate cancer were predicted
in the United States 263. The American Cancer Society estimates that one in nine men will
eventually develop prostate cancer, making it the third most common cancer in the US
behind only breast and lung cancers (Table. 1-1)264. Although early stage disease is often
treated successfully with surgery, radiation, and/or androgen deprivation therapy (ADT),
advanced prostate cancer remains a moving target. Advanced disease typically manifests
in the skeleton, brain and lung where metastases are often sensitive to first- and secondgeneration ADT. However, in a short period, the cancer becomes castrate resistant or
androgen independent (CRPC). As with all other bone-metastatic malignancies, bonemetastatic CRPC remains incurable and so there is an urgent and unmet clinical need to
identify new therapeutic targets for the treatment of the disease.

3.1

Prostate cancer
Overall, patients with early stage prostate cancer have a 5-year overall survival

rate nearing 100%265. This is attributed to three main reasons: that 1) prostate cancer
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tends to be a slow growing malignancy, 2) it tends to occur in men later in life, and that 3)
localized disease is treatable. Watchful waiting (active surveillance) is a common practice
in elderly patients with stable primary disease, considering the reduced quality of life by
invasive treatment options outweighs the statistical likelihood of the cancer progressing
to significantly impact lifespan in patients.

3.1.1 Prostate cancer bone metastasis
Most patients that succumb to prostate cancer do so with advanced disease.
Advanced prostate cancer frequently metastasizes to the skeleton where lesions are
often sensitive to first- and second-generation ADT but castration resistance eventually
emerges. In the bone, prostate cancer causes extensive remodeling and bone formation
that results in intense pain and heightened risk of pathologic fracture

266.

Research over

the past decades have identified key factors prostate cancers secrete to control osteolysis
and osteogenesis processes and generate mixed bone pathologies267. These changes in
bone remodeling reciprocally produce important factors for cancer survival and growth.
Bone-metastatic castrate-resistant prostate cancer (bmCRPC) is currently incurable and
appears to be refractory even to recent advances in immunotherapy such as checkpoint
inhibitors 268-270.

3.1.2 Castrate-resistant prostate cancer
Androgen is important in the development and maintenance of male reproductive
organs, bone and muscles; androgen deficiencies in these organs incur significant
physiological consequences in men271-273. Prostate cancer cells rely on androgen
signaling to grow. Various iterations of androgen deprivation therapies (ADTs) directed at
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limiting the bioavailability of androgen has therefore enjoyed much success in treating
newly-diagnosed patients. However, whereas patients typically initially respond, a
significant portion of patients ultimately present with recurring disease that is no longer
sensitive to ADTs and are castrate resistant (CRPC)274-276. CRPCs typically circumvent
the need for external sources of androgens by 1) inducing androgen overexpression in
neighboring tissues, such as adipocytes, 2) expressing mutant constitutively-active forms
of the androgen receptor (AR), or 3) synthesizing their own androgen for autocrine
signaling274, 276, 277.

3.1.3 Emerging therapies in CRPC
Therapy-resistant advance prostate cancer is a significant clinical issue impacting
10-20% of all prostate cancer patients278, 279. Prostate cancer has been shown to develop
resistance not only to traditional chemotherapies such as docetaxel and cabazitaxel, but
also towards ADTs, such as abiraterone, enzalutamide and apalutamide264,

280, 281.

Therefore, current efforts are geared towards the discovery of reagents to treat CRPC.
For example, targeted therapies such as PARP-inhibitor olaparib and rucaparib disrupt
DNA damage repair capacity in prostate cancer cells282-284. When used as adjuvant
therapies in conjunction with DNA-damaging chemotherapies, prostate cancer cells are
unable to recover from genotoxic stress and continue proliferating. This thereby reduces
survival and promotes apoptosis of cancer283, 285. PARP inhibitors are currently an FDAapproved treatment option for CRPC patients who have exhausted standard of care
therapy options.
Immunological approaches for treating prostate cancer are also underway286.
Although immunotherapies have not generally demonstrated efficacy in the treatment of
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prostate cancer, some such as Sipuleucel-T (Provenge) therapy have successfully been
approved by the FDA287, 288. Sipuleucel-T is a treatment strategy in which a patient’s own
autologous peripheral blood mononuclear cells are extracted and engineered in vitro to
strongly recognize the patient’s cancer cells. Reintroduction of these reprogrammed
immune cells into patient will enhance the anti-tumor immune response. Other groups are
alternatively exploring the use of chimeric antigen receptor T cell therapy (CAR-T) in
prostate cancer289, 290. CAR-T therapy is a method in which patient-derived T cells are
engineered to express a receptor to actively recognize tumor-specific antigens ex vivo
and then delivered back into the patient to directly home to and kill the cancer cells.
Prostatic stem cell antigen (PSCA) and prostate-specific membrane antigen (PSMA) are
prostate cancer-associated antigens currently being targeted in CAR-T cell therapy
research and development291-293.
Bone metastasis has also been a focus for developing targeted therapies. Radiocompounds such as strontium-89, bevacizumab and atrasentan are currently being tested
to inhibit cancer-associated bone remodeling294-297. These efforts are in addition to
bisphosphonates, which are already being used in bmPC to treat osteolytic disease by
inhibiting osteoclast formation and activity298, 299.

3.1.4 Targeting bone-metastatic castrate-resistant prostate cancer
While these targeted therapies continue to evolve, efforts continue to also focus
on understanding AR biologies in CRPC. To this end, our studies have focused on factors
differentially regulated in CRPC, such as AVPR1A and VAV3280, 281.
VAV3 is a coactivator of AR in PC and contributes to castration resistance in PC300302.

Increased VAV3 correlates with poor clinical outcome for PC303. AR-V7 is a
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constitutively-active form of AR and is a common way in which PC develop castration
resistance and is enhanced by VAV3304-306. Work done by Zhao et al. identified arginine
vasopressin receptor 1a (AVPR1A) as the most down-regulated dual target gene of ARV7 and VAV3. AVPR1A is a G protein-coupled receptor (GPCR) that signals via G
proteins Gq/11 in classical target tissues305. The three vasopressin receptor subtypes,
AVPR1A, AVPR1B, and AVPR2, have the same physiological ligand, arginine
vasopressin (AVP) but are distinct in their tissue expression profiles and functions.
AVPR1A is expressed in the vascular smooth muscle cells, cardiomyocytes,
hippocampus, kidney, bone, liver, and select breast and non–small cell lung cancer cell
lines307-314. An orally available selective AVPR1A antagonist, relcovaptan, has shown
efficacy and safety in clinical trials of Raynaud’s syndrome, dysmenorrhea, and preterm
labor315, 316. Relcovaptan was well tolerated, and no side effects were reported in clinical
trials317, 318.
Publicly available datasets from human PC specimens show that a substantial
proportion of men with CRPC present with AVPR1A gene copy number amplification, and
there are also increased amounts of AVPR1A mRNA in advanced PC cases compared
to primary disease319-321. We demonstrated that AVPR1A depletion greatly decreased
CRPC growth but had negligible effect in androgen-dependent PC, AR-negative PC, or
nontumorigenic prostate epithelial cells, which did not express detectable AVPR1A
mRNA. AVPR1A conferred castration resistance to androgen-dependent PC in vitro and
in vivo. Relcovaptan substantially inhibited tumor growth in three distinct highly relevant
preclinical PC settings: an early CRPC progression model, a local CRPC invasion model,
and an end-stage CRPC model of growth in the bone metastatic niche. Together, our
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findings indicate that AVPR1A is a promising therapeutic target for CRPC that can be
translated rapidly to the clinic because of the existence of safe and effective antagonists
established in phase 1 and 2 clinical trials.

3.2

Materials and Methods

3.2.1 Cell Culture and Reagents
C4-2B prostate cancer cells were obtained from L. Chung (Cedar Sinai Medical
Center, Los Angeles, CA) and were cultured in RPMI supplemented with 100 IU/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 10% FBS. RWPE-1 cells were
cultured in Keratinocyte-SFM supplemented with full growth factor kits. Cell lines were
used within 6 months of resuscitation. Cell cultures were maintained at 37 °C in a
humidified atmosphere of 5% CO2. Relcovaptan (SR 49059) was purchased from Axon
Medchem.

3.2.2 Intratibial injection experiments
Studies involving animals were conducted under a protocol approved by the
Institutional Animal Care and Use Committee of Moffitt Cancer Center. Established
methodology of intratibial injection has been described322. Luciferase-expressing C4-2B
cells (105 in 10 µl saline) were inoculated into tibias of castrated SCID mice. Contralateral
limbs received sham injections of saline alone to serve as an internal baseline control for
bone remodeling. One week after the injection, bioluminescence was measured (IVIS200)
to ensure equal tumor take and subsequently the mice were randomized into vehicle
control (n=7; 0.3% methylcellulose in saline, daily oral gavage) and relcovaptan (n=8,
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50mg/Kg, daily oral gavage) groups. Bioluminescence was measured twice weekly as a
readout for tumor growth. Individual mice were sacrificed as their bioluminescence signal
reached instrument detection limit (RLU = 2 x107 ph/sec/cm2/sr). Remaining mice were
sacrificed after 83 days and bone tissue was collected from all xenografts and sham mice.
High-resolution μCT were performed to analyze bone volume. Bone volume were
quantified by imageJ. Tartrate-resistant acid phosphatase (TRAP) staining and pancytokeratin staining (Sigma-Aldrich, C2562) were performed for analyzing bone
remodeling and C4-2B tumor burden in tibia.

3.2.3 Statistical analysis
All normally distributed data were tested for significance using two-tailed
Student’s t-test. Results are expressed as mean ± SEM. One-way ANOVA followed by
the Bonferroni t test or a two-tailed Student t test was used where appropriate, and
significance was accepted at P < 0.05.

3.3

Results

3.3.1 AVPR1A expression is controlled by AR-V7 in CRPC
In an initial genomic array, Zhao et al identified AVPR1A to be the most
downregulated gene common between both CRPC cells (22Rv1) which have been
inducibly-silenced for AR-V7 and for VAV3 (data not shown). These results were
confirmed in 22Rv1 cells stably depleted of AR-V7 and VAV3 (Fig. 3-1a). Furthermore,
AVPR1A was only upregulated in androgen-independent compared to -dependent VAV3overexpressing cells (Fig. 3-1b). Analyses of publicly-available clinical datasets further
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demonstrated that AVPR1A is significantly overexpressed in human patient 1) castrateresistant and 2) metastatic disease (Fig. 3-1c). These results indicate AVPR1A
overexpression is characteristic of advance metastatic CRPC cells.

Figure 3-1. AVPR1A expression is controlled by AR-V7 and VAV3 and is important in
CRPC. (a) VAV3 or AR-V7 was stably depleted by shRNA in 22Rv1 cells analyzed by
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) for AVPR1A
mRNA (Student’s t test, **P < 0.01). One experiment was done in triplicate. (b) AVPR1A
mRNA was quantified in VCaP xenograft tumors with (VAV3) or without (GFP) VAV3
overexpression harvested before castration (androgen dependent) or at the end of the
study (CRPC). The following xenograft tissues were evaluated: androgendependent/GFP (n = 3), androgen-dependent/VAV3 (n = 3), CRPC/GFP (n = 5), and
CRPC/VAV3 (n = 7) (one-way analysis of variance (ANOVA) with Bonferroni correction,
**P < 0.01). (c) Tamura PC datasets were obtained and analyzed using National Center
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) (24) to show
AVPR1A mRNA in human hormone-sensitive specimens versus CRPC samples (**P <
0.01).

3.3.2 AVPR1A is important for survival and proliferation of CRPC cells in vitro
and in in vivo xenograft models
To understand the role of AVPR1A in CRPC growth and progression, CRPC cell
lines both positive and null for AR were counted over time following AVPR1A knockdown
by shRNA. AVPR1A silencing consistently reduced the proliferation of AR-positive cells
compared to their respective wild type control (Fig. 3-2a). These findings were reproduced
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in wild type cells that were silenced by AVPR1 inhibitor, relcovaptan (data not shown).
Further supplementary immunoblotting analyses using AVP to rescue AVPR1A knock
down-induced growth suppression revealed that, in line with other published literature.
AVPR1A signals through MAPK pathway and that AR-control cell proliferation depends
on AVPR1A expression (data not shown) 323, 324.

Figure 3-2. AVPR1A knockdown reduces CRPC proliferation and progression. (a) ARpositive CRPC cell lines were transduced with shAVPR1A or shGFP (negative control),
followed by cell counting on the indicated days. Cell numbers were normalized to day 0
for each time point. ☐, shGFP; ● , shAVPR1A. Summary of three independent
experiments performed in triplicate is shown (Student’s t test, *P < 0.05 and **P < 0.01).
(b) Androgen-dependent LNCaP cells stably expressing either empty vector or AVPR1A
were injected subcutaneously into immunocompromised mice. Mice were castrated when
tumors reached 100 mm3. LNCaP xenograft tumor volumes (empty vector, n = 19;
AVPR1A, n = 19) were measured at the indicated time points (up to 4 weeks) after
castration, and fold change was plotted (compared to tumor volume at the time of
castration on day 0). Tumor growth of the empty vector group was compared to that of
the AVPR1A group at the same time points (Student’s t test, *P < 0.05). (c) Subcutaneous
VCaP xenografts (bilateral) were established in SCID mice, and mice were castrated (CX)
when tumors reached 250 to 300 mm3. Vehicle or relcovaptan treatment (TX) was
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initiated 7 days after castration and continued for 14 days. Fold changes (relative to day
0) in tumor volume of vehicle- (n = 10) and relcovaptan-treated (n = 13) mice were
calculated and plotted. Tumors from vehicle- and relcovaptan-treated mice were
compared at the same time points. (Student’s t test, *P < 0.05, **P < 0.01, and ***P <
0.001).

The role of AVPR1A in CRPC progress was next examined in vivo using CRPC
cells either overexpressing AVPR1A in a subcutaneous mouse model, or treated with
AVPR1A inhibitor Relcovaptan in an orthotopic mouse model. AVPR1A genetic
overexpression and pharmacologic inhibition in castrated mice resulted in significantly
increased and decreased growth of androgen-dependent CRPC cells, respectively (Fig
3-2b and c).

3.3.3 Relcovaptan treatment significantly reduced bone-metastatic CRPC growth
in vivo
PC typically metastasizes to the skeleton, generating both bone-destructive and
bone-forming lesions, which are regulated by osteoclasts and osteoblasts, respectively325.
To mimic the growth of late-stage CRPC in bone, luciferase-labeled C4-2B cells were
introduced directly into the tibias of castrated SCID mice. Similar to the subcutaneous
and orthotopic tumor models, relcovaptan decreased castration-resistant tumor growth in
the bone microenvironment (Fig. 3-3a). Over the 83 days of treatment, relcovaptan did
not affect mouse body weights (Fig. 3-3b), appetite, or general behavior. Instead,
relcovaptan substantially improved mouse survival rate by prolonging the time to reach
the predetermined maximal tumor burden (Fig. 3-4).
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Figure 3-3. Relcovaptan decreases the growth of bone CRPC and protects against bone
CRPC-induced osteogenesis. (a) SCID mice were castrated and, 1 week later, intratibially
inoculated with luciferase-expressing C4-2B CRPC cells. Mice were randomized into
vehicle (n = 7) and relcovaptan groups (n = 8) and treated daily for 83 days.
Luminescence was measured twice weekly over the course of the study and compared
between mice treated with relcovaptan and vehicle at each time point (Student’s t test, *P
< 0.05). Representative images (right) and luminescence quantitation (left) from vehicleand relcovaptan-treated groups at day 83 are shown (Student’s t test, *P < 0.05). (b) body
weights were measured on a weekly basis.

Figure 3-4. Relcovaptan improves overall survival of bmCRPC tumor-bearing mice.
Survival curves are shown for all mice treated with relcovaptan or vehicle (log-rank test,
*P < 0.05).
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Consistent with in vitro observations, relcovaptan treatment increased CRPC
apoptosis as measured by cleaved caspase 3 expression in ex vivo histological sections
although proliferation was not significantly changed according to phosphor-histone H3
staining (Fig. 3-5). Genetic deletion or pharmacological inhibition of AVPR1A limits bone
remodeling326. We therefore assessed the impact of relcovaptan on CRPC-induced bone
disease. C4-2B cells commonly generate osteogenic lesions in in vivo bone metastasis
models322.

As

expected,

high-resolution

micro–computed

tomography

(μCT)

demonstrated that vehicle-treated tumor-bearing tibias display much higher bone-to-total
volume ratio (BV:TV) than vehicle-treated tumor-naïve tibias (sham) (Fig. 3-6a).
Relcovaptan administration in tumor-bearing tibias presented BV:TV comparable to
BV:TV of vehicle-treated tumor-naïve tibias, potentially indicating that relcovaptan
disrupted the PC-to-bone signaling resulting in preserved normal bone status (Fig. 3-6a).
Furthermore, relcovaptan treatment had negligible effects on BV:TV in tumor-naïve tibias
(Fig. 3-6a). Analyses of BV:TV in tissue sections by immunohistochemistry confirmed
μCT results (Fig. 3-6b and c).
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Figure 3-5. Relcovaptan induces CRPC apoptosis in vivo. Representative images show
dual immunofluorescence staining for proliferation (pHH3 in red, upper panels) and
apoptosis (CC-3 in red, lower panels) within the CRPC compartment (pCK in green).
Percent tumor cell positivity was measured for triplicate randomized sections from each
of three mice per group (Student’s t test, *P < 0.05).

Figure 3-6. Relcovaptan treatment protected against CRPC-associated bone growth. (a)
μCT scan analysis was performed on tibias from vehicle- and relcovaptan-treated mice
bearing C4-2B bone metastases and contralateral tibias that received sham injections of
saline (Student’s t test, *P < 0.05; n.s., not significant). (b) Gross micrograph illustrates
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tumor burden by tartrate-resistant acid phosphatase staining in each group, dashed circle
represents area of magnification, and pan-cytokeratin (green) indicates C4-2B cells. (c)
Ratio of trabecular bone volume (BV) to total volume (TV) in sections derived from the
vehicle- and relcovaptan-treated groups was quantified (Student’s t test, *P < 0.05).
3.4

Future for AVPR1A blockade for the treatment of CRPC
Our unbiased transcriptomic studies designed to define downstream targets of AR-

V7 and the versatile AR coactivator, VAV3, in CRPC resulted in the identification of
AVPR1A as a dually regulated target gene. We prioritized the evaluation of AVPR1A as
a potential therapeutic target for PC because AVPR1A mRNA is increased in aggressive
PC compared to primary disease and clinically safe and effective subtype-selective
AVPR1A antagonists are available315, 327. Both AVPR1A depletion and ectopic expression
studies support the notion that AVPR1A is sufficient to drive CRPC progression.
Preclinical experiments showed that AVPR1A blockade with relcovaptan inhibited CRPC
in three distinct preclinical stages of human disease: newly emergent CRPC, primary and
locally invasive established CRPC, and CRPC growth in the late-stage bone metastatic
niche. This study describes AVPR1A as an actionable therapeutic target for CRPC, as
summarized in the model (Fig. 3-7).

Figure 3-7. AVPR1A is a signaling effector and drug target for CRPC.
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AVPR1A mRNA is expressed in several human small cell lung and breast cancer
cell lines, where it appears to have proproliferative effects323, 328-331. Consistent with a
mitogenic/prosurvival role of AVPR1A, we found that AVPR1A depletion resulted in
substantial growth inhibition in CRPC cells. AVPR1A was expressed in the AR-positive
CRPC cell lines: 22Rv1, CWR-R1, and the LNCaP CRPC derivatives LNCaP-abl and C42B. In contrast, AVPR1A mRNA was below the limits of detection in androgen-dependent
LNCaP, AR-negative PC cell lines PC3 and DU145, and nontumorigenic prostate
epithelial cells RWPE-1. The lack of reliable anti-AVPR1A antibodies precluded our ability
to demonstrate either native or overexpressed AVPR1A protein in CRPC cells. Although
we first identified AVPR1A as a dual target of VAV3 and AR-V7, the basis for the
expression of AVPR1A in an AR-positive line such as C4-2B CRPC, which lacks AR-V7,
is unknown and will need to be investigated in future studies.
The physiologic ligand, AVP, stimulated rapid canonical responses in AVPR1Aexpressing PC cells, including intracellular calcium release and phosphorylation of ERK.
These effects were blocked by the AVPR1A subtype-selective antagonist, relcovaptan,
consistent with AVPR1A signaling via Gq/11 in CRPC. Furthermore, forced expression of
AVPR1A in nontumorigenic prostate epithelial cells evoked AVP-mediated calcium
release, indicating that receptor expression was sufficient and therefore that prostate
lineage cells retain the other components of this signaling pathway.
Phosphoproteomic assays revealed that CREB was phosphorylated in response
to AVP treatment, and its phosphorylation was through AVPR1A signaling based on
inhibition by relcovaptan. CREB mediates PC progression332-336 and has been reported
to promote PC bone metastasis337, 338. Further analysis suggests that AVP signals via an
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AVPR1A/ERK/CREB pathway in CRPC. CREB regulates the transcription of cell cycle
genes, such as cyclin A and cyclin D1339-341. We observed that AVPR1A depletion or
antagonism decreased cyclin A, consistent with ERK/CREB signaling in CRPC cell
proliferation. Despite the finding that AVP acutely promoted pro-proliferative and survival
signaling, AVP did not stimulate CRPC cell proliferation. The lack of such AVP-mediated
long-term effects might be due to differences in culture conditions because cell
proliferation experiments need to be conducted in serum-containing medium. Under these
conditions, AVPR1a might be sufficiently active without additional ligand. We found that
AVPR1A depletion greatly decreased CRPC cell proliferation and that ectopic expression
of AVPR1A was sufficient for castration-resistant growth.
We used the commercially available relcovaptan for preclinical assessment of
AVPR1A antagonism in PC. This small-molecule inhibitor can be given orally, exhibits
subtype specificity342, 343, and has been effectively and safely used in several clinical trials
for Raynaud’s syndrome, dysmenorrhea, and preterm labor316,

317.

In addition, other

vaptan-type AVPR1A antagonists are currently under clinical investigation for anxiety,
post-traumatic stress disorder, autism, and other behavioral indications; thus, AVPR1A
antagonists’ safety and efficacy for long-term use is being established (clinical trial
identifier: NCT03504917, NCT03036397, and NCT02922166)344.
Relcovaptan decreased CRPC growth in three preclinical mouse models of newly
emergent castration-resistant disease, established CRPC in prostate (orthotopic)
xenografts, and of late-stage bone metastasis after intratibial injection of CRPC cells.
Although relcovaptan greatly decreased tumor growth, xenografts did not appear to
regress in any of the three in vivo models. Relcovaptan in combination with other standard
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PC therapeutic approaches might result in complete tumor regression, which should be
investigated in future studies. Specifically, since MAPK pathway is downstream of
AVPR1A signaling, it would be interesting to see if Relcovaptan may synergize with
existing drugs such as Tremetinib and enhance the specificity of the MEK inhibition in
CRPC.
Relcovaptan also protected against cancer-induced bone disease. PC cells
promote osteoclast and osteoblast activity with the resultant increase in bone remodeling,
releasing growth factors such as transforming growth factor β that can promote PC cell
survival and growth in the bone microenvironment. AVPR1A is an important regulator of
osteoclast function326, and limiting osteoclast function by relcovaptan might have clinical
relevance by preventing the CRPC cells from access to bone-derived growth and survival
factors. In the context of the tumor-bone microenvironment, we therefore posit that
relcovaptan might directly and indirectly limit CRPC growth. In our bone-metastatic CRPC
model, further studies are warranted to definitively examine if Relcovaptan directly limits
pathologic bone remodeling. These studies may include evaluating differentiation and
activity of osteoclast and osteoblasts treated with Relcovaptan in in vitro assays.
Our preclinical data indicate that pharmacological targeting of AVPR1A is efficient
and effective. We did not observe any obvious toxicity of relcovaptan, and AVPR1A
inhibition had benefit for end-stage bone-metastatic CRPC, for which therapeutic options
are limited. Although relcovaptan inhibited CRPC growth in three mouse models with
distinct tumor microenvironments, a limitation of our study is the use of human cell lines
in immunocompromised mouse tumor xenograft models. Together, the data support
therapeutically targeting AVPR1A as a treatment strategy for aggressive PC, including
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for bone-metastatic CRPC, and for alleviating or preventing skeletal-related diseases and
pain to improve patients’ quality of life and survival.
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Chapter 4.

Understanding cancer bone metastasis as a multicellular system

through a computational bone remodeling framework
Note to reader: Portions of this chapter have been published in Lo and Baratchart et al.
BioRxiv doi: 10.1101/2020.10.13.338335

345

and in Lo et al. Frontiers in Endocrinology

doi: 10.3389/fendo.2018.00247 346, and have been permitted for reproduction by BioRxiv
CC-BY-NC 4.0 (Appendix E) and Frontiers in Endocrinology CC-BY licenses (Appendix
B), respectively.

In the preceding chapters, two preclinical examples were presented by which
targeted approaches against MMP-13 and AVPR1A have demonstrated therapeutic
promise in reducing cancer bone diseases in multiple myeloma and castrate-resistant
prostate cancer, respectively. These studies, and many others, demonstrate the
complexity of interactions that are occurring in the cancer microenvironment. For example,
MMP-13 has >100 substrates, many of which can have effects on cancer cell progression
in addition to CXCL7. Further, Relcovaptan can have distinct effects on the bone
microenvironment surrounding prostate metastases, and there could be direct and
indirect effects of this reagent on prostate cancer. How then do we address this
complexity? Recently, mathematical modeling solutions have emerged.
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4.1

Current theoretical math models of cancer bone metastasis and the

importance of normal bone remodeling
Mathematical modeling allows for efficient interrogation of multicellular interactions,
such as between cancer and bone stromal populations, that are difficult to examine using
traditional experimental approaches. Previous reports, including from our group, have
successfully demonstrated the feasibility of this approach to enhance our understanding
of how cells interact in the bone ecosystem to coordinate homeostasis and cancer-bone
interactions347-357. There are a number of mathematical modeling approaches that can be
employed, such as ordinary differential equation (ODE) models that can be used to
evaluate bone cell populations in normal and disease processes355,

358-362.

Individual

cellular dynamics can also be considered by representing the cell populations as either a
continuous spatial field whose dynamics are described by a set of partial differential
equations (PDE)363, 364, or as individual agents in an agent-based model approach358.
Although the creation of the majority of these models are motivated by experimentallyderived biology, few are able to make biologically-relevant accurate predictions. We
recognized that an accurate and predictive bone metastasis model must first begin by
accurately depicting normal bone remodeling response to environmental perturbations
such as from injury and disease. This crucial first step ensures that cancer cells, when
subsequently integrated into the model, would be subject to the same regulatory
mechanisms existing in normal bone remodeling.
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4.1.1 Bone injury repair
Bone healing subsequent to injury or trauma is a significant clinical problem in
orthopedics and rehabilitation107, 365, 366. Understanding the processes involved and how
cells coordinate and control each phase of injury repair can reveal opportunities to
accelerate healing and improve patient outcomes while reducing cost. Currently, the
phases of bone injury repair in diaphyseal, epiphyseal or metaphyseal fractures have
been well characterized107, 367-370. For example, in critical non-union fractures, a rapid
inflammatory response is followed by callus formation. The callus is then mineralized by
infiltrating mesenchymal stromal cells (MSCs) that differentiate into cartilage, and boneforming chondrocytes and osteoblasts respectively107,

365.

Subsequently, activated

osteoclasts mediate resorption and clearing of the ossified callus 107. In addition to
osteoblasts and osteoclasts, other cell types are also involved in the bone healing
process, such as resident and infiltrating immune cells that exert pro- and antiinflammatory activities depending on environmental cues105, 107, 371, 372. This is evidenced
by the fact that acute pro-inflammatory factor administration (e.g TNF𝛼) can improve bone
repair whereas prolonged administration has the opposite effect373-377.

4.1.2 Macrophage roles in bone remodeling and injury repair
Macrophages are phagocytic cells of the innate immune system responsible for
maintenance of tissue homeostasis. Myeloid in nature and originating from hematopoietic
stem cells that mature and differentiate into myeloblasts and monocytes, macrophages
are noted for their diverse morphology and function across various tissues 378-380.
Traditionally, due to their myeloid origins and bone-specific functions, osteoclasts are
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considered the bone-resident macrophage population. However, roles for pro- and antiinflammatory macrophages in controlling and coordinating osteoclast and osteoblast
bone remodeling have been described. For example, IFNγ- and IL-12-stimulated NOS2
and TNF positive pro-inflammatory macrophages can promote osteoclast formation and
bone resorption381,

382.

Conversely, anti-inflammatory macrophages are thought to

contribute to bone formation383.
A distinct population of bone-resident macrophages, osteomacs, have been
described, and recently studies have shown important roles for these cells in modulating
osteoblast activity in both bone homeostasis and injury repair384. Osteomacs are
morphologically characterized as mononuclear cells that form canopy-like structures
around osteoblasts and can occupy as much as 75% of both murine and human endosteal
and trabecular bone surfaces that are under active remodeling 141, 385-387. Histologically,
osteomacs are distinct from osteoclasts and are F4/80-positive but TRAP-negative.
Additionally, other groups have shown osteomacs to express common macrophage
markers such as CD68, but also more specific markers such as Mac-3 and CD169385, 386,
388.

Although osteomacs can be stimulated by receptor activator of nuclear kappa B ligand

(RANKL) and colony stimulating factor-1 (CSF-1/M-CSF) to become osteoclasts in vitro,
monocytes and other myeloid precursors were found to be more efficient osteoclast
precursors 385. These data indicate that osteomacs are a plastic, yet distinct cell type, with
specific functions in the bone marrow microenvironment. Indeed, further studies have
revealed that osteomacs have diverse roles in regulating osteogenesis and osteolysis.
Osteoblasts become inefficient as they age and need to be replenished to ensure proper
homeostatic bone turnover386. During normal bone turnover, osteomacs engulf apoptotic
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osteoblasts in a process called efferocytosis, which induces the secretion of TGFβ, TNF
and oncostatin M that facilitate osteoblastogenesis and bone formation 141, 385, 386. This
mechanism has been confirmed in various in vitro and in vivo contexts. For example,
removal of osteomacs from bone marrow-derived osteogenic co-cultures reduced
osteoblast number and osteoblastic mineralization387. The MAFIA (MAcrophage FasInduced Apoptosis) murine model is one in which administration of ligand AP20187 can
systemically suppress macrophage differentiation. Reduced osteoblast occupancy of the
endosteal bone surfaces was observed in maturing MAFIA mice following AP20187
administration387, 389. Congruently, parathyroid hormone (PTH)-induced bone anabolism
in the MAFIA model was suppressed upon macrophage ablation 372. Interestingly, when
murine macrophages were depleted by clodronate liposome-induced apoptosis,
osteoblast numbers remained stable387, 389. Further comparison between two methods of
macrophage depletion showed that transient macrophage apoptosis induced osteomac
expansion and efferocytosis, which further enhanced osteoblast activity372,

386, 390.

Additionally, C57BL/6 mice bone marrow treated with trabectedin, a chemotherapy
antagonist of macrophages, showed diminished phagocytic genetic signature,
efferocytotic osteomac-induced RUNX2 positive osteoblastogenesis, and associated
BV/TV status146. During bone fracture repair, osteomacs can also sense apoptotic
damaged cells in response, initiate inflammation and immune recruitment through
secretion of immune attractant factors such as chemokine (C-C motif) ligand 2 (CCL2)
and M-CSF141. Additionally, LPS-stimulated osteomacs express TNF and NOS2, and
suppress osteoblast activity in vitro385. In vivo, bone fracture induced pro-inflammatory
polarization of immune macrophages and osteomacs to secrete TNF and IFNβ, driving
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osteoclastogenesis and osteolysis385. In fact, osteomacs have been shown to associate
with osteoclasts at catabolic sites, substantiating their distinction from osteoclasts, and
supporting their additional roles in regulating osteolysis141. These studies indicate that
osteomacs can direct the transition between osteolysis and osteogenesis by directly
modulating the expansion and activity of osteoclasts and osteoblasts for repair in the
event of bone injury386. Taken together, these studies demonstrate the complex roles of
bone-resident macrophages in bone remodeling391,

392.

How they contribute to the

progression of bone-metastatic prostate cancer and respond to applied therapies has not
been fully elucidated at this juncture.

4.1.3 Myeloid polarization in bone injury repair
The diversity of macrophage function owes to its versatility in polarizing and
responding to environmental cues105, 371, 372, 386. Macrophages, depending on signaling
cues, can polarize into pro- or anti-inflammatory phenotypes. Traditionally, these
phenotypes have been referred to as M1 and M2, but more recently it has been
recognized that there are a spectrum of phenotypes across the M1/M2 continuum.
Inflammatory stimuli released by necrotic or damaged tissue, such as interferon-gamma
(IFNγ), interleukin-12 (IL-12) and reactive oxygen species (ROS) promote polarization
into a pro-inflammatory phenotype393-397, leading to the secretion of pro-apoptotic
cytokines such as tumor necrosis factor (TNF) to induce apoptosis of neighboring cells.
Pro-inflammatory macrophages can remove apoptotic neutrophils and cellular debris
through phagocytosis and efferocytosis398-402 and participate in the adaptive immune
response by presenting disease-associated antigens to T and B cells that specifically
target infectious agents or diseased cells403-405. Following injury/infection resolution,
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secretion of factors including interleukin-10 (IL-10) and transforming growth factor beta
(TGFβ) by fibroblasts and platelets promote the polarization of anti-inflammatory
macrophages

406.

Anti-inflammatory macrophages suppress further inflammation by

secreting TGFβ, vascular endothelial growth factor (VEGF) and ROS that will deactivate
T cells and promote TH2 response

407-410.

These factors will also stimulate expansion of

fibroblasts, endothelial cells and other cell types for tissue repair 411, 412. In the bone, these
critical immune-/ or healing-stimulatory functions ensure that osteoclast and blast
activities are temporally regulated to properly and timely heal the bone subsequent to
trauma. There are, however, a number of gaps in our understanding of monocyte and
macrophage dynamics and polarization states over time, including but not limited to: 1)
the precise contributions of pro- versus anti-inflammatory macrophages in coordinating
the injury response, 2) whether macrophages are directly involved in population dynamics
and activities of osteoclasts and osteoblasts during bone injury, and 3) the main
mechanisms that govern pro- and anti-inflammatory macrophages population dynamics.
Although in vitro and in vivo experimentation techniques can capture the behavior of
individual populations with high resolution, they do not allow for understanding the
simultaneous interplay between multiple cell types whose numbers change over time.
This obstacle can be overcome with the integration of experimental data with
computational approaches to model the interactions occurring during bone injury repair.

4.1.4 Existing mathematical models of bone injury repair
Various mathematical models of bone remodeling have been proposed in the
context of not only bone injury repair but other disease contexts such as cancer and
osteoporosis as described previously413-415. Although these models have been used to
87

examine bone injury repair and homeostasis, they have largely focused on the interaction
between bone-building osteoblasts and bone-resorbing osteoclasts358-361,

364.

Some

models have considered immune populations but they remain theoretical and are not
driven by biological data that provides quantitative information for each population and
various timepoints throughout the bone injury repair process 416, 417.

4.1.5 Building biological data-driven bone injury repair models
To address this, we used an in vivo model of bone injury to longitudinally measure
changes in pro-and anti-inflammatory monocytes and macrophages in addition to
osteoblast and osteoclast numbers and bone volume at the site of injury. We then used
the obtained biological data combined with empirically-derived parameters curated from
literature to first power a non-coupled ODE model of bone injury repair that examines the
impact of infiltrating immune cells on osteoblast and osteoclast activity over time in regard
to bone volume dynamics. The ODE model generated herein, demonstrated that the
temporal interplay between myeloid-derived pro- and anti-inflammatory populations are
critical in driving osteoblast and osteoclast response but interestingly, using a constant
rates of bone formation and resorption, the mathematical model failed to recapitulate the
bone volume dynamics. Further interrogation of the model demonstrated that the rate of
osteoclast resorptive activity must vary greatly over the course of injury resolution to
return the bone volume to homeostasis. This insight has not been considered to date and
underscores the value of mathematically modeling complex multicellular biological
processes. The ODE model is subsequently coupled by integrating biologically-relevant
feedback mechanisms between cellular species, such that the model no longer depended
on artificially imposed inhibitory parameters to return populations to baseline levels. The
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robustness of the coupled ODE model was demonstrated by both accurately
recapitulating our in vivo dataset but also accurately predicting a separate, modified bone
injury repair dataset derived from an independent study.

4.2

Materials and Methods

4.2.1 Intratibial Bone Injury Model
All animal studies were designed and performed in accordance with Guidelines for
the Care and Use of Laboratory Animals published by the National Institutes of Health,
and approved by the University of South Florida’s Institutional Animal Care and Use
Committee under IACUC Protocol R5857-CCL. Additionally, studies abided by relevant
ARRIVE guidelines. 5-6-week-old male immune-competent C57BL/6 mice were
purchased from Jackson Laboratory with consideration for study statistical significance
and power (n=30). Surgically prepared mice (n=25) were sterilized with chlorhexidine and
subject to non-critical bone injury by intratibial injection using a 28-gauge (0.3062mm
diameter) syringe by penetration through the knee epiphysis to mid-shaft. Five mice
remained uninjured and were euthanized at baseline, and, subsequently, randomly
selected injured mice were euthanized at days 1, 2, 3, 7 and 14 (n=5/time point) for
histological and flow cytometry analyses. Histological and FACS data were obtained in a
blind manner to parameterize subsequent mathematical models.

4.2.2 Micro-Computed Tomography
Injured tibias harvested from mice from all time points were centralized and were
subjected to micro-computed topography (μCT) scanning using Scanco μ35 scanner to
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derive bone volume data. Individual bone scans were deidentified using numerical codes
during, and reidentified following data analysis in a blinded fashion. A gap of 100μm from
the tip of growth plate towards the midshaft was avoided to ensure the high bone density
nature of the growth plate does not mask potential differences in bone volume associated
with the injury. Each bone was then scanned every 6μm for a total span of 1000𝜇m along
the midshaft. Trabecular bone histomorphometry was subsequently performed after
contouring each slice scan and reconstructing the 3-dimension volume of interest
structure of each bone using the built-in morph function (n=30 bones; 5/time point). This
process was performed repeatedly using different contours to generate bone status
dynamics of the whole trabeculae, the region surrounding the injury, and of the injury itself
(Fig. 4-2).

4.2.3 TRAcP Staining
Tibia bones from all time points were decalcified with 14% EDTA every other day
for 3 weeks for further staining quantitation and analyses following μCT scans. Formalin
fixed paraffin embedded (FFPE) bones were sectioned at 4μm thickness. Multiple slides
sectioned at different depths from each bone were pooled for all time points, and were
baked at 42°C overnight to improve adhesion while retaining enzymatic activity for
tartrate-resistant acid phosphatase (TRAcP) enzyme-based staining for osteoclast
numbers. Deparaffined and rehydrated sections were pre-incubated in basic stock
solution with napthol-ether substrate for 1 hour at 37°C and developed in pararosaniline
dye and sodium nitrite for 10mins, also at 37°C. Sections with red osteoclasts were further
counterstained with hematoxylin to visualize bone tissue morphology. Fixed slides were
imaged at 20X using Evos Auto brightfield microscopy to include injury site and its
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immediate periphery. All TRAcP positive (red) multinucleated osteoclasts within 5𝜇m
radius from injury were counted, and mathematically converted to osteoclasts / bone
marrow volume (#OCL/μm3) for each slide for each bone at each time point. This region
of is consistent in area with the μCT analysis parameters to ensure consistency in data.

4.2.4 Immunofluorescence Staining and Quantitation
Additional FPPE tibia bone sections were baked at 56°C in preparation for
immunofluorescence staining of osteoblast (RUNX2 at 1:500; Abcam Cat. No. ab81357)
and nuclear staining (DAPI). Slides were processed in batch similar to TRAcP staining
methodology. Deparaffined and rehydrated slides were subject to heat-induced antigen
retrieval method. Sections were then blocked and incubated in primary antibodies diluted
in 10% normal goat serum in TBS overnight at 4°C. Subsequently, slides were stained
with secondary Alexa Fluor 568-conjugated antibody at 1:1000 at room temperature for
1 hour under light-proof conditions. Stained slides were stained with DAPI for nuclear
contrast and mounted for imaging at 20X using Zeiss upright fluorescent microscope to
include the injury site as well as the immediate peripheral tissue. All RUNX2 positive cells
(red staining colocalizing with DAPI) within 5𝜇m radius from injury were counted and
mathematically converted to osteoblasts / bone marrow volume (#OBL/μm3) for each
bone at each time point. Again, this methodology ensured consistency across all acquired
datasets.

4.2.5 Flow Cytometry and Analysis
Harvested contralateral injured tibias (n=30; 5/time point) had ends removed and
were subjected to centrifugation at 16,000g for 5 seconds for isolation of whole bone
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marrow for flow cytometry staining and analysis. Red blood cells were lysed using RBC
Lysis Buffer from Sigma Aldrich (Cat. No. R7757-100ML) as per manufacturer’s
guidelines. Live bone marrow cells were subject to FcR-receptor blocking (1:3;
BioLegend; Cat. No. 101319) and viability staining (1:500; BioLegend; Cat. No. 423105).
Samples were then stained by cell-surface conjugated antibodies from BioLegend diluted
in autoMACS buffer (Miltenyi; Cat. No. 130-091-221) for phenotyping myeloid cells:
CD11b-BV786 (1:200; Cat. No. 101243), LY-6C-Alexa Fluor 488 (1:500; Cat. No.128021)
and LY-6G-Alexa Fluor 700 (1:200; Cat. No. 561236). Cells were then fixed with 2%
paraformaldehyde in dark prior to intracellular staining. Fixed cells were permeabilized
using intracellular conjugated antibodies to assess polarization status: NOS2-APC
(1:100; eBioscience; Cat. No. 17-5920-80) and ARG1-PE (1:100; R&D; Cat. No.
IC5868P). Appropriate compensation and fluorescence-minus-one (FMO) controls were
generated in parallel either with aliquots of bone marrow cells or Rainbow Fluorescent
Particle beads (BD Biosciences; Cat. No. 556291). All antibody concentrations were
titrated prior to injury study using primary bone marrow cells to ensure optimal separation
and detection of true negative and positive populations. Stained controls and samples
were analyzed using BD Biosciences LSR flow cytometer. All datasets were batch
analyzed to ensure optimal consistent gating stringency.

4.3

Mathematical and computational methods

4.3.1 Model Parameterization
Basic ODE model. Osteoblast (OB) and osteoclast (OC) cellular and bone (B) dynamics
were described using ordinary differential equations in an ODE model. Osteoblast and
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osteoclast equations are composed of a homeostatic source term, a clearance term, and
an injury-triggered expansion term. The osteoblast clearance parameter (δOB) was fixed
from literature and in order to ensure osteoblast homeostasis level, the source term (HOB)
was fixed at δOB*OB0, where OB0 represents the initial level of osteoblasts. The osteoblast
proliferation rate (γOB) and duration of expansion (Tanab) were calibrated in fitting the
osteoblast dynamics to the experimental data. The osteoclast decrease rate (InhibOC), the
decrease duration (TantiCatab), the replenishment time (TCatab) and the replenishment rate
(ROC) were calibrated in fitting the osteoclast dynamics to the experimental data. The
homeostatic clearance parameter was fixed to ROC/OC0 in order to ensure osteoclasts
returned to the initial homeostasis level.
The bone equation is composed of two terms: a bone resorption term, proportional
to the number of osteoclasts and to bone volume, and a bone formation term, which is
proportional to osteoblast number. The resorption term is proportional to bone volume
since osteoclast resorption is also limited by the amount of available bone. Conversely,
osteoblast-mediated bone formation is independent of available bone. A range of possible
resorption rates was derived from published measurements. In test fitting experimental
data, the bone formation parameter was initially fixed at δBOC0B0/OB0, where B0 is the
initial bone level, in order to ensure that bone level remains at homeostasis when
osteoclast and osteoblast levels are at equilibrium. In a subsequent test fit, both δB and
ΠB are freely optimized, allowing the model the option to negotiate between fitting the
data versus eventually returning to homeostasis.
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Piecewise linear temporal variation of bone resorption and formation rates. The basic
ODE model was further used to study time-dependent bone remodeling rates by
redefining bone resorption and formation rate parameters as explicit piecewise linear
functions of time. Although the cellular dynamics of osteoclast and osteoblast were
imposed from the previous fit, the successive slopes of the piecewise linear function and
the initial bone resorption/ formation rate were all estimated from fitting the resulting bone
dynamics to bone experimental data. The parameter space for the optimization was
defined as follows: The slopes were allowed to be positive or negative, with the constrain
that the activity rates cannot become negative or go beyond the upper bound defined by
literature. Using the piecewise linear approach, the basic model informed the necessary
temporal changes in activity rates to fit to experimental data and also returning eventually
to baseline.

Enhanced ODE model including polarized monocytes/macrophages. Total and polarized
monocytes and macrophage cells were included into the basic ODE model. The fixed
clearances/lifespans parameters for each myeloid population were derived from
literature, whereas all other parameters were calibrated in fitting to the experimental data.
The osteoblast and osteoclast population fits were retained from the basic ODE model.
For the bone equation, homeostatic bone resorption rate (δB), pro-inflammatory
monocytes/macrophages-stimulated

bone

resorption

parameter

(α)

and

anti-

inflammatory macrophages-stimulated bone formation parameter (β) were all calibrated
while fitting the experimental bone dynamics. The homeostatic bone formation rate (ΠB)
was fixed such that ΠB =δBOC0B0/OB0, so bone level is ensured to remain at homeostasis
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when osteoclast and osteoblast levels are at homeostasis in the absence of injury (no
polarized monocytes and macrophages). The injury event in the enhanced model is
additionally described as initial transient increase in total and pro-inflammatory monocyte,
and pro-inflammatory macrophage numbers between days 0-1. Anti-inflammatory
macrophages were subsequently increased from days 0-2. The magnitude of their
increases was determined by fitting to experimental data. With the exception of a second
wave of pro-inflammatory cell increase between days 3 and 7, myeloid populations were
allowed to return to baseline at rates estimated from fitting to the experimental data.

Coupled ODE model integrates intercellular feedback mechanisms. Various aspects of
the enhanced ODE model were modified/replaced with biologically-relevant feedback
mechanisms based on published literature to generate the coupled ODE model. Namely,
the following changes were implemented:
•

The individual changes to population numbers meant to simulate the multifaceted
effects of a bone injury were unified under an additional “bone injury factor” specie
explicitly described by its own differential equation. Specifically, the bone injury will
simultaneously induce 1) monocyte expansion, 2) pro-inflammatory polarization,
and 3) osteoblast expansion. This injury specie would continue to influence
dynamics of these cellular populations until it is gradually subsequently removed
by the pro-inflammatory cells it generates. The magnitude of the injury effects were
calibrated to fit the biological data, and can then be adjusted to represent smaller
or larger injuries.

95

•

Instead of the injury directly acting on osteoclast numbers, anti-inflammatory
macrophages arising from the injury will emerge and suppresses osteoclast
numbers. Osteoclast numbers will remain suppressed and only rebound as antiinflammatory cells are cleared. Additionally, Osteoclast replenishment is driven by
the presence of osteoblasts.

•

Pro-inflammatory cells inhibition by anti-inflammatory macrophages were included
in addition to its main function in stimulating osteoblast bone formation rate. This
inhibition mechanism allows for the efficient clearance of pro-inflammatory cells
following an injury-induced expansion

•

Osteoclast differentiation was assumed to be proportional to the macrophage
population, with a transition term representing fusion into osteoclasts 418-420. This
term

had

an

additional

contribution

from

pro-inflammatory

monocytes/macrophages such that pro-inflammatory cells stimulated baseline
fusion rate of macrophages into osteoclasts.
•

Beyond the homeostatic monocyte replenishment term needed to counteract the
clearance term to maintain the population at steady state, monocyte expansion
terms were added to reflect response to injury. Macrophages, however, didn’t have
additional injury-induced expansion term given the experimental data. Conversely,
macrophage transition term into osteoclasts was added in addition to its
homeostatic clearance term

•

Whereas both monocytes and macrophages will transition into pro-inflammatory
cells directly proportionally to the amount of injury factor stimulation, anti-
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inflammatory macrophages are slower to arise out of the total macrophage pool as
they are cued by the presence and amount of pro-inflammatory cells.

4.3.2 Population homeostasis
In order to estimate the homeostatic cell replenishment parameters, we set them
equal to the clearance term (lifespan) which was either based on literature values or
calibrated directly from experimental data.

4.3.3 ODE Solver
The ODE45 function of Matlab was used to solve the differential equation system.
The experimental baseline values (time 0) were used as initial conditions.

4.3.4 Parameter estimation method
To estimate parameters facilitating goodness of fit, we defined the following
objective function:

Where i represents the time point index and j the variable index, 𝛼 represents the
parameter set used to evaluate the model function f, Dij represents the experimental data
of variable j at time point i, and σi represents the experimental error. The choice of this
functional form instead of the sum of the squares of the residuals was motivated to avoid
that one fit variable would be “sacrificed” to the benefit of another one. This way, we
ensure that all variables are equally well fitted.
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● In order to minimize this function representing the error estimate between data and
model, we used the Matlab function fminsearch with a penalization term to stay in
a parameter range set with reasonable boundaries.
● AIC criterion is defined as follows:

Where p is the number of parameters.

4.4

Results

4.4.1 Osteoclast and osteoblast numbers fluctuate dynamically in response to
bone injury
The stages and duration of non-critical bone injury largely follow the same
program, whereby subsequent to injury, early inflammation and hematoma occur rapidly,
followed by the formation of a callus that is subsequently mineralized by bone-forming
osteoablasts367, 368, 421. The callus is then remodeled via the activity of bone resorbing
osteoclasts106,

107, 146, 387, 422-425

(Fig. 4-1a). Osteoblasts and osteoclasts are critical

mediators of these steps and their numbers shift accordingly during each phase of repair.
Existing theoretical models of bone remodeling assume osteoblast and osteoclast
activities are constant over time and therefore, their numbers directly predict bone
dynamics359-361, 364. To evaluate this prevailing assumption, we first asked if modeling
osteoclast and osteoblasts alone was sufficient to accurately predict corresponding bone
remodeling dynamics using experimental data. To generate parameters to power this
basic ODE model, we used an experimental model of bone injury repair: non-critical injury
resulting from direct intratibial penetration via the knee epiphysis into the medullary
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canal426-429 (Fig. 4-1b). Tibias from mice were collected prior to injury at baseline (day 0),
and at day 1, 2, 3, 7 and 14 (n = 5 mice/time point) following injury. High-resolution μCT
analysis of uninjured tibia established baseline bone volume (BV/TV) (Fig. 4-1c and d).
Our data show that after injury, bone volume around the injury site diminished over a 48hour period, prior to a robust increase in mineralized bone content between days 2 and
7. By day 14, the bone volume returned toward baseline values. We directed our μCT
and histological analyses on the area surrounding the bone injury rather than the entire
bone marrow since our goal was to quantify cellular dynamics and changes specifically
in response to injury; values that could be diluted by measurements in non-injured areas
of the medullary canal (Fig. 4-2). Focusing on the site of injury and surrounding area,
histologically, we observed sequential increases in osteoblasts followed by osteoclasts,
findings that are qualitatively consistent with our BV:TV μCT analyses and are in line with
previous published observations429-431 (Fig. 4-1c and d).

4.4.2 Bone repair dynamics cannot be computationally recapitulated using
constant osteoblast and osteoclast activity rates
To date, bone resorption and formation rates have been difficult to measure in vivo.
Despite various in vitro studies showing that osteoblast and osteoclast activity can be
controlled by inflammatory factors and cytokines119,

377, 418, 432-441,

existing theoretical

mathematical models of bone remodeling largely assume that resorption and formation
rates per cell are fixed/constant over time. Since measuring whether osteoblast and
osteoclast activities vary over time in vivo during bone injury repair is experimentally
challenging, we employed an integrated experimental and mathematical approach to
address this knowledge gap.
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Figure 4-1. Osteoblast (OBL) and osteoclast (OCL) numbers temporally fluctuate
dynamically as bone heals from injury. (a) schematic summarizing published dynamics of
OBL and OCL following bone injury. (b) schematic depicting the experimental workflow
to induce bone injury in mice and generate bone, osteoblast and osteoclast dynamic data.
(c) representative images of micro-computed tomography revealed trabecular bone
status (BONE). Decalcified bones were stained and quantified for OBL by RUNX2
immunofluorescence staining (OBL), and OCL by tartrate-resistant acid phosphatase
(TRAcP) staining (OCL). (d) quantitation of temporal dynamics of bone volume,
osteoclast and osteoblast population.
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Figure 4-2. Analyses of bone status reveal most intense bone remodeling at site of bone
injury. Micro-computed tomography analysis was performed using scanned data from
three sets of contours for each bone: 1) the whole trabecular perimeter (Red), 2) the injury
site and adjacent tissue (Blue) and 3) the injury only (Grey). Data is plotted as total bone
volume over total volume (BV/TV).

Using the obtained biological data and publicly-available parameter values
regarding osteoblast and osteoclast behavior (Fig. 4-1c, Fig. 4-3 and Table 4-1), we
developed an initial mathematical data-driven basic ODE model to recapitulate the control
of bone repair exclusively by these two populations (Fig. 4-4a). This basic ODE model
simulated the bone injury event as a transient osteoblast (OBL) expansion and a
decrease in osteoclast (OCL) population from day 0 to 2 (see mathematical and
computational methods). Fits to the rest of the OCL and OBL population data were
optimized within the parameter space defined by published literature, such as regarding
cellular lifespan and proliferation rates (Fig. 4-4b and Table 4-1). Optimal fits with greatest
R2 value and number of residuals less than 1 (#R<1) were subsequently used for
estimating bone volume dynamics. Using these OCL and OBL optimized fits, the ODE
model attempted to recapitulate experimental bone dynamics by sampling constant bone

101

resorption rates within a range previously described in literature117-119,

429.

A

corresponding bone formation rate was estimated in each sampling as to ensure a return
to baseline bone volume at the end of the injury repair process (Fig. 4-4a #). Interestingly,
using this iterative approach, the ODE predictions largely overestimated the bone volume
dynamics compared to the experimental data (Fig. 4-5). In fact, the best-fitted iteration,
that used the lowest published OCL resorption rates118, only achieved an R2 value of
0.4554, and #R<1 of 2/5 (Fig. 4-4c). This indicated that either published measurements
of in vitro bone resorption/formation parameters do not reflect in vivo rates, and/or that
bone resorption/formation rates by osteoclasts and osteoblasts are variable over time
during the course of injury repair. To address this, we alternatively fitted the basic model
to bone dynamics data while allowing the optimization algorithm to freely determine an
optimal combination of constant bone resorption and formation rates that were not forced
to return to baseline bone volume subsequent to injury (Fig. 4-4a &). This resulted in
improved bone volume dynamic fits during injury repair but, of note, the final bone volume
reached by the ODE was 70% lower compared to that of baseline (Fig. 4-4d). Taken
together, these data suggest that osteoclast and osteoblast activity rates must vary
greatly during injury response in order to return the bone to homeostasis during injury
repair time-frame. This raised the question as to what cellular/environmental cues are
potentially responsible for controlling their activities.
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Figure 4-3. Relationship between osteoblast, osteoclast and bone per published literature.
Number of publications were consulted not only to derive relationship between three
species but also numerical parameters applicable for ODE modeling.

Table 4-1. Parameters extracted from published literature were combined with temporal
dynamics data in ODE model to estimate previously unknown parameters needed to fit
bone data. apposition rates from confined model (#) were calculated in fashion to offset
resorption rates derived from publication, to maintain constant bone volume at
homeostasis.
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Figure 4-4. Osteoblast (OBL) and osteoclast (OCL) activities as measured at
homeostasis do not allow accurate bone prediction during injury repair in vivo. Histological
quantitation of tibia bones parameterizes mathematical ordinary differential equation
(ODE) model of bone injury repair. (a) ordinary differential equations (ODE) describing
dynamics of OCL and OBL population are paired with published parameters to form an
initial ODE model to predict bone repair dynamic. Schematic depicts OCL resorb (red line)
and OBL form bone (green line). ODE expressions with unknown value (red) were
estimated as the model optimizes fits to in vivo data. (b) model produces accurate fits to
OCL and OBL dynamics. (c) model falsely predicts bone dynamics given OBL and OCL
fits in the first 14 days following bone injury when it samples various publication-derived
OCL resorption rates (each dashed line represents one sampling). OBL bone formation
rates are mathematically estimated in each sampling to ensure predictions will eventually
return to homeostasis (#). (d) alternatively, ODE model was allowed to freely seek out a
combination of resorption and formation rates to best fit data within the 14-day time period
(&).
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Figure 4-5. Testing fits to bone dynamic using published constant osteoclast resorption
rates. Representative model iterations testing bone resorption rates equally spaced
across the literature-derived range of possible values.
4.4.3 Polarized pro- and anti-inflammatory monocytes and macrophages emerge
in distinct temporal waves during bone injury repair
Monocytes and macrophages are key cellular species in the bone ecosystem and
their pro- and anti-inflammatory functions have been implicated in the bone injury repair
process and in the regulation of osteoblast/osteoclast activity111, 371, 422, 429, 442, 443. Studies
have shown for example that, 1) myeloid cells are polarized in bone injury and
inflammation, 2) pro-inflammatory factors and myeloid cells stimulate osteoclast activity,
and 3) anti-inflammatory/wound-healing factors and myeloid cells stimulate osteoblast
activity (Fig. 4-6 )105,

107, 373, 389, 425, 430, 442, 443.

Based on this rationale, we therefore

hypothesized that fluctuations in the number and polarization status of myeloid
populations control osteoclast and osteoblast activity during bone repair. To test this
hypothesis, we reanalyzed the non-critical bone injury experiment. Tibias from mice were
collected at baseline prior to injury (day 0), and at day 1, 2, 3, 7 and 14 (n = 5/time point)
post-injury. Flow cytometry was used to measure changes in myeloid populations over
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time 371, 396, 412, 444-453 (Fig. 4-7a-c and Fig. 4-8). Our results show that there are significant
increases in pro-inflammatory monocytes and macrophages within the first 48 hours that
are subsequently rapidly depleted upon the infiltration of anti-inflammatory macrophages
between 24 and 72 hours (Fig. 4-7c). Interestingly, in accordance with observations from
other in vivo studies, we observed a smaller second wave of pro-inflammatory monocytes
between days 6 and 8454-456 (Fig. 4-7c and d).

Figure 4-6. Relationship between pro- and anti-inflammatory myeloid cells and
osteoblast, osteoclast and bone. Numerous published literatures were consulted to not
only derive relationship between myeloid and bone cells, but also to derive quantitative
parameters potentially useful in ODE modeling.

Figure 4-7. Transient waves of pro- and anti-inflammatory monocytes and macrophages
alternate dynamically during bone injury repair. Flow cytometry performed on tibia bone
marrow harvested from C57BL/6 mice at various time points after injury (n=30; 5/ time
point) reveals diverse myeloid dynamics and polarization. Time points corresponds to
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time points from histological data. Total monocyte (CD11b+ LY-6CHI LY-6G-; a) and
macrophage (CD11b+ LY-6CLO LY-6G-; b) and their respective pro- and antiinflammatory subsets (c) each uniquely fluctuates following bone injury (Student t-test
compares all time points to its Day 0 for each subset; *p<0.05 **p<0.005 ***p<0.0005
****p<0.00005 nsp>0.05). (d) temporal dynamics of pro and anti-inflammatory monocytes
and macrophage numbers are normalized as fold change relative to levels at
homeostasis. Dashed lines show timings of pro- and anti-inflammatory polarization are
mutually exclusive.

Figure 4-8. Flow cytometry gating strategy for detection of polarized monocytes and
macrophages. (a) table detailing combination of markers used to discern each
subpopulation of interest within the heterogeneous bone marrow. (b) flow chart detailing
the process by which the whole bone marrow is gradually dissected to reveal the cells of
interest.
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4.4.4 Integration of polarized myeloid cells control of bone remodeling activity
recapitulates bone healing dynamics
Previous studies have reported pro- and anti-inflammatory myeloid control of
osteoclast and osteoblast activity; however, these observations are largely derived from
in vitro settings

108, 141, 381, 382, 388, 391, 432, 442, 457-460.

To address this, we integrated the

experimental quantitative data collected from each of these populations via flow cytometry
into the basic ODE framework to derive an enhanced ODE model (Fig. 4-9a and b).
Specifically, we allowed osteoclast activity to be stimulated from baseline in proportion to
the presence of pro-inflammatory cells by a model-estimated constant factor of α.
Likewise, we allowed osteoblast activity to be stimulated from baseline in proportion to
the presence of anti-inflammatory cells by a model-estimated constant factor of β. These
assumptions are based on empirical data from published in vitro experimental data141, 381,
382, 388, 391, 432, 442, 457-460.

We then asked the enhanced ODE model to optimize for levels of

α and β that are needed to accurately recapitulate bone volume dynamics. Of note, we
did not integrate anti-inflammatory monocyte data as the experimental data demonstrated
this population remains consistently low levels that did not fluctuate throughout the course
of bone injury repair (Fig. 4-7c). Importantly, in our model optimization, the range of
osteoblast and osteoclast activities that could be influenced by infiltrating myeloid cells
were limited to published values (Fig. 4-3). Given these restraints, the model nevertheless
estimated an optimal set of parameters that significantly recapitulated the bone volume
dynamics (R2= 0.9362; #R<1 =5/5) (Fig. 4-9c). The optimized model reveals that although
osteoblast activity remains relatively constant, osteoclast activity changes dramatically
over time. Furthermore, in this expanded ODE model, the bone volume returned to
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baseline levels subsequent to injury, underscoring the biological validity of our model
assumptions and reinforcing the importance of myeloid-derived infiltrating cells in
controlling the activity of osteoblasts and in particular osteoclasts in the process.

Figure 4-9. Integration of pro- and anti-inflammatory myeloid populations to modulate
OCL and OBL activity sufficiently improves model fit to experimental bone data. (a) ODE
expands to six populations and allows manually-fitted pro- and anti-inflammatory cells to
enhance bone resorption and formation rates, respectively. Individual equations are
shown next to schematic of ODE framework, model estimates amount of influence
polarized myeloid cells have on bone remodeling activity to optimize fit to data
(expressions in red). (b) Manual fits to pro- and anti-inflammatory monocytes (Pro- and
Anti-MONO, respectively), anti-inflammatory macrophages (Anti-MAC) are represented
by solid lines through error bar of data. (c) myeloid data was used to predict bone
dynamics given OBL and OCL fits. Statistical analysis of resulting fits on OCL, OBL and
bone are shown (R2).
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4.4.5 Osteoclast resorption activity does not correlate with osteoclast number
during bone injury repair
Upon further analysis of the results generated by our expanded ODE model, we
noted a disconnect between the dynamics of osteoblast and osteoclast activity versus
their population numbers (Fig. 4-10a). The model predicts that osteoblast mineralizing
activity varies slightly over time 1.21x10-6 to 2.63x10-6 mm3/cell/day; however, the model
predicts that a range of 4.26x10-7 to 7.28x10-6 mm3/cell/day is required for osteoclast
activity (Fig. 4-10a and b). These data suggest that, whereas osteoblast activity only
increases by 2-fold, a 17-fold increase in osteoclast activity is required to recapitulate
injury dynamics and also return to the bone volume to homeostasis. Importantly, the noted
ranges for osteoclast activity fall within those values reported in independent studies (Fig.
4-10b and Fig. 4-3)117-119. Our enhanced model is the first to posit that the rate at which
osteoclast resorbs mineralized matrix in bone healing can vary greatly depending on cues
from the surrounding microenvironment.
We also submit that this variation in resorptive activity is driven by infiltrating proand anti-inflammatory monocytes and macrophages. To this end, we returned to our basic
ODE model (Fig. 4-4) and asked how osteoclast activity need to change overtime in order
to fit to the bone data. In this agnostic approach, we no longer restricted osteoclast
resorption to constant rates over time but defined a piecewise linear function of time for
osteoclast resorption rate (Fig. 4-11a and b, Mathematical and Computational Methods).
Independent of the parameters chosen for the initial piecewise slope conditions, the
optimization algorithm identified a functional form composed of two waves: initially intense
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Figure 4-10. OCL and OBL activities and numbers do not correlate and vary distinctly
across in bone injury repair. (a) OBL and OCL activity rate dynamics (filled curves plotted
on the right y-axis) are plotted against their population dynamics (unfilled curves plotted
on the left y-axis). Activity is temporally distinct from population dynamics, both combine
to recapitulate bone dynamics. (b) table detailing the known parameters used by model
to estimate/infer unknown parameters.

and transient between days 1 and 2, followed by a milder but persistent wave starting
after Day 3 (Fig. 4-11c; orange line). We noted this temporal profile was very similar to
that of experimental data regarding the pro-inflammatory monocytes and macrophages
populations (Fig. 3c and Fig. 4-11c). This result further supports that pro-inflammatory
cells contribute significantly to osteoclast behavior and therefore bone healing dynamics
(Fig. 4-11). We used a similar approach to determine variable osteoblast activity and
defined a piecewise linear function of time, for the bone formation rate (Fig. 4-12a).
Interestingly, this model did not recapitulate bone volume dynamics despite the freedom
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to change bone formation rate over time (Fig. 4-12b; R2=0.6796). These data further
support a role for pro-inflammatory myeloid cells in controlling osteoclast, and less so
osteoblast activity, and therefore bone volume during injury repair.

4.4.6 Mathematical modeling reveals key insights into myeloid behaviors during
bone injury repair
Because of the ability of the ODE model to recapitulate the temporal dynamics of
the cellular populations involved in bone injury repair, we can investigate the precise
timing at which to administer therapies to further shorten bone-healing time. Likewise, we
can examine cellular behavior in response to a different sized injury, or even in a different
bone injury context, such as non-union fractures. These points will be best addressed
once we are able to improve our ODE model with reciprocal mechanisms and fully couple
the system. Our next efforts focused on integrating the interplay between macrophages
and how their polarization states control not only each other, but also how osteoblasts
and osteoclasts coordinate bone injury repair. To this end we built a coupled ODE model
using the enhance ODE model as the foundation framework describing seven cell
populations as well as the bone volume temporal dynamics.
We first curated common literature observations and hypotheses regarding
osteoblasts, osteoclasts, monocyte and macrophage behavior during tissue injury healing
(Table 4-2). Bone injury generates factors which trigger 1) osteoblast expansion, 2)
monocyte/macrophage polarization, and 3) monocyte infiltration 365. We assume that the
amount of bone injury factors is proportional to the bone damage induced and are the
primary driver of myeloid response. Myeloid cells are known to infiltrate the bone and
polarize into pro-inflammatory status to clear cellular debris when exposed to injury112

Figure 4-11. Agnostic approach showing necessary temporal changes to osteoclast
activity to recapitulate bone dynamics. (a) constraint on osteoclast resorption was
loosened in initial osteoblast-osteoclast-bone model to ask what are temporal changes
necessary to allow accurate recapitulation of bone dynamics. (b) model was able to
generate accurate bone fits given this loosened constraint. (c) predicted osteoclast
activity dynamics was plotted against experimental pro-inflammatory monocyte and
macrophage dynamics to demonstrate similarity.
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Figure 4-12. Agnostic approach showing temporal changes to osteoblast activity does
not recapitulate bone dynamics. (a) constraint to osteoblast resorption was loosened in
initial osteoblast-osteoclast-bone model to ask what are temporal changes necessary to
allow accurate recapitulation of bone dynamics. (b) even with the loosened constraint,
model failed to generate plausible bone fits.
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Table 4-2. Established biological behaviors and functions of naïve and polarized myeloid
cells. Framework for a comprehensive and coupled 9-specie coupled ODE model is
constructed based off of summarizing commonly known published interactions between
each species (>7 references per interaction).
Description

Supplementary References

Osteoclast and osteoblast activity are
4, 50, 114, 116, 136-147
coupled
Osteoblasts expand in response to bone 3, 4, 8-11, 50, 95, 114, 116, 144, 145,
injury and infection
149
Bone injury induces inflammation and
4, 7, 11, 70, 96, 113, 142, 143, 145,
monocyte and macorpahge polarization
150-153
Anti-inflammatory cells suppress
10, 11, 69, 77, 91, 96, 98, 136, 141,
inflammation and pro-inflammatory cells
153, 154
Pro-inflammatory drive anti-inflammatory
7, 69, 88, 91, 98, 150, 151
polarization of naïve myeloid cells
Polarized myeloid cells remove celular
2, 11, 59, 77, 86, 89, 91, 95-98, 141,
debris, apoptotic cells and clear infection
148, 151, 152, 156, 157
Monocyte/macrophage are osteoclast
4, 8 ,83, 113, 114, 118, 136, 137, 139precursors
142, 145, 158, 159
Bone injury recruits inflammatory
4, 9-11, 70, 86, 95, 113, 141, 143, 144,
monocytes from circulation
150, 151, 154, 160

Figure 4-13. Differential equations for the coupled ODE models and its corresponding
estimated parameters. Expressions in ODE equations govern behaviors of each
population and are parameterized by published values when available, such as the
natural lifespan of monocytes (𝛿Mo in 𝑑𝑀𝑜⁄𝑑𝑡). Parameters with no reference publication
were estimated to obtain best possible fits to temporal dynamics data (parameters in red).
associated factors (Table 4-2).
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Therefore, an injury variable was additionally built into the model that drives the initial
pro-inflammatory response by monocytes/macrophages. In the model, this injury variable
is consumed with a decay rate proportional to the number of pro-inflammatory cells
(Equations on Fig. 4-13). Then, based on existing literature, we devised a hypothesistesting scheme in which we interrogated various combinations of a diverse repertoire of
biological mechanisms described in literature (data not shown), to define a strict set of
behaviors regarding monocyte/macrophage control of osteoclast and osteoblast numbers,
and the mechanistic relationship between pro- and anti-inflammatory myeloid cells which
are crucial for 1) coupling of the ODE model, while 2) preserving the robust fits to the
experimental data (Fig. 4-14 and Table 4-2):
•

Osteoclast dynamics: osteoclasts are derived from macrophage population (blue
arrow); osteoblasts stimulate osteoclast expansion

(green arrow); anti-

inflammatory macrophages inhibit osteoclast formation and life span (red arrow;
Fig. 4-14a)
•

Osteoblast dynamics: bone injury factors stimulate osteoblast expansion, in
addition to homeostatic coupling with osteoclast activity (Fig. 4-14b)

•

Monocyte-macrophage dynamics: polarized populations are derived from their
naïve

source

populations;

bone

injury

factors

drive

pro-inflammatory

monocytes/macrophages polarization; proinflammatory monocytes/macrophages
drive subsequent anti-inflammatory macrophages polarization; anti-inflammatory
macrophages reciprocally suppress pro-inflammatory macrophages (Fig. 4-14c)
This coupled ODE framework (Fig. 4-14d) was parameterized by rates and values
evidenced in available literature. Using these parameters, the coupled ODE model
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Figure 4-14. Coupled ODE model fits to experimental data. Literature-derived biological
interactions (a-c) were integrated into the enhanced ODE model and manual fits were
removed (d). Simulation plots generated from the introduction of injury factor at Day 0,
and corresponding statistical assessment of the coupled ODE model demonstrate
accurate fits across all species.
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Table 4-3. Biological description of each mathematical variable with data-derived initial
homeostatic conditions.

Table 4-4. Integrated and calibration-estimated parameters of the coupled ODE model.
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calibrated the rest of the parameters to optimize the overall fit to the myeloid and bone
remodeling experimental data both at homeostasis (Table 4-3), as well as throughout
injury repair (Table 4-4). The statistical test results demonstrate that this model, despite
having to simultaneously fit seven cellular population and the bone experimental
dynamics, successfully recapitulates the in vivo process (Fig. 4-14e). We used an
agnostic approach to select and combine intercellular interactions that replaces manually
imposed cellular dynamics. The coupled ODE model recapitulated our experimental data
in a self-sufficient manner in which cellular populations mutually regulate each other. This
is crucial when modeling bone injury repair in the context of treatments, where the
manually imposed fits governing normal bone injury repair simulations might no longer
apply.

4.4.7 Model simulations are in accordance with independent published
experimental data
Analysis of the literature reveals a number of factors that are important regulators
of bone injury repair such as tumor necrosis factor alpha (TNFα), interleukin-4 (IL-4),
interferon-γ (IFNγ) and oncostatin M (OSM)

375, 376, 433-435, 438, 440, 441, 461, 462.

For example,

studies in mice genetically deficient for OSM exhibited reduced bone formation and
osteoblasts numbers at the non-critical bone injury site429, 458. OSM is produced by antiinflammatory macrophages and promotes osteoblast expansion and activity 429, 458, 463, 464.
To assess the robustness of our bone injury repair mathematical model we simulated the
effect of OSM depletion on osteoblast number and determined if the model would
recapitulate the qualitative temporal dynamics of osteoblast, osteoclast population and
bone volume as shown in an independent experimental dataset429. We found that
119

reducing the effect of anti-inflammatory macrophages on osteoblast expansion by 50%
and mineralization activity by 90% yielded similar osteoblast, osteoclast and bone
dynamics to those obtained in OSM-deficient mice (Fig. 4-15a). Of note, osteoblast and
bone levels are below control osteoclast number remain largely unchanged between
treatment and control in both the experimental data and model predictions. Although not
examined in vivo, the mathematical model also generated corresponding predictions of
the effect of OSM depletion on monocyte/macrophage dynamics (Fig. 4-15b).

4.5

Discussion: an in silico model system of myeloid inflammation and

osteoclast and osteoblast response to injury
The complex cellular mechanisms that control bone injury repair can be difficult to dissect
given the complexity of the bone marrow microenvironment using traditional biological
approaches but key insights have been made. For example, genetic and pharmacologic
approaches reveal that macrophages play important roles in bone healing as well as
osteoclast differentiation388,

393,

399,

437,

450.

Yet, how macrophage populations

quantitatively interact with each other or other cell types in the bone environment directly
or indirectly over time can be challenging to identify with this approach. For instance,
though polarized macrophages have been observed at sites of bone injury alongside
osteoblasts and osteoclasts, the rates at which polarized macrophages stimulate the
activities of these bone cells remained difficult to evaluate and furthermore, quantitate.
Computational approaches allow simultaneous interrogation of multicellular systems in
which a mathematical model can infer parameter values that might be otherwise
unknown. Despite this advantage, existing mathematical models of bone remodeling
largely focus only on osteoclast, osteoblast and the bone; and those which integrate
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Figure 4-15. Bone repair dynamics in oncostatin M (OSM)-depleted bone predictions.
Bone repair temporal data for OCL, OBL and bone, in presence or absence of OSM, is
retrieved and plotted from a murine in vivo bone fracture healing study performed by
Guihard P, et al. on the top panel (solid line = WT, dashed line = OSM-null;
http://doi.org/10.1016/j.ajpath.2014.11.008). (a) reduction in OBL bone formation rate and
mineralization activity, allow model to qualitatively reproduce OBL, OCL and bone
dynamics in OSM-null dataset (lower panel; solid line = unmodulated, dashed line = OSM/-). (b) corresponding myeloid predictions.
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additional populations are theoretical 359, 362, 365-371, 423. As shown here, we have integrated
both our experimental and published data into a mathematical framework which models
interactions between myeloid cells, osteoclasts and osteoblasts, and the bone from
published literature. We have concluded that bone repair cannot be recapitulated if we
assume osteoclast and osteoblast activities are constant over time. Our basic ODE model
failed to derive accurate bone fits despite using both published and freely estimating
constant activity rates. Therefore, based on the literature, we subsequently focused on
myeloid-derived monocytes and macrophages that have noted roles in contributing to
bone injury repair388, 393, 399, 437, 450, and the enhanced ODE demonstrated that the dynamic
waves of polarized monocytes and macrophages and their temporal control of bone
remodeling activity sufficiently allowed for the accurate recapitulation of bone repair.
Another major finding from our analyses is the extent to which osteoclast
resorptive activity can be modulated subsequent to osteoblast mineralization of the injury
site. Existing empirical data have recorded osteoclast resorptive activities in the range of
1x10-8 to 5x10-5 mm3/cell/day117-119. Here, our estimations suggest that osteoclast activity
varies by 17-fold magnitude over time within this published range and that proinflammatory monocyte and macrophages are critical for regulating this effect. These data
underscore how mathematical modeling can provide important biological insights. It
should be noted that though other mathematical models have been proposed to explore
mechanisms of bone repair dynamics365, 367, 368, 370, 423, the study presented herein, to our
knowledge, is the first to leverage longitudinal biological data on multiple cellular
populations and integrate this information into a mathematical model.
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Additional quantitative insights provided by the enhanced ODE model include
estimations on monocyte and macrophage proliferation rates as well as the rates at which
pro- and anti-inflammatory cells polarize and modulate osteoclast and osteoblast activity,
respectively, during the repair process. This information can be critical for therapies that
target specific myeloid populations during bone injury repair in a bid to accelerate bone
healing. Our study also reveals rapid expansion of pro-inflammatory monocytes and
macrophages in the first 24 hours with anti-inflammatory macrophages emerging shortly
thereafter and persisting for up to 48 hours. Interestingly, pro-inflammatory cells
moderately rebound upon the clearance of anti-inflammatory cells (between days 6 and
8, Fig. 4-7c), suggesting a second wave of inflammation that is in keeping with other
reports461-463. Conflicting reports suggest this could be due to 1) emergence of antiinflammatory macrophages having an inhibitory effect on pro-inflammatory population, or
2) myeloid plasticity and repolarization408, 409, 450, 453, 472-475.
One caveat of our study is that the flow cytometric analysis is performed on cells
isolated from the whole bone marrow, as opposed to only the volume of interest in
histological datasets (Fig. 4-2). An alternative could be to perform multiplex image
cytometry of the site of injury for the various myeloid populations of interest. We suspect
that, while this would allow for more accurate quantitation of the myeloid cell populations
infiltrating the site of information, the overall trends and shifts in those populations over
time would remain similar to our flow cytometry data. Additionally, our model does not
consider the potential roles of other cell types in the bone ecology that could contribute,
such as T cells. Our model also doesn’t differentiate between various differentiation
stages and activities of osteoblast cells despite studies, including recently by Wolock et
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al., that offer alternative markers besides RUNX2 to look at osteoblast lineage
commitment and actviity465, 466. Nonetheless, our results suggest that modeling myeloid
populations provides enough resolution to satisfactorily explain the process of non-critical
bone injury repair. Importantly, our unbiased test (Fig. 4-11 and Fig. 4-12) yielded
osteoclast activity dynamics that qualitatively resonated with the population dynamics of
pro-inflammatory monocytes and macrophages, supporting the importance of the myeloid
population in regulating bone volume resorption. Our theoretical framework is flexible
enough however that the effects of other immune cells such as T cells could be included
in future iterations of our ODE model.
Building on our findings with the basic and enhanced ODE, the coupled ODE
model captures the dynamics of seven cell populations, the bone mass and the clearance
of the injury. The interplay between the different populations poses a challenge in regard
to the reconciliation between model dynamics and experimental data but gives credence
to the novel insights it has allowed us to uncover. These include 1) Our combined
mathematical and experimental approaches suggest that anti-inflammatory macrophages
are key for early osteoclast inhibition and pro-inflammatory phenotype suppression 2)
pro-inflammatory macrophages are involved in osteoclast activation (bone resorptive
activity), whereas osteoblastic cells promote osteoclast differentiation, and 3) antiinflammatory macrophages promote both osteoblast expansion and bone-forming
activity.
The coupled ODE model explicitly models the clearance of bone injury factors by
pro-inflammatory cells. Experimentally, we observe a rapid expansion of proinflammatory monocytes and macrophages in the first 24 hours which quickly clears and
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then rebound slowly as anti-inflammatory macrophages emerging shortly thereafter and
persisting for up 48 hours. With the natural depletion of the anti-inflammatory population,
our model suggests the remaining injury factors ushers a second expansion of proinflammatory macrophages and monocytes that in turn enhance osteoclast formation and
activity. This increased activity is essential for the resorption of the mineralized callus at
the site of injury and the return to bone homeostasis in the given time frame. To our
knowledge very few reports have proposed a role and mechanism for this second
inflammatory wave during bone healing. A role of MSCs and osteoblastic cells has been
proposed for a second increase in inflammatory cytokines like TNF476. However, this two
waves pattern has been observed in larger spectrum of inflammatory contexts, not only
in bone372, 438, 477, 478, suggesting that this temporal profile is not bone specific. Importantly,
to our knowledge the present study is the first to propose a mathematical framework of
bone healing where bone and immune cell populations are fully coupled and to inform
such a model with experimental longitudinal data of all these populations.
Interestingly, predictions by the coupled ODE model shows anti-inflammatory
OSM depletion induces increase in anti-inflammatory macrophage population and a
transient decrease in pro-inflammatory populations. Although these predictions were not
experimentally examined by the independent study, they did however measure dynamics
of pro- and anti-inflammatory cytokines in their control group. The cytokine dynamics
profiling, such as with IL-1β and IL-10 (data not shown)436, surprisingly mirror the
dynamics of pro- and anti-inflammatory cells observed in our experimental model.
Together, our model predictions not only are in qualitative accordance with this
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independent experimental dataset but potentially also accurately reveal the status of
polarized myeloid cells not examined in this independent study.
Our coupled ODE model indicates that pro-inflammatory macrophages do not repolarize into an anti-inflammatory phenotype given the time frame, which goes against
studies suggesting macrophage plasticity and reprogramming, at least in the context of
bone injury repair. Although not disputing the possibility that macrophages can repolarize,
our results suggest that, based on the timing of the acquired experimental timing points,
repolarization does not appear to be the main mechanism that recapitulates macrophage
polarization dynamics. Additional insights provided by the coupled ODE model include
estimations on macrophage lifespan during the healing process and the contributory roles
of pro-inflammatory macrophages and monocytes to the process. This information can
be critical for therapies that target specific myeloid populations during bone injury repair
in a bid to accelerate bone healing.
Another important aspect that our model currently neglects is that of bone quality
which requires a different set of data acquisition techniques and further refinement of the
mathematical approach. Moreover, bone healing is a spatially regulated process and
having this aspect included in the model would be an exciting refinement in order to
explore further mechanistic aspects of bone structure and regeneration.
Through our computational approach, we have integrated established biology into
a mathematical framework describing cell population dynamics during non-critical bone
injury repair. One potential application of our framework is to investigate how time to
healing subsequent to bone injury can be reduced. Existing studies have shown that bone
healing times can be impacted in modulating pro- and anti-inflammatory macrophages111,
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383, 442, 465.

Although the model is parameterized with mouse data, there is much overlap

between mice and humans with respect to the phases of the bone injury repair program.
Thus, using our existing workflow, we can conceivably re-parameterize our model with
human patient-derived data to further its potential as a relevant prospective tool for the
clinic.
In conclusion, we have developed a coupled ordinary differential equation (ODE)
model of the bone ecosystem that considers the interplay between 8 key cellular
populations during bone injury repair. This modeling approach yields a number of novel
findings regarding macrophage dynamics and macrophage impact on osteoblasts and
osteoclasts dynamics. It further yields a number of novel insights regarding myeloid
control of osteoclast- and osteoblast-mediated bone resorption and formation activities
over time. Moreover, the model can also provide novel insights into phenomena that are
hard to measure in vivo such as rate of pro- or anti-inflammatory polarization over time.
A better understanding of bone healing will have clinical translatability allowing, for
instance, to accelerate the process and improve patient outcomes. The model accounts
for coupling between these population and will be useful in developing therapeutic
strategies/interventions that shorten healing times. Further, the model has broad
applicability and can be used as a platform to examine other bone diseases such as
osteoarthritis and skeletal malignancies such as bone-metastatic prostate cancer
(bmPC). The integration of bmPC into the existing framework requires us to understand
the multi-faceted roles macrophages play along its entire metastatic cascade.
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4.6

Future directions: integrating cancer into the coupled ODE model
Our current coupled ODE of bone remodeling and healing is driven solely by a

“bone injury” described in the form of a 1) reduction in bone volume, 2) expansion of
monocytes, and 3) stimulation of pro-inflammatory myeloid polarization. The model then
autonomously simulates the subsequent multicellular interactions that ultimately returns
the bone and each cellular population to baseline, as well as predict biologically-relevant
treatments outcomes. The wealth of available knowledge of how prostate cancers can
potentially interface with macrophages and osteoclast/osteoblasts in the bone
microenvironment is summarized in our published review (see Appendix B)457. Our next
step is to replace the “bone injury” with prostate cancer. By reprogramming our model to
become vulnerable to the different ways in which prostate cancers can disrupt bone
homeostasis, we are using the model to independently fit our longitudinal myeloid data of
progressive bmPC, derived from an in vivo study using the syngeneic RM-1 prostate
cancer cells in C57BL/6 mice (Fig. 4-16). This dataset was derived using the same flow
cytometry analytical pipeline as was used for the derivation of the bone injury data, with
the inclusion of an additional antibody to detect cytokeratin-positive prostate cancer cells.
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Figure 4-16. Prostate cancer-mediated myeloid infiltration and polarization response.
Intratibial model of syngeneic prostate cancer cells (RM-1) grown in C57BL/6 mice
(n=5mice/time point) were analyzed over 14 days using same flow cytometry analysis
pipeline as for bone injury model. Prostate cancer was labeled and detected using
antibody against cytokeratin (CK).

In our preliminary integration, we describe prostate cancer’s 1) stimulation of proinflammatory polarization, 2) activation of osteoclast resorption, and 3) expansion of
osteoblasts64, 88, 162, 360, 457. Using this framework, we are able to generate decent fits to
some populations, such as pro-inflammatory monocytes, but not others, such as antiinflammatory macrophages (Fig. 4-17). This indicates additional prostate cancer
interactions with the bone stroma need to be examined. Once optimized, this bmPC ODE
model will be used to test myeloid-targeted treatments, to identify promising therapeutic
strategies against cancer progression, and even expand to model multiple myeloma
disease progression.
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Figure 4-17. Preliminary prostate cancer integration and ODE data fits. (a) prostate
cancer’s interactions with the myeloid and bone-remodeling populations were integrated
in replacement of the bone injury factors. (b) preliminary model fits to experimental
dataset.
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Chapter 5.

Interdisciplinary understanding of the tumor-bone relationship and

future directions
The current oldest evidence of hominin cancer is that of a fossilized malignant
growth suspected to be an osteosarcoma, on the metatarsal of a, now 1.7 million-year
old human ancestor467. Although it is arguably biased that skeletal preserve better than
soft-tissue fossils, the far reaches of skeletal malignancies have nonetheless been
documented since the dawn of civilizations, ranging from the Greeks, to the Romans and
the Egyptians468-471. Despite its prevalence through time, patients presenting with bonemetastatic diseases still face a lack of curative therapeutic options. Through advances in
fields such as tumor microenvironment, onco-immunology, cancer metabolism, cancer
genomics and proteomics, researchers around the world, as a global community, have
made tremendous headway in understanding the complex relationships between the
cancer and its host stroma and environment. These advancements are a distinct leap
from just centuries ago, when the focus of oncology was solely on understanding and
targeting the cancer itself. In the case with skeletal malignancies, cancers depend on the
bone marrow environment to provide essential growth factors and nutrient to further their
growth. This parasitic relationship unfortunately often dysregulates bone homeostasis
and results in hematologic and osteal pathologies, such as anemia, leukopenia,
osteolysis and osteogenesis. In chapters 2 and 3, we detailed two examples of skeletal
malignancies: one of which generates an osteolytic disease, and the other an osteogenic
disease.
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Advanced multiple myeloma generates osteolytic lesions throughout the skeleton
of patients, and we have characterized the role of MMP-13, specifically, host-derived
MMP-13 in this vicious cycle. Notably, we demonstrate that myeloma can enhance MMP13 is expression by stromal MSCs and osteoblastic bone-lining cells. Although MMP-13
has been shown to possess a host of collagenolytic and non-collagenolytic proteolytic, as
well as non-catalytic activities, we’ve identified that myeloma-induced MSC MMP-13
processes and controls the bioavailability of MSC-secreted cytokines and thereby
indirectly regulates the abundance and activity of osteoclasts. Specifically, we
demonstrated that MMP-13-expressing MSCs produce pro-osteoclastogenic factor
CXCL7, and that the genetic ablation, or pharmacologic neutralization of MMP-13
reduces MSC-driven osteoclast formation and bone resorption. Given the importance of
MMP-13 in myeloma progression, we unsurprisingly noted that both genetic and
pharmacologic ablation of MMP-13 in myeloma-bearing mice not only reduced cancerinduced

osteolysis,

but

significantly

improved

overall

survival.

Crucially,

the

improvements in survival rivaled that of in vivo studies using standard of care treatments,
such as bortezomib and melphalan183. Together, these results provide intriguing rationale
for various future directions with MMP-13 in multiple myeloma:
•

CXCL7-mediated osteoclast biology represents one mechanism by which
myeloma-driven MMP-13 contributes to osteolysis. What are additional MMP13 substrates also dysregulated in multiple myeloma that also contribute to
cancer-induced osteolysis?
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•

Does the dysregulation of CXCL7 bioavailability and bioactivity by MMP-13
change the behavior of other cell types, such as neutrophils and platelets, in
which CXCL7 has known roles in?

•

Given the promising results from the preclinical myeloma models, what are the
opportunities for translating MMP-13-targeted therapies to the clinic?

•

Our group has generated chimeric drug molecules that dually act as a MMP-2
inhibitor and a bisphosphonate which inhibits osteoclast. Could MMP-13
inhibitors be engineered in the same way to improve its efficacy in multiple
myeloma?

•

Our data points to MMP-13 having direct roles in myeloma growth and
survival, but the exact mechanism of action awaits further examination

Castrate-resistant prostate cancer (CRPC) also commonly manifests in the bone
marrow niche (bmCRPC) and poses a significant clinical problem. As the name suggests,
bmCRPC are resistant to standard of care hormone-deprivation therapies, adding an
additional layer to the treatment of the disease. In a significant subset of CRPCs, the
prostate cancer cells express a constitutively active variant of the androgen hormone
receptor, AR-v7. This variant not only circumvents the need for an activating androgen
ligand, but also induces downstream expression of genes important for the mitogenic
pathways, such as AVPR1A. We demonstrated that AVPR1A is important for the growth
and resistance of CRPC in both a subcutaneous and orthotopic in vivo CRPC models of
pharmacologic AVPR1A inhibition using Relcovaptan. The prostate-to-bone vicious cycle
generates mixed bone disease, and AVPR1A is a regulator of osteoclast function. In an
in vivo model of bmCRPC, we observed that Relcovaptan resulted in delayed cancer and
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bone disease progression. Furthermore, Relcovaptan treatment significantly extended
survival of tumor-bearing mice, owing to direct inhibition of CRPC growth, but also
indirectly limiting pathologic bone remodeling, which is responsible for providing
necessary factors for prostate cancer growth. The results of this study reveal additional
questions yet to be answered:
•

Having established the preclinical efficacy for relcovaptan in the treatment of
CRPC, how can we bring the drug to CRPC patients in the clinic?

•

Can we synthesize novel compounds that have improved selectivity and
potency inhibiting AVPR1A compared to Relcovaptan?

•

In addition to AVPR1A, are there other molecular pathways that also have
potentially dual roles in CRPC progression but also osteogenic bone disease
we can target therapeutically?

In the progression of both multiple myeloma and prostate cancer, the essential role
of the bone remodeling stroma is highlighted. Computational tools such as mathematical
modeling is increasingly being used to synthesize the ever-expanding knowledge on the
complex mechanisms governing tumor-stromal relationships in cancer. As math models
slowly integrate more and more benchtop discoveries, they become increasingly accurate
and reliable in recapitulating cancer biology. In Chapter 4, we describe our construction
of an ODE-based mathematical model from the ground up, with the goal of eventually
having a tool that can be universally used to understand and predict treatment outcomes
in various myeloid-mediated osteal pathologies, including prostate cancer and multiple
myeloma. To build such as tool, we focused extensively on accurately recapitulating bone
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remodeling at the biologically-relevant scale using in vivo experimental data. We devised
an in vivo model of bone injury repair to derive longitudinal data describing the population
dynamics of polarized myeloid and bone remodeling populations, and the corresponding
bone volume. We then incorporated biological mechanisms in bone injury repair derived
from published literature, and constructed a coupled computational model that accurately
describes our experimental data, and was ultimately also able to accurately predict bone
injury repair outcomes in an independent in vivo study where osteoblast numbers were
genetically suppressed. Importantly, the validation of the model has allowed us to move
forward with the integration of cancer populations. The creation of this computational tool
inspires various future directions in understanding and treating skeletal-related
pathologies:
•

We are now engineering the model to simulate and predict bone injury
treatment outcomes which has significant clinical implications in orthopedics,
especially in inflammation-driven diseases, such as inflammatory arthritis.

•

As described, we are using an in vivo longitudinal dataset of bmPC to guide
us in advancing our coupled ODE to model prostate cancer bone diseases.
Such model would allow us then to explore the efficacy of various myeloidtargeted treatment modalities. This process could be expanded to include
other skeletal malignancies, such as multiple myeloma.
•

The contribution of other immune and bone populations has not been
examined. Future iterations of the coupled ODE could integrate these
populations and study their contributions to bone remodeling dynamics

In closing, I reflect upon my past didactic training in higher education and leading
up to my first research experience as an undergraduate student in an evolutionary biology
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laboratory from 2010-2012. During those years, fields in science were seemingly
extremely compartmentalized and distinct from each other; genetics was genetics,
microbiology was microbiology, and developmental biology was developmental biology.
These fields/disciplines seemed like independent schools of thought. However, in just a
matter of a few short years, as I am nearing the end of my doctoral training, I have come
to observe the blurring of the boundaries. In my personal experiences, my dissertation
projects have incorporated perspectives and technologies from a vast range of disciplines,
from molecular signal transduction pathways in cancer, to flow cytometric analyses of
polarized immune populations, to mouse models of disease progression, and to
mathematical modeling of bone turnover. I believe my interdisciplinary training is
absolutely crucial, because to examine the excruciating details of one side of cancer is to
miss all the others, and I believe we have to be ever-challenging ourselves, to incorporate
new philosophies and perspectives into our own thoughts. Moving forward, I am excited
what the future years of cancer research will discover, and how these discoveries will help
to eradicate this deadly disease.
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Abstract
Bone-metastatic prostate cancer is common in men with recurrent castrate-resistant disease. To
date, therapeutic focus has largely revolved around androgen deprivation therapy (ADT) and
chemotherapy. While second generation ADTs and combination ADT/chemotherapy approaches
have been successful in extending overall survival, the disease remains incurable. It is clear that
molecular and cellular components of the cancer-bone microenvironment contribute to the
disease progression and potentially to the emergence of therapy resistance. In bone, metastatic
prostate cancer cells manipulate bone-forming osteoblasts and bone-resorbing osteoclasts to
produce growth and survival factors. While osteoclast-targeted therapies such as
bisphosphonates have improved quality of life, emerging data has defined important roles for
additional cells of the bone microenvironment including macrophages and T cells.
Disappointingly, early clinical trials with checkpoint blockade inhibitors geared at promoting
cytotoxic T cell response have not proved as promising for prostate cancer compared to other
solid malignancies. Macrophages, including bone-resident osteomacs, are a major component of
the bone marrow and play key roles in coordinating normal bone remodeling and injury repair.
The role for anti-inflammatory macrophages in the progression of primary prostate cancer is well
established yet relatively little is known about macrophages in the context of bone-metastatic
prostate cancer. The focus of the current review is to summarize our knowledge of macrophage
contribution to normal bone remodeling and prostate-to-bone metastasis, while also considering
the impact of standard of care and targeted therapies on macrophage behavior in the tumor-bone
microenvironment.
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INTRODUCTION
In 2018 alone, approximately 28,000 deaths from prostate cancer were predicted 1. While early
stage disease is often treated successfully with surgery, radiation, and/or ADT, advanced prostate
cancer remains a moving target. Advanced disease typically manifests in the skeleton where
metastases are often sensitive to first- and second-generation ADT. However, in a short period,
the cancer becomes castrate resistant (CRPC). In bone, prostate cancer causes extensive bone
remodeling and formation that results in intense pain and heightened risk of pathologic fracture 2.
These symptoms drastically reduce the patients’ quality of life and contribute substantially to
disease morbidity and mortality. Bone-metastatic castrate-resistant prostate cancer (mCRPC) is
currently incurable and appears to be refractory to recent advances in immunotherapy such as
checkpoint inhibitors 3-5. However, immune-based therapies such as Sipuleucel-T have been
beneficial for some patients indicating that there may be room for alternative strategies in targeting
the immune microenvironment of bone mCRPC. Despite macrophages constituting 8-15% of
healthy adult male bone marrow, their role in the context of the bone-metastatic CRPC remains
relatively underexplored.
MACROPHAGE FUNCTION IN TISSUE HOMEOSTASIS
Macrophages are phagocytic cells of the innate immune system responsible for maintenance of
tissue homeostasis. Myeloid in nature and originating from hematopoietic stem cells that mature
and differentiate into myeloblasts and monocytes, macrophages are noted for their diverse
morphology and function across various tissues 6-8. For example, microglia are residential
macrophages of the brain and play an important role in regulating synapse behavior 9. These cells
have further demonstrated roles in immune modulation of inflammatory response to brain trauma
at the blood-brain barrier 10. Other organ-specific macrophages include kupffer cells which
turnover heme molecules through phagocytosis and degradation of hemoglobin in the liver 11, 12,
and alveolar macrophages which engulf and eliminate dust particulates and microbes from the air
on the luminal side of the mucosal-epithelium lining in the lung 13, 14. Precursor and mature
macrophages derived from the bone marrow also circulate the body, surveying and infiltrating
sites of injury and infection to regulate local responses. Macrophages are known for their
plasticity, and depending on signaling cues, can polarize into pro- or anti-inflammatory
phenotypes. Traditionally, these phenotypes have been referred to as M1 and M2, but more
recently it has been recognized that there are a spectrum of phenotypes across the M1/M2
continuum. Inflammatory stimuli released by necrotic or damaged tissue, such as interferongamma (IFNγ), interleukin-12 (IL-12) and reactive oxygen species (ROS) promote polarization
into a pro-inflammatory phenotype 15-19, leading to the secretion of pro-apoptotic cytokines such
as tumor necrosis factor (TNF) to induce apoptosis of neighboring cells. Pro-inflammatory
macrophages can remove apoptotic neutrophils and cellular debris through phagocytosis and
efferocytosis 20-24 and participate in the adaptive immune response by presenting diseaseassociated antigens to T and B cells that specifically target infectious agents or diseased cells 2527
. Following injury/infection resolution, secretion of factors including interleukin-10 (IL-10) and
transforming growth factor beta (TGFβ) by fibroblasts and platelets promote the polarization of
anti-inflammatory macrophages 28. Anti-inflammatory macrophages suppress further
inflammation by secreting TGFβ, vascular endothelial growth factor (VEGF) and ROS that will
deactivate T cells and promote TH2 response 29-32. These factors will also stimulate expansion of
fibroblasts, endothelial cells and other cell types for tissue repair 33, 34.
MACROPHAGE ROLES IN BONE REMODELING AND INJURY REPAIR
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In the bone marrow, osteoclast and osteoblasts are bone-specific cell populations that serve to
resorb and mineralize the bone, respectively. The activities of these two populations are tightly
coupled to ensure balanced bone turnover as well as returning the bone to homeostasis
subsequent to injury. Osteoclasts are found residing on osteal surfaces and are histologically
characterized as tartrate-resistant acid phosphatase (TRAP) positive and multi-nucleated 35, 36.
Osteoclasts migrate to sites of active bone remodeling by chemotaxis, where they are involved in
demineralization and resorption of the bone matrix 37-39. Upon apoptosis of the osteoclast,
mesenchymal stem cell (MSC)-derived osteoblasts rebuild the bone matrix via the deposition of
type I collagen and hydroxyapatite 40. Traditionally, due to their myeloid origins and bone-specific
functions, osteoclasts are considered the bone-resident macrophage population. However, roles
for pro- and anti-inflammatory macrophages in controlling and coordinating osteoclast and
osteoblast bone remodeling have been described. For example, IFNγ- and IL-12-stimulated
NOS2 and TNF positive pro-inflammatory macrophages can promote osteoclast formation and
bone resorption 41, 42. Conversely, anti-inflammatory macrophages are thought to contribute to
bone formation 43.
A distinct population of bone-resident macrophages, osteomacs, have been described,
and recently studies have shown important roles for these cells in modulating osteoblast activity
in both bone homeostasis and injury repair 44. Osteomacs are morphologically characterized as
mononuclear cells that form canopy-like structures around osteoblasts and can occupy as much
as 75% of both murine and human endosteal and trabecular bone surfaces that are under active
remodeling 45-48. Histologically, osteomacs are distinct from osteoclasts and are F4/80 positive
but TRAP negative. Additionally, other groups have shown osteomacs to express common
macrophage markers such as CD68, but also more specific markers such as Mac-3 and CD169
45, 46, 49
. While osteomacs can be stimulated by receptor activator of nuclear kappa B ligand
(RANKL) and colony stimulating factor-1 (CSF-1/M-CSF) to become osteoclasts in vitro,
monocytes and other myeloid precursors were found to be more efficient osteoclast precursors
45
. These data indicate that osteomacs are a plastic, yet distinct cell type, with specific functions
in the bone marrow microenvironment. Indeed, further studies have revealed that osteomacs
have diverse roles in regulating osteogenesis and osteolysis. Osteoblasts become inefficient as
they age and need to be replenished to ensure proper homeostatic bone turnover 46. During
normal bone turnover, osteomacs engulf apoptotic osteoblasts in a process called efferocytosis,
which induces the secretion of TGFβ, TNF and oncostatin M that facilitate osteoblastogenesis
and bone formation 45, 46, 48. This mechanism has been confirmed in various in vitro and in vivo
contexts. For example, removal of osteomacs from bone marrow-derived osteogenic co-cultures
reduced osteoblast number and osteoblastic mineralization 47. The MAFIA (MAcrophage FasInduced Apoptosis) murine model is one in which administration of ligand AP20187 can
systemically suppress macrophage differentiation. Reduced osteoblast occupancy of the
endosteal bone surfaces was observed in maturing MAFIA mice following AP20187
administration 47, 50. Congruently, parathyroid hormone (PTH)-induced bone anabolism in the
MAFIA model was suppressed upon macrophage ablation 51. Interestingly, when murine
macrophages were depleted by clodronate liposome-induced apoptosis, osteoblast numbers
remained stable 47, 50. Further comparison between two methods of macrophage depletion
showed that transient macrophage apoptosis induced osteomac expansion and efferocytosis,
which further enhanced osteoblast activity 46, 51, 52. Additionally, C57BL/6 mice bone marrow
treated with trabectedin, a chemotherapy antagonist of macrophages, showed diminished
phagocytic
genetic
signature,
efferocytotic
osteomac-induced
RUNX2
positive
53
osteoblastogenesis, and associated BV/TV status . During bone fracture repair, osteomacs can
also sense apoptotic damaged cells in response, initiate inflammation and immune recruitment
through secretion of immune attractant factors such as chemokine (C-C motif) ligand 2 (CCL2)
and M-CSF 48. Additionally, LPS-stimulated osteomacs express TNF and NOS2, and suppress
osteoblast activity in vitro 45. In vivo, bone fracture induced pro-inflammatory polarization of
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immune macrophages and osteomacs to secrete TNF and IFNβ, driving osteoclastogenesis and
osteolysis 45. In fact, osteomacs have been shown to associate with osteoclasts at catabolic sites,
substantiating their distinction from osteoclasts, and supporting their additional roles in regulating
osteolysis 48. These studies indicate that osteomacs can direct the transition between osteolysis
and osteogenesis by directly modulating the expansion and activity of osteoclasts and osteoblasts
for repair in the event of bone injury 46. Taken together, these studies demonstrate the complex
roles of bone-resident macrophages in bone remodeling 54, 55. How they contribute to the
progression of bone-metastatic prostate cancer and respond to applied therapies has not been
fully elucidated at this juncture.
MACROPHAGES PROMOTE PRIMARY PROSTATE CANCER PROGRESSION
Just as in other cancers, chronic inflammation in prostate cancer is thought to serve as a prelude
to tumorigenesis 56. In fact, in cases of premalignant prostatic inflammatory atrophy, macrophages
were observed coalescing at sites where inflammation-driven neoplasia caused disruptions in the
epithelial lining of the prostate 57. In primary prostate cancer, pro- and anti-inflammatory tumor
associated macrophages (TAMs) have been found to comprise a significant portion of the immune
cells infiltrating the tumor microenvironment with studies beginning to dissect roles for each
population in regards to progression of the disease 58, 59. The exact pro- and anti-inflammatory
constitution of TAMs vary across cancer types, but protective roles for TAMs have been described
in prostate cancer. For example, macrophages located in the tumor-peripheral stroma correlated
with increased recurrence-free survival 60, while macrophages expressing CD204, a marker
associated with activation of antigen presentation in dendritic cells, correlate with better overall
survival and prognosis 60-62. However, for the most part, macrophages have been found to
contribute to, or directly promote, primary prostate cancer progression with individual patient
cohort and meta-analysis studies identifying that macrophage infiltration correlates with disease
aggressiveness and poor prognosis in prostate cancer 63-67. With respect to therapy, the density
of anti-inflammatory macrophages in the primary disease correlates with extracapsular and
biochemical recurrence following radical prostatectomy and/or ADT 63, 65, 66, 68.
The tumor-promoting roles of anti-inflammatory macrophages are thought to revolve
around their immune-suppressive and angiogenic effects, both of which are important hallmarks
of prostate cancer progression 68-71. Prostate cancer cells have been shown to secrete factors
such as CSF-1 and CCL2 that lead to the recruitment of monocytes and macrophages that
facilitate these processes 68, 72-78. Once recruited to the microenvironment, macrophages are
exposed to a milieu of environmental cues that can drive their polarization into pro- or antiinflammatory states 58. For example, exposure to tumor-derived IL-10 and -13 promotes
macrophage polarization into an anti-inflammatory state. Subsequently, macrophages secrete
factors such as epidermal growth factor (EGF), platelet derived growth factors (PDGF), and VEGF
that promote cancer cell proliferation and angiogenesis of the tumor microenvironment 69, 79-83.
Furthermore, ARG1 and TGFβ positive anti-inflammatory macrophages, along with myeloidderived suppressor cells and regulatory T cells, collectively suppress inflammation and immune
response within the tumor microenvironment 84-88. Both pro- and anti-inflammatory macrophages
can also modulate T cell expansion and cytotoxicity by regulating the bioavailability of L-arginine,
an important amino acid for T cell activity and survival 89. In addition, NOS2 positive proinflammatory macrophages synthesize nitric oxide that can promotes T cell TH1 expansion 90, 91.
Conversely, anti-inflammatory macrophages expand during TH2 response and additionally
suppress T cell proliferation through expression of co-inhibitory molecule PD-L2 30. Importantly,
macrophages can also contribute to the activity of non-immune cells in the tumor
microenvironment, such as cancer-associated fibroblasts (CAFs). Macrophage-secreted factors
such as TGFβ are known potent regulators of CAFs that also promote tumor growth and invasion
into the peripheral tissue to facilitate metastasis 68, 71, 92, 93.
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MACROPHAGE ROLES IN ESTABLISHING THE PRE-METASTATIC BONE MARROW
NICHE?
While much is known about the role of macrophages in primary prostate cancer progression, less
is known about how their polarization states in the bone marrow contribute to, or protect against
prostate cancer metastasis to the bone and subsequent establishment. TNF, TGFβ, and VEGFA
can be secreted by primary prostate cancer cells into circulation 94, which can activate marrow
cell populations including bone-resident macrophages and hematopoietic progenitor cells.
Furthermore, these tumor-derived factors have been shown to induce the recruitment of
immunosuppressive myeloid populations into the bone that support immune-evasion and ease
the establishment of circulating tumor cells 95.
Emerging evidence has also defined important roles for prostate cancer-derived
exosomes in the genesis of receptive pre-metastatic niches 96, 97. Exosomes are nanometer-sized
vesicles that can be shed in large numbers by cancer cells. The cargo contents of cancer cellderived exosomes vary greatly but can contain cell-adhesion molecules, receptor tyrosine
kinases, proteases, miRNAs and miRNA processing machinery, mRNA and DNA 98, 99. Injection
of mice with exosomes derived from human prostate cancer peripheral blood or murine prostate
cancer cells lines (TRAMPc1) demonstrated impaired murine osteoclast formation and enhanced
osteoblast differentiation suggesting that prostate cancer-derived exosomes play a role in tipping
the balance toward bone formation, a common hallmark of bone-metastatic prostate cancer 100,
101
. Milk fat globule-EGF factor 8 protein (MFG-E8) was found in human prostate cancer patient
exosomes, and tissue biopsies. MFG-E8 has been shown to mediate macrophage efferocytosis
of apoptotic osteoblasts and cancer cells; these macrophages then exhibit an anti-inflammatory
phenotype and in turn promote immune suppression through expression of TGFβ and ARG1 102,
103
. Characterization of prostate cancer-derived exosomes has identified various proteins and
miRNA that can promote metastasis. Among the miRNA identified, miRNA-21 is particularly
interesting given that it is upregulated in bone-metastatic prostate cancer and has known roles in
regulating osteoclasto- and osteoblastogenesis 23, 97, 104, 105. Additionally, miRNA-21 is known to
regulate macrophage phagocytosis of necrotic or diseased tissue in the context of wounding 23.
Other miRNA identified in prostate cancer-derived exosomes that can influence osteoclast and
osteoblast differentiation include miRNA-128 and -183 95, 97.
Collectively, these studies show that bone marrow macrophages contribute to bonemetastatic outgrowth of disseminated prostate cancers whereby cancer-derived signals or
exosomes significantly influence macrophage activity in the pre-metastatic niche. In turn, these
changes appear to be permissive for prostate cancer cell colonization of bone.
TUMOR-ASSOCIATED MACROPHAGES IN METASTATIC CASCADE OF PROSTATE
CANCER
The role of TAM in the metastatic dissemination of primary prostate cancer has been extensively
studied and reviewed. Here we reference a few published seminal review articles that outline the
molecular and cellular communication between tumor-associated macrophages and primary
prostate cancers resulting in tumor vascularization, epithelial-to-mesenchymal transition,
intravasation and eventual colonization of distal sites, including, specifically, the skeletal bone
marrow 58, 83, 106-109.
MACROPHAGES IN THE PROGRESSION OF ESTABLISHED PROSTATE TO BONE
METASTASES
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Once actively growing in the skeleton, prostate cancer cells manipulate the cells of the bone
microenvironment to promote areas of extensive osteolysis and osteogenesis. Osteoclasts have
traditionally been regarded as a specialized bone-resident macrophage population due to their
myeloid lineage and phagocytic nature in bone resorption, which leads to the release of bone
matrix-sequestered factors that feed the metastatic prostate cancer cells 110-112. While
macrophages can fuse and form into osteoclasts in response to RANKL 113, 114, the role of
individual macrophage populations in controlling prostate cancer-bone interaction remains
relatively underexplored. Recent observations in patient biopsies have implicated the role of
osteal macrophages in established bone-metastatic prostate cancer 115. CD68 positive
macrophages were detectable at high density within the tumor whereas osteoclasts and
osteomacs were found at the tumor-bone interface, suggesting potentially differential functions
for each population in the growing lesions 115. Studies have also defined causal roles for
macrophage populations in the growth of prostate cancer in bone. For example, intratibial
inoculation of RM1 prostate cancer cells into macrophage-depleted bone marrow of MAFIA mice
resulted in decreased pathologic osteolysis 107, 116. Additionally, depleting macrophages using
clodronate liposome prior to tumor inoculation significantly impacted cancer growth in bone 116.
Further evidence supporting contributory roles for macrophages in the progression of bonemetastatic prostate cancer lesions has been provided using similar total macrophage depletion
approaches 107, 115. Additionally, roles for osteomacs in the cancer-bone microenvironment have
also been described, where CD169 positive tumor-associated osteomacs were found to facilitate
tumor-induced pathologic osteogenesis. Interestingly, CD169 negative macrophages have been
shown to promote tumor growth 115 and phenotypically resemble CD206 positive antiinflammatory macrophages found in primary prostate cancer 109, 117. Taken together, these studies
suggest macrophages contribute to prostate cancer metastasis and growth in the bone
microenvironment (Figure 1). However, deeper investigations into the precise roles of pro- and
anti-inflammatory macrophages and osteomacs in the process are warranted.
MACROPHAGE RESPONSE TO STANDARD OF CARE TREATMENTS/THERAPIES.
As discussed, macrophage polarization can have protective or contributory roles; however, the
impact of standard of care approaches on macrophage behavior has not been explored in depth
thus far. For men with bone-metastatic CRPC, treatment options largely focus on radiation
therapy to alleviate pain and reduce tumor burden, or therapeutics that target the cancer cells
such as chemotherapy and ADT. Although castrate-resistant, CRPC prostate cancer cells remain
dependent on androgen signaling via the expression of constitutively active androgen receptor
splice variants, and/or autocrine expression of their own androgen 118-120. Underscoring this
dependency on androgens or the AR receptor for survival, second generation ADTs
(enzalutamide and abiraterone) have been shown to significantly improve overall survival. In
murine xenograft models, enzalutamide treatment of C4-2B and TRAMPc1 prostate tumors
induced STAT3-mediated CCL2 expression and recruitment of CCR2 positive macrophages,
enhancing angiogenesis and tumor invasion 121-123. Other second generation ADTs such as
abiraterone, have also been shown to upregulate cancer cell CSF1 expression to promote
macrophage infiltration, wound healing and, subsequently, tumor proliferation 75. Additionally,
ADT drives tumor secretion of IL-10 and -13 that contribute to the polarization of macrophages
into an anti-inflammatory phenotype 75. While in-depth studies have not examined the precise
effects of second generation ADT on macrophage behavior in bone-metastatic disease, it is
plausible that the drugs may have actions similar to those noted at the primary site by promoting
an anti-inflammatory phenotype. Critically, little work has been done to explore the role of ADT on
bone-resident macrophages. As discussed, osteomacs appear to be key regulators of bone
formation, and androgen depletion may impact the ability of osteomacs and osteoblasts to
generate bone. This would be beneficial in reducing the aberrant osteogenesis associated with
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bone-metastatic prostate cancer, although it could promote systemic osteoporosis, a
phenomenon noted in men undergoing chronic ADT treatment 124.
Taxane chemotherapies such as docetaxel and cabazitaxel are also used for the
treatment of advanced prostate cancer patients. These drugs inhibit microtubule disassembly
during mitotic chromosome segregation and induce apoptosis in neoplastic cells, and they are
commonly given to patients with mCRPC who have failed ADT 125-128. Interestingly, for
chemotherapy-sensitive CRPC, docetaxel has immune-stimulatory effects and can inhibit
myeloid-derived suppressor cells, while promoting a switch in macrophages from an anti- to proinflammatory phenotype 129, 130. However, bone-metastatic CRPCs eventually become resistant
to docetaxel, at which point they progress. In the case of chemotherapy-resistant cancer, the
cancer cells can now secrete inflammatory cytokines such as IL-6 and -8, to recruit and
differentiate monocytes and endothelial cells, for immune suppression and angiogenesis
respectively 131-134. Specifically, IL-6-induced mature macrophages are subsequently driven by
other secreted cytokines such as IL-4 to anti-inflammatory states to induce immune suppression
131
. IL-6 also induces prostate cancer survival by inducing Bcl/Stat-mediated survival signaling 131.
Docetaxel can also induce CCL2 expression in cancer cells, a potent factor that not only induces
prostate cancer growth and is correlated with disease progression, but also recruits antiinflammatory macrophages that drive tumor progression 74, 131, 135-139. Anti-inflammatory
macrophages may also promote bone formation but studies have shown that docetaxel impacts
bone remodeling by suppressing osteoclast formation and osteoblast expansion, therefore
potentially off-setting the contribution of anti-inflammatory macrophages to cancer-induced bone
disease 140.
Newer therapies being employed in the clinic may also have important effects on
macrophage behavior in bone. For example, radium-223 is an alpha-emitting radionuclide that
binds to calcium and promotes prostate cancer cell death in the neighboring vicinity. The
treatment has been successful in extending the overall survival of men with bone-metastatic
CRPC. The apoptosis induced by radium-223 may increase the bioavailability of tumor antigen in
a cytotoxic microenvironment. Since macrophages are strong antigen presenting cells that
mediate T cell antigenicity, it will be interesting to explore whether peripheral macrophages
become pro-inflammatory and immune-stimulatory 141. However, the effects of radiation therapy
can be double edged. In humans, myelosuppression, leukopenia and lymphopenia, were noted
in radium-223 patients 142, 143. Further, in multiple cancer models, radiotherapy has been
demonstrated to enhance macrophage infiltration, and over time, the polarization of macrophages
into an anti-inflammatory phenotype may promote angiogenesis and cancer cell
survival/recurrence 144-146. Taken together, these studies indicate that while applied therapies are
initially successful in limiting disease progression, the emergence of resistant disease is often
coupled/correlate with changes in macrophage polarization. Whether chronic exposure to
standard of care therapies alters the microenvironment which in turn facilitates the emergence of
resistant cancer cells remains to be determined. Converse, little is known as to whether the
evolution of resistant cancer cells in response to therapy impacts the behavior of the surrounding
microenvironment.
CAN MACROPHAGE-BASED THERAPIES BE IMPACTFUL FOR THE TREATMENT OF
BONE-METASTATIC PROSTATE CANCER?
The addition of therapies geared at blocking macrophage function, in particular anti-inflammatory
function, in combination with standard of care treatments may yield more effective and durable
responses in addition to preventing the recurrence of resistant disease. The role of macrophages
in promoting the progression of numerous solid malignancies has been described, and as a
consequence, translational studies have been geared toward the development of targeted
therapies that can either deplete myeloid populations and/or alter the polarization status of
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macrophages. Numerous factors control macrophage infiltration and polarization but can have
dual tumor-promoting and -protective effects. For example, correlative and causal roles for TNF
in the progression and metastasis of prostate cancer have been described 147-153. Given the roles
of TNF in inflammatory diseases such as arthritis, it is unsurprising that biologicals targeting either
the ligand or the receptor have been an active area of research. In the cancer setting, TNF can
promote tumor growth and angiogenesis with preclinical trials demonstrating efficacy for TNF
blocking reagents 154. Conversely, however, tumor-protective roles have been described in
addition to potential risks for the development of cancers such as soft tissue sarcoma. This,
combined with the potential for adverse toxicity associated with TNF inhibition, has diminished
enthusiasm for the application of TNF inhibitors in the cancer setting. However, more encouraging
results for other targets that impact macrophage behavior have been noted including, CCL2/CCR-2, IL-4 and CSF1R.
CCL-2 CCL2 is expressed by prostate cancer cells, and while it can promote cell growth and
invasion in an autocrine manner, it has also been shown to be a key driver of CCR2-expressing
(CCL2 receptor) macrophages and monocyte recruitment 73, 155, 156. Moreover, the role of CCL2
seems particularly relevant in the context of bone-metastatic disease where CCL2-expressing
prostate cancers recruit endothelial cells and osteoblasts to drive angiogenesis and osteogenesis,
respectively, both of which enhance the progression of the disease 73, 157. Underscoring the
importance of CCL2 in the tumor-bone microenvironment, studies demonstrated that
neutralization of CCL2 with a monoclonal antibody (C1142) was successful in both attenuating
tumor growth as well as bone pathology in various preclinical models 156, 158. As a result, the
humanized version, CNTO 888 (Carlumab), was developed to neutralize CCL2 signaling function
in advanced prostate cancer. While the drug was well-tolerated in clinical trials, no anti-tumor
activity was noted as a single agent for the treatment of metastatic CRPC 158-161. Given that
targeting CCL2, or the receptor CCR2, in other diseases has been shown to be impactful in
reducing inflammatory responses, it is possible that combination with standard of care treatments
may result in more profound effects. Interestingly, heightened levels of CCL2 were noted in
patients that developed resistance to docetaxel, and pre-clinical studies in which docetaxel and
C1142 were combined demonstrated significant inhibition of bone-metastatic cancer growth and
associated bone disease 139, 162, 163. Surprisingly, a phase I clinical trial combining docetaxel with
CNTO 888 demonstrated tolerability but not a suppression of serum CCL2 levels or tumor
response. This may indicate higher dosing is required to block the CCL2-CCR2 axis or a
combination of CNTO 888 with CCR2 specific antibodies such as MLN1202 is needed to achieve
effective responses in humans 164. In addition to potentially depleting macrophages from the bonetumor microenvironment, CCL2/CCR2 therapies can also reduce osteoclast recruitment and
formation thereby protecting the patient from skeletal-related events such as pathologic fracture
157, 165
.
IL-4/ IL-4R. Interleukin 4 (IL-4) is an anti-inflammatory cytokine found upregulated in various solid
malignancies that can promote tumor growth by driving anti-inflammatory macrophage
polarization which in turn facilitates tumor proliferation, angiogenesis and metastasis 166-168. This
effect may be concentration dependent as high levels of IL-4 have an anti-tumor effect 169-171. In
prostate cancer, IL-4 trends with PSA expression and can stimulate IL-4 receptor (IL-4R) positive
prostate cancer cells to grow and metastasize via downstream activation of JAK/STAT6 pathway
172
. IL-4 can also promote anti-tumor immunity. While IL-4 supports proliferation of T cells, it
converts mature CD8 T cell from TH1 to TH2 response; this transition suppresses their cytolytic
potential and leads to immune evasion and tolerance 168. IL-4 expression is especially heightened
in hormone-refractory versus hormone-sensitive prostate cancer 169, 172. In the context of ADT,
studies have shown that IL-4 can induce AR signaling reactivation, independent of androgen,
suggesting IL-4 over expression as a resistance mechanism to restore cancer growth in
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androgen-depleted prostate cancer 172, 173. Combination of anti-IL-4 agents with ADT may
therefore extend tumor ADT sensitivity. To this end, IL-4-targeted therapies are in development
for the treatment of asthma and allergic responses. However, the anti-cancer effects of the
therapy could be lessened due to the potential impact of IL-4 blockade on the activity of cytotoxic
immune cells. Adverse systemic effects may also be an issue, but strategies that focus on cancer
cell- or TAM-specific delivery may be of use. Furthermore, IL-4 has been shown to limit osteoblast
proliferation and induce the expression of IL-6 while inhibiting osteoclastogenesis 174, 175.
Therefore, while inhibiting IL-4 may exacerbate the cancer associated bone disease, it would also
inhibit IL-6 expression by osteoblasts which in turn may prevent macrophage-mediated resistance
to chemotherapy 176.
CSF1/CSF1R. Prostate cancer-derived colony stimulatory factor 1 (CSF1) can lead to the
recruitment of CSF1 Receptor (CSF1R) positive macrophages. In the tumor, CSF1 signaling
promotes macrophage survival and polarization into a ARG1, CD206 and IL-10 positive antiinflammatory phenotype, while simultaneously inhibiting a NOS2 and IL-12 positive proinflammatory phenotype 75-77. Additionally, tumor-derived CSF1 recruits MDSC, and these
immunosuppressive myeloid infiltrates are particularly important in tumor survival and progression
76
. Interestingly, standard of care therapies such as radiation and ADT promote CSF1 expression
by prostate cancer cells leading to increased infiltration of macrophages 75, 77. The CSF1/CSF1R
axis is known to play a role in macrophage infiltration and anti-inflammatory polarization in other
cancers and several anti-CSF1R agents have been developed, including GW2580 and PLX3397.
These agents have demonstrated significant success in abrogating therapy-induced CSF1R
positive macrophage infiltration using animal models of cancer progression including prostate
cancer 75, 77, 177-179. Further, treatment with ADT and PLX3397 or GW2580 reduced macrophage
infiltration compared to either therapy as a single agent 75. This indicates that combination ADT
and anti-CSF1R therapy would be clinically beneficial. Currently, several clinical trials are ongoing
that will test the efficacy and impact of CSF/CSF1R inhibitors. For prostate cancer, recent studies
have shown that PLX3397 delays the emergence of CRPC by reducing the number of infiltrating
TAM and a phase II clinical trial was performed in a small cohort of bone-metastatic CRPC
patients with results pending (NCT 01499043). Various other combination therapy studies for
prostate cancer using ADT with PLX3397 and other anti-CSF1R agents are underway and it will
be interesting to see how well they perform relative to when used as single agents 78. Of note,
blockade of CSF1R signaling in mice significantly reduced osteoclast number, leading to
increased bone mass that may be useful in offsetting ADT-associated osteoporosis 180.
CONCLUSIONS
Bone-metastatic CRPC is currently incurable and will be present in over 90% of the men that
succumb to the disease. While ADTs and chemotherapy have improved overall survival rates,
more work is required to help control and/or eradicate the disease. This can be achieved by
understanding the cellular and molecular mechanisms involved. To this end, clear roles for the
stromal and immune components of the tumor microenvironment have been described.
Macrophages represent a large component of the immune infiltrate, and depending on their
polarization state, can contribute to the progression of the disease. Many standard of care
therapies focus on elimination of the cancer cell but indirectly, these therapies also impact the
behavior of the surrounding macrophage population and lessen therapeutic efficacy. The factors
controlling macrophage infiltration and polarization are the focus of translational efforts with
several reagents in clinical trials. Combination therapies such as ADT with anti-CCL2/CCR2 or
anti-CSF1R inhibitors may prove to significantly extend the overall survival of men with bonemetastatic CRPC. Further, given the role of macrophages in controlling bone remodeling,
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dampening macrophage activity may reduce prostate cancer-induced osteogenesis, thereby
directly improving patient quality of life.
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FIGURE

Figure B-1. Macrophage roles in the context of the bone metastatic prostate cancer. Upon
recruitment to the site of metastasis by CCL2 and or CSF-1, macrophages may polarize (blue
arrows) into pro- or anti-inflammatory states depending on environmental cues. Tumor
associated macrophages have protective (red arrow) or contributory effects (green arrow)
directly on prostate cancer. Importantly, macrophages, including bone-resident osteomacs,
impact osteoclast and osteoblast function (green arrows) thereby also indirectly regulating
prostate cancer progression in bone. Asterisks denote factors to which small molecule or
biological inhibitors have been developed.
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